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The self-assembled layered adsorption of proteins onto nanoparticle (NP) surfaces, once in contact 
with biological fluids, has been termed the ‘protein corona’ and it is gradually seen as a determinant 
factor for the overall biological behavior of NPs. Here, we describe the previously unreported in vivo 
protein corona formed in human systemic circulation. The human-derived protein corona formed 
onto PEGylated doxorubicin-encapsulated liposomes (Caelyx®) was thoroughly characterized 
following the recovery of liposomes from the blood circulation of ovarian carcinoma patients. In 
agreement with our previous investigations in mice, the in vivo corona was found to be molecularly 
richer in comparison to its counterpart ex vivo corona. The intravenously infused liposomes were 
able to scavenge the blood pool and surface-capture low molecular weight, low abundant plasma 
proteins that could not be detected by conventional plasma proteomic analysis. This study describes 
the previously elusive or postulated formation of protein corona around nanoparticles in vivo in 






























































































The surface identity of nanoparticles (NPs) is modified once injected in the bloodstream 
because of their spontaneous interaction with a wide range of surrounding proteins and other 
biomolecules.[1] The spontaneous and layered adsorption of proteins onto NPs has been termed 
the ‘protein corona’.[2] Even though surface modification of NPs with hydrophilic polymers (e.g. 
PEGylation) results in diminution of protein adsorption onto NPs surfaces, the complete elimination 
of protein corona formation has not been achieved so far by such functionalization strategies.[3-7] 
During the last decade protein corona research has gained popularity with a flurry of attempts 
made to molecularly characterize corona profiles after the ex vivo incubation of NPs with biofluids 
(mainly plasma) and more recently, in vivo (in rodents).[4-7]  
The biological effects arising from the presence of biomolecules onto NPs surfaces can be 
both unfavorable and advantageous to their biomedical applications.[1, 8] It is now reasonably 
established that the protein corona defines the NP surface characteristics and forms the interface 
between NPs and biological systems, also referred by some to as the ‘bio-nano’ interface. The 
presence of the protein corona mediates the interaction of NPs with cells and has been shown to 
significantly impact on their cytotoxicity, cellular internalization and targeting capability.[9, 10] 
 Among a plethora of nanoscale drug delivery systems, liposomes (phospholipid-based 
vesicles) are considered to be the most clinically-established nanomedicine constructs.[11] The 
substantial reduction in the cardiotoxicity of doxorubicin upon encapsulation within PEGylated 
liposomes led to the approval of the first nanoscale anti-cancer agent (Doxil®, Caelyx®) by the 
FDA in 1995 for the treatment of for AIDS-related Kaposi Sarcoma and in 1999 for the treatment of 
recurrent ovarian carcinoma.[12, 13] This liposomal construct shows superiority to free doxorubicin 
owing to its prolonged blood circulation time, the stable retention of the drug in the interior of 
liposomes while in blood circulation, leading to an overall improved toxicity profile and enhanced 
tumor accumulation.[12, 14] 
Despite the clinical track record of liposomes for more than 20 years, the role that protein 
corona plays in liposomal pharmacology has been barely studied. To date, only a few studies 
describe the molecular composition of the protein corona formed around NPs in vivo. [4-6, 15]  In the 
vast majority of investigations, NPs are characterized after their ex vivo interaction with plasma 
proteins (mouse or human), extrapolating on the erroneous assumption that corona fingerprints 
formed under such a static biological setting can reﬂect the dynamics and molecular richness of the 
in vivo milieu.[1]  




































































to investigate the in vivo protein corona formation and its evolution onto clinically-used liposomes 
after their intravenous administration (tail vein) in rodents. These studies revealed that the molecular 
composition of the in vivo protein corona cannot be sufficiently predicted by the ex vivo plasma 
incubation of NPs.[4-6] Blood flow dynamics, the interaction with blood circulating cells and immune 
responses triggered after NPs administration are some of the factors that cannot sufficiently be 
simulated by ex vivo studies and could explain the differences observed between the ex vivo and in 
vivo formed protein coronas.[1] Although in vivo models shed light on our understanding of the self-
assembly mechanism of the protein corona formation under more biologically-relevant settings, 
extrapolation of data from mice to humans should be made with extreme caution.[16] Nanoparticle-
based systems that work efficiently in rodent disease models often fail to offer similar efficacy in 
humans.[17] Yet, the formation of a protein corona around blood-circulating nanoparticles in humans 
has not been experimentally described at all, let alone studied as a potential factor to explain such 
discrepancies between preclinical and clinical achievements. 
 In the present study, we attempted to investigate and characterize the in vivo protein corona 
formation in humans. PEGylated, doxorubicin-encapsulated liposomes (Caelyx®) were infused 
intravenously in six patients with platinum-resistant recurrent ovarian carcinoma and subsequently 
recovered from the blood circulation immediately on completion of their first cycle of Caelyx® 
treatment. Liposomes were isolated from blood components along with their formed protein corona 
which was quantitatively and qualitatively characterized using a battery of techniques. The data 
indicated that an in vivo human protein corona forming around intravenously-infused liposomal 
nanoparticles can be reproducibly identified and molecularly described. The human in vivo protein 
corona was rich in multiple low molecular weight and low abundant plasma proteins that could not 
be detected by conventional plasma proteomic analysis, which revealed the potential utilization of 













































































Results and Discussion 
  
Physicochemical characterization of liposomes and human in vivo corona-coated 
liposomes. To characterize the in vivo formed, human-derived protein corona, PEGylated 
doxorubicin-encapsulated liposomes were recovered from the blood circulation of ovarian 
carcinoma patients (n=6) at the end of their first cycle of intravenous Caelyx® infusion (at a dose of 
40 mg/m2), for platinum-resistant disease (Figure 1A). Patient clinical and basic blood analysis 
characteristics are summarized in Table S1. The physicochemical properties of the commercially 
available PEGylated doxorubicin-encapsulated liposomes (Caelyx®) were investigated by dynamic 
light scattering (DLS), ζ-potential measurements and negative stain transmission electron 
microscopy (TEM) before and after their intravenous infusion in patients and are summarized in 
Figures 1B and 1C. Liposomes had a mean hydrodynamic diameter of 82.6 nm, a negative 
surface charge of −33.8 mV and displayed low polydispersity values (<0.1) representing a narrow 
size distribution (Figure 1B). TEM imaging showed well-dispersed, drug-encapsulated round 
shaped vesicles, with their size correlating that of DLS measurements (Figure 1C).  
Immediately after the completion of the intravenous infusion of Caelyx® (that lasted for 
approximately 90 mins), blood (~10ml) was collected and plasma was prepared without delay by 
centrifugation. A two-step purification protocol (size exclusion chromatography and membrane 
ultrafiltration) was then employed for the isolation of liposome-corona complexes and the complete 
elimination of unbound proteins, as we have previously described (Figure S1).[4, 5] It should be 
noted that although the protein corona is often described as a multi-layered structure consisting of 
an inner layer of tightly bound proteins (‘hard corona’) and an outer dynamically-bound layer of 
proteins (‘soft corona’), current purification protocols might disturb loosely bound biomolecules. 
Therefore, the existence and the biological relevance of the ‘soft corona’ remain unclear and we 
can only refer to the analytically accessible protein corona.[18] 
Dynamic light scattering measurements of corona-coated liposomes demonstrated that their 
size distribution broadened (Figure 1B). Formation of the corona is often associated with an 
increase in the mean nanoparticle diameter since layers of proteins are adhered onto the NP 
surface. In the case of soft nanomaterials however, adsorption of proteins could also lead to a 
reduction in their mean diameter due to osmotic “shrinkage”. This has been previously reported [4, 5, 
19] and also observed here in the case of human in vivo and ex vivo corona-coated liposomes 
(Figures 1B and S2). In addition, our data showed that the mean surface charge of liposomes 
remained negative after their interaction with plasma proteins (Figure 1B and S2) in agreement 




































































positively charged proteins, as electrostatic interactions are not the only driving force at the NP–
protein interface.[20]   
Moreover, TEM imaging revealed well dispersed and corona-coated liposomes that retained 
an intact structure after recovery and purification (Figure 1C). Although protein corona is usually 
illustrated as a dense layer covering the entire surface of a nanoparticle, this has not been 
experimentally confirmed. In agreement with our previously reported observations in rodents,[4, 5] 
the human in vivo protein corona did not appear to coat entirely the liposome surface. Cryo-EM 
imaging of the recovered liposomes further confirmed the presence of a protein corona adsorbing 
around the doxorubicin-encapsulated (Caelyx®) liposomes, but without fully covering their surface 
(Figure 1C). Similarly, Kokkinopoulou M et al., have recently described the protein corona formed 
around polystyrene NPs as an undefined and unfolded network surrounding the NP surface.[21] 
Moreover, small vesicular structures surrounding the liposome surface could be observed by TEM 
in Figure 1C. We hypothesize that these could be either osmotically shrunk liposomes or blood-
circulating extracellular vesicles adsorbed onto the surface of liposomes. Based on these 
observations, further studies will be needed to explore the adherence of other molecules or 
vesicular structures onto the surface of blood-circulating NPs. 
 
Characterization of the human in vivo protein corona.  Previous anti-opsonisation studies have 
emphasized that the total amount of protein adhered onto NPs can be used to predict the NPs 
blood circulation time.[22-24] Even though the overall protein adsorption is moderated by the PEG 
chains present onto the NPs surface, it cannot be fully suppressed.[3-5] In agreement with these 
previous findings, the present study demonstrated that PEGylated nanoscale surfaces are not 
entirely inert and interact with plasma proteins upon intravenous administration in humans.  
 To investigate the total amount of protein adsorbed, we calculated the protein binding ability 
(Pb), defined as the amount of protein associated with each µmole of lipid. As shown in Figure 2A, 
the average Pb value observed was 1532 µg of protein/ µmole of lipid, that is more than 10 times 
higher than what was obtained for the same liposome composition (produced in the laboratory) 
after injection in healthy CD-1 mice.[5] Whether this is a result of mouse-to-human differences 
and/or due to the neoplastic disease present at an advanced stage in the patients that participated 
in this study, is difficult to conclude and will require further investigation. Ex vivo incubations of 
Caelyx® liposomes with plasma samples, obtained from the same patients before Caelyx® infusion 
were performed as a control. As shown in Figure S3, a significantly lower average Pb value was 




































































human plasma samples cannot predict the formation of protein corona under realistic in vivo 
conditions.[4]  
The manner in which proteins adsorb and pack onto the NP surface is highly dependent on 
their physicochemical properties and especially their size, shape and functionalization. However, 
concrete relationships between the nanomaterial synthetic identity and their ensuing biological 
identity in physiological environments remain vague and unpredictable.[1] Distinct proteins could be 
either enriched or displayed weak affinity for the NP surface depending on the balance between 
their rates of association (Kon) and dissociation (Koff).[25] It has previously been shown by us in vivo 
[5] and others in vitro [26, 27] that the protein corona is a temporally dynamic entity. In complex 
biofluids, such as blood, proteins present at high concentrations are characterized by high Kon 
values and therefore have high possibility to interact with the surface of NPs. However, these 
proteins might be replaced by other molecules of lower abundance, but of higher binding energy 
(characterized by low Koff values). Our previous time evolution studies in rodents revealed that a 
molecularly rich in vivo protein corona was formed around PEGylated liposomal doxorubicin 
(Caelyx®) as early as 10min post-injection. Even though the total amount of protein adsorbed and 
the identity of the corona proteins did not significantly change, the abundance of each protein 
fluctuated over time, indicating that competitive exchange processes were taking place. 
Interestingly, liposomes were coated by a complex mixture of low MW proteins at all different time 
points of investigation.[5] 
To examine whether our previous observation in rodents applies also under the in vivo 
conditions in humans, we comprehensively identified the protein molecules that self-assembled to 
form the corona around the intravenously infused liposomes by mass spectrometry. Surface-bound 
proteins were classified according to their molecular weight. As illustrated in Figure 2B, plasma 
proteins with MW < 80 accounted for almost 80% of the protein coronas formed. It is possible that 
the low MW proteins identified (Figure 2B) have high affinity and interact directly with the surface 
of PEGylated liposomes and/or they are trapped between other corona-carrier proteins that are 
adhered to the NPs surface.  
To further understand the protein composition of the in vivo human corona, the average 
value (n=6 patients) of relative protein abundance (RPA) for each identified protein was calculated. 
Figure 2C summarizes the 20 most abundant proteins associated onto the surface of recovered 
Caelyx® liposomes for all patients. The most abundant corona protein was full-length cDNA clone 
CS0DD006YL02 (with accession number Q86TT1; SwissProt database). To the best of our 
knowledge, this protein has not been previously reported to associate with the surface of liposomes 




































































shown to interact with maltose-functionalized PEGylated hybrid magnetic NPs after their incubation 
with fractionated human plasma sample.[28] The 20 most abundant proteins identified in each 
patient and their respective RPA values are also shown in Table S2 to further illustrate the 
consistency of the above observation. The fact that the most abundant corona proteins were 
common between the 6 patients illustrates the consistency of liposome-protein interactions. Out of 
445 corona proteins identified, 122 were repeatedly detected in all patients (Figure S4 and Table 
S5).  
In agreement with our previous investigations of the liposomal protein coronas in mice,[5] 
immunoglobulins, lipoproteins and complement proteins were the most abundant classes of 
proteins, contributing to 28%, 9% and 4% of the total protein content respectively (Figure 2D and 
Tables S2-S3). The presence of opsonins (such as immunoglobulins), known to activate the 
mononuclear phagocytic system (MPS), can favor recognition and clearance of the blood-
circulating PEGylated liposomes used in this study. However, the PEG-mediated inhibition of 
interactions between nanoparticles and circulating blood cells has been proposed to explain their 
long circulation time.[29] As the molecular identification of the human corona suggests, lipoproteins 
were the second most abundant class of proteins, proposed to have dysopsonic activity (i.e. favor 
long blood circulation), possibly via competitive binding for the liposomal surface with opsonic 
proteins.[30] The high affinity and adherence of lipoproteins to the lipid surface of Caelyx® NPs 
observed, was not surprising considering that blood circulating lipoproteins are involved in lipid and 
cholesterol transport and metabolism. 
 Intravenously infused, doxorubicin-encapsulated PEGylated liposomes have also been 
shown to interact with the complement system, in some cases triggering a transient and mostly 
mild hypersensitive reactions known as C-activation related pseudoallergy (CARPA).[31, 32] Despite 
the presence of several key complement cascade proteins in the liposomal corona involved in the 
classical (complement C1s and C1qb, C4b binding protein) alternative (complement factor h, 
complement C3) and in lectin (mannan-binding lectin serine protease) pathways of activation 
(Figure 2D and Table S3), none of the patients in our study experienced a clinically symptomatic 
reaction to Caelyx® infusion. 
 
Patient-by-patient blood-circulation proteome analysis. Blood predominantly contains high 
abundance, high MW proteins, such as albumin and immunoglobulins, that hamper the detection of 
the lower MW blood proteomic fractions.[33] There is an urgent need for tools to facilitate the 
discovery of new and, more importantly, combinations of protein molecule panels to improve early 




































































high-throughput proteomic discovery platforms that will enable the identification of blood-buried 
molecules are of immediate clinical importance.  
The fact that albumin ‘masking’ was largely eliminated from in the in vivo human-derived 
corona prompted us to investigate further whether liposomes interacted with plasma proteins that 
could not be directly detected by plasma proteomic analysis. Proteins associated with liposomes in 
vivo were separated by SDS-PAGE and visualized by Imperial Protein stain, as illustrated in Figure 
3A. Contrary to plasma control, the distinct bands of corona proteins, even at the low MW region, 
confirmed the ability of liposomes to surface-capture low abundant proteins minimizing the ‘noise’ 
from highly abundant proteins (Figure 3A).  
Low molecular weight proteins are easily cleared from blood circulation (mainly through 
proteolytic plasma clearance), which limits their detection by conventional plasma proteomic 
analysis.[34-36] The only way a small molecule can remain in the blood circulation for longer periods 
is to adhere to a long-circulating high abundance protein, such as albumin. [35, 36] The adherence of 
smaller MW biomolecules onto the surface of NPs once injected in the bloodstream, could 
significantly increase their blood circulation and allow their successful ‘enrichment’ for detection. 
Therefore, the characterization of the purified corona proteins can be employed as a ‘fractionation’ 
plasma tool that addresses the signal-to-noise challenge.  
The nanoparticle-mediated capture of low MW proteins from biofluids has been so far 
attempted exclusively ex vivo. For instance, Nanotrap® technology developed by Liotta and co-
workers, uses core shell hydrogel nanoparticles as protein harvesters. This technology is based on 
the NP-mediated size and charge dependent fractionation of complex biofluids, such as plasma 
and urine, prior to proteomic analysis. The porous outer shell of NIPAm (N-isopropylacrylamide) 
NPs blocks the entry of high MW proteins, while the internal core contains covalently attached 
chemical affinity baits which capture low MW proteins.[37, 38]   
To compare the human corona proteins with the plasma proteome, we analyzed plasma 
samples obtained from the same patients before the infusion of Caelyx®. The Venn diagram in 
Figure 3B illustrates the number of common and unique proteins between the liposomal corona 
and plasma, as identified by mass spectrometry. A significantly higher total number of proteins was 
detected in the corona samples in comparison to the number of proteins identified when plasma 
samples were analyzed (Figure 3B). In addition, the most abundant plasma proteins were not the 
predominant corona proteins, as depicted in Figure 3C and Tables S3 and S4. Strikingly, the most 
abundant corona protein (full-length cDNA clone, CS0DD006YL02), which contributed to 8% of the 
total protein content, was not detected in any of the plasma control samples (Figure 3C and Table 




































































spectrometry analysis of arachnoid cyst fluid,[39] peritoneal effluent[40] and saliva[41], current 
proteomic approaches fail to detect this low abundant protein in complex mixtures like plasma.  
The above findings prompted us to further investigate the molecular composition of the ex 
vivo protein corona after the incubation of Caelyx® liposomes with plasma samples obtained from 
the same ovarian carcinoma patients before Caelyx® infusion. In agreement with our previous data 
in rodents, a more complex molecular fingerprint was detected for the in vivo protein corona in 
comparison to its counterpart ex vivo corona (Figure S5). Despite the fact that the cDNA clone 
CS0DD006YL02 protein was not detected by mass spectrometry in any of the control plasma 
samples, it was identified as the most abundant protein of both the in vivo and ex vivo formed 
protein coronas (Figure 2A and Table S6). Control investigations of the ex vivo corona formed 
onto Caelyx® liposomes upon incubation with plasma samples from healthy volunteers (Table S6) 
were also performed. The cDNA clone CS0DD006YL02 protein was found to be the 5th most 
abundant protein in the control cohort suggesting that tumorigenesis may affect the dynamics of 
corona formation. Overall, the above data provide an initial evidence that the liposome protein 
corona results in an ‘enriched’ sampling of the blood proteome which renders the need for much 
more work on the biomarker discovery front necessary, but beyond the scope of this study. 
Previously unreported experimental evidence that a biomolecule corona self-assembles 
around nanoparticles in humans while in their blood circulation has been offered in the present 
study. The successful recovery and purification of corona-coated lipid bilayer vesicles from the 
blood circulation of ovarian carcinoma patients allowed the proteomic analysis of the human in vivo 
protein corona. We demonstrated that the clinically-used liposomal nanoparticles interact and can 
be stably coated with a complex mixture of plasma proteins, including low MW and low-abundant 
molecules otherwise ‘masked’ under the overwhelming signal of highly abundant proteins (such as 
albumin and immunoglobulins). The corona-based elimination of this ‘masking’ effect, enabled the 
uncovering of multiple protein molecules that could not be detected by plasma sample analysis 
performed in comparison. This work is thought to act as the impetus for many future studies needed 
to improve our further understanding of how the human in vivo biomolecule corona can affect the 
overall clinical performance of NPs, but also provide the technology springboard to allow the clinical 











































































Ethical Approvals. This project was reviewed and approved by the Manchester Cancer Research Centre 
Biobank Sample Access Committee and all sample collection was conducted under the MCRC Biobank 
Research Tissue Bank Ethics (ref: 07/H1003/161+5). 
 
Blood sample collection. Caelyx® is indicated for the treatment of advanced ovarian cancer in women who 
have failed a first-line platinum-based chemotherapy. Patients receive in total 6 cycles of Caelyx with cycle 
frequency 28 days. Eligible cases for this study included women with recurrent ovarian cancer commencing 
single agent Caelyx® for the first time, at a dose of 40 mg/m2. Caelyx® contains 2mg/ml doxorubicin 
hydrochloride encapsulated in a PEGylated liposomal formulation (16 mg lipid content). Based on 
established pharmacokinetic data for the clinically-used PEGylated liposomes encapsulating doxorubicin, the 
time of blood collection (after the completion of infusion that lasted for approximately 90 mins), the majority of 
injected liposomal nanoparticles are still in blood circulation.[14, 42]  
 
Paired plasma samples (before and immediately after cycle 1 infusion) were collected into commercially 
available anticoagulant-treated tubes (K2 EDTA BD Vacutainer®). Plasma was then prepared by inverting 10 
times the collection tubes to ensure mixing of blood with EDTA and subsequent centrifugation for 12 minutes 
at 1300 RCF at 4 °C. Following centrifugation supernatant was immediately collected into labelled Protein 
LoBind Eppendorf Tubes and samples were maintained on ice while handling. 
 
Separation of corona-coated liposomes from unbound and weakly bound proteins. Corona-coated 
liposomes were separated form excess plasma proteins by size exclusion chromatography followed by 
membrane ultrafiltration as we have previously described.[4, 5]  
 
Ex vivo protein corona formation. To investigate the ex vivo protein corona, Caelyx® liposomes were 
incubated with plasma samples obtained from the same 6 patients prior to Caelyx® infusion and from healthy 
donors. Considering the impact of the anti-coagulant agent on the formation of protein corona,[43] the same 
protocol was followed for the preparation of plasma samples, as described above for the in vivo experiment 
(K2 EDTA BD Vacutainer® tubes, centrifugation for 12 minutes at 1300 RCF at 4 °C). The ex vivo protein 
corona was allowed to form using the same liposome concentration (0.15 mM) as that extracted in 1 mL of 
plasma from intravenously injected patients. Liposomes were incubated with plasma for 90 min at 37°C in 
orbital shaker at 250 rpm. The purification of the ex vivo corona-coated liposomes was performed as 
described above for the in vivo recovered liposomes. 
 
Size and zeta potential measurements using dynamic light scattering (DLS). Liposome size and surface 
charge were measured using Zetasizer Nano ZS (Malvern, Instruments, UK).  
 
Transmission Electron Microscopy (TEM). Liposomes were stained by uranyl acetate solution 1% and 
visualized with transmission electron microscopy (FEI Tecnai 12 BioTwin) before and after their in vivo 
interaction with plasma proteins. Samples were diluted to 0.5 mM lipid concentration and carbon Film Mesh 
Copper Grids (CF400-Cu, Electron Microscopy Science) were used.  
 
Cryo-electron Microscopy. EM grids of liposomes were prepared in a FEI Vitrobot using 3μL of sample 
absorbed to freshly glow-discharged R 3.5/1 Quantifoil grids. Grids were blotted for 4-5 s in a 95% humidity 
chamber before plunge freezing in to liquid ethane. Data were imaged on a Tecnai T20 (FEI) electron 
microscope operating at 200 keV with a Gatan 626 cryo stage. Images were recorded on a 4K Gatan 
Ultrascan CCD camera under low-dose conditions  between 0.5 and 2.0 μm defocus and at 3.8 Å/pixel and 
had a maximum electron dose of <25 electrons/Å2. 
 
SDS-PAGE electrophoresis. Proteins associated with 0.025 μM of liposomes were loaded onto a 4-20% 
NOVEX Tris-Glycine Protein Gel (ThermoFisher Scientific). The gel was run until the proteins neared the end 






































































Quantification of adsorbed proteins. Proteins associated with recovered liposomes were quantified by 
BCA Protein assay kit according to manufacturer's instructions.  To make sure that liposomes in solution do 
not interfere with the absorbance at 562 nm we measured the absorbance of corona-coated liposomes in 
HBS buffer and subtract it from the total absorbance, measured when corona-coated liposomes were mixed 
with the BCA reagent. Lipid concentration was quantified by Stewart assay and Pb values (μg of protein/µM 
lipid) were then calculated. 
 
Mass Spectrometry. In-gel digestion of corona (40ug) and plasma (5ul) proteins was performed prior to LC-
MS/MS analysis, as we have previously described.[4-6] Digested samples were analysed by LC-MS/MS using 
an UltiMate® 3000 Rapid Separation LC (RSLC, Dionex Corporation, Sunnyvale, CA) coupled to a Q 
Exactive™ Hybrid Quadrupole-Orbitrap™ (Thermo Fisher Scientific, Waltham, MA) mass spectrometer. Data 
produced were searched using Mascot (Matrix Science UK), against the SwissProt_2016_04 database with 
taxonomy of [human] selected. 
 
The Scaffold software (version 4.3.2, Proteome Software Inc.) was used for relative protein quantification 
based on spectral counting. Protein identifications were accepted if they could be established at greater than 
99.0% probability and contained at least 2 identified peptides. Semi quantitative assessment of the protein 
amounts was conducted using normalized spectral countings as previously described.[4-6] Heatmaps of 
Relative Protein Abundance (RPA) values were prepared using Plotly 2.0 software.  
 
Statistical analysis. Statistical analysis of the data was performed using GraphPad Prism software. One-
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Figure 1: The effect of protein corona formation on the physicochemical characteristics and 
morphology of liposomes. (A) Schematic description of the experimental design. PEGylated, doxorubicin-
encapsulated liposomes (Caelyx®) were infused intravenously in patients with recurrent ovarian carcinoma 
and subsequently recovered from the blood circulation immediately on completion of their first-ever cycle of 
Caelyx® treatment. Corona coated liposomes were isolated from blood components and protein corona was 
quantitatively and qualitatively characterized; (B) Table shows the mean diameter (nm), ζ-potential (mV) and 
polydispersity index (PDI) values of bare and corona-coated liposomes recovered from the blood circulation 
of 6 adenocarcinoma patients. Representative size and ζ-potential distributions of corona-coated liposomes 
recovered from Patient 1 are also shown; (C) Negative stain TEM and Cryo-EM imaging of liposomes after 
their I.V injection and recovery from ovarian carcinoma patients. All scale bars are 100nm. 
 
Figure 2: Characterization of in vivo protein corona: (A) The total amount of proteins adsorbed in vivo 
onto liposomes recovered from the blood circulation of ovarian carcinoma patients. Pb values (μg of 
protein/µM lipid) represent the mean and standard deviation from 6 patients; (B) Classification of the corona 
proteins identified according to their molecular mass; (C) Most-abundant proteins (top-20) identified in the 
protein corona of PEGylated doxorubicin-encapsulated liposomes by LC-MS/MS. Relative protein abundance 
(RPA) values represent the average and standard deviation from 6 ovarian carcinoma patients; (D) The 
relative percentage of immunoglobulins, lipoproteins and complement proteins identified in the protein 
corona. The percentage of relative protein abundance (%RPA) for each protein class represents the average 
from 6 ovarian carcinoma patients. 
Figure 3: Blood-circulation proteome analysis: (A) Imperial stained SDS-PAGE gel of corona proteins 
associated with liposomes in the blood circulation of 6 ovarian carcinoma patients and plasma control; (B) 
Venn diagram reports the number of unique and common proteins between corona and plasma proteins and 
their respective overlaps as identified by LC-MS/MS. Proteins were identified in at least one of the six plasma 
and/or corona samples; (C) Heatmap of RPA (%) of corona and plasma proteins, as identified by LC-MS/MS. 
Only proteins with RPA>1% on at least one of the samples are shown. Protein-rows are sorted according to 
the RPA% values (from highest to lowest) of the first sample (plasma, patient 1). The full list of proteins 



















































































































































































































































































































Figure S1: Separation of protein corona coated liposomes from unbound proteins. Corona-coated 
liposomes were separated from excess plasma proteins by size exclusion chromatography followed by 
membrane ultrafiltration. Immediately after plasma preparation, plasma samples were loaded onto a 
Sepharose CL-4B (SIGMA-ALDRICH) column (15x1.5cm) equilibrated with HBS. Fractions containing 
liposomes (fractions 4,5&6) were then pooled together and concentrated to 500 μl by centrifugation using 
Vivaspin 6 column (10000 MWCO, Sartorious, Fisher Scientific) at 3000rpm. Vivaspin 500 centrifugal 
concentrator (1 000 000 MWCO, Sartorious, Fisher Scientific) was then used at 3000 rpm, to further 
concentrate the samples to 100 μl and to ensure separation of protein-coated nanoparticles from the 
remaining large unbound proteins. This procedure results in the filtration of unbound proteins while corona-
coated liposomes because of their higher MW remain at the top of the membrane. Imperial stained SDS-
PAGE shows that any remaining proteins in Chromatographic Fractions 4,5 and 6 were removed to the 
filtrate of Viva Spin  (wash1) and no proteins remained at the top of the membrane (column residue). Column 















































































Figure S2: The effect of the ex vivo formed protein corona on the physicochemical characteristics of 
liposomes.  Mean diameter (nm), ζ-potential (mV) and polydispersity index (PDI) values and representative 
size and ζ-potential distributions of bare and corona-coated liposomes incubated ex vivo with plasma 
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Figure S3: Comparison of in vivo vs. ex vivo protein coronas. The total amount of proteins adsorbed 
onto liposomes in vivo after recovery from the blood circulation of ovarian carcinoma patients and after their 
ex vivo incubation with plasma samples obtained from the same patients before the infusion of Caelyx®. Pb 
values (μg of protein/µM lipid) represent the mean and standard deviation from 6 patients;** indicates p<0.01 

























































































Figure S4: Characterisation of the in vivo protein corona: Venn diagram reports the number of unique 
and common proteins between the liposomal coronas formed in 6 ovarian carcinoma patients and their 
respective overlaps as identified by LC-MS/MS. The full list of common proteins identified in the liposomal 

















































































Supporting Figure 5 
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Figure S5: Blood-circulation proteome analysis. Total number of proteins identified by mass spectrometry 
analysis of plasma samples obtained from ovarian carcinoma patients and corona samples formed ex vivo 
and in vivo. Values represent the mean and standard deviation from 6 patients; * indicates p<0.05 




















































































Supporting Table 1 
 
Table S1: Patient cohort clinical and basic blood characteristics. 
Age (yrs) Median 71 (56-77) 
Prior lines of chemotherapy Median 2 (range 2-3) 
Histological subtype High grade serous carcinoma- 5 
Moderately differentiated carcinoma NOS-1 
FIGO stage at diagnosis IIIC-5 
IVA-1 
Baseline CA125 (at commencement of Caelyx) (U/ml) Median 665 (103-3081) 
Albumin (at commencement of Caelyx) (g/L) Median 41 (30-44) 











































































Supporting Table 2 
Table S2: Most-abundant proteins (top-20) identified by LC-MS/MS in the protein corona of PEGylated 





Identified Proteins RPA% Identified Proteins RPA%
1 Full-length cDNA clone CS0DD006YL02 7.68 Serum albumin 5.47
2 Ig mu chain C region(A0A087X2C0) 5.42 Full-length cDNA clone CS0DD006YL02 4.90
3 Ig mu chain C region(A0A087WYJ9) 5.17 Fibrinogen beta chain 3.95
4 Fibrinogen beta chain 5.17 Ig mu chain C region(A0A087X2C0) 3.53
5 Alpha-2-macroglobulin 3.49 Ig mu chain C region(A0A087WYJ9) 3.40
6 Fibrinogen alpha chain 3.25 Alpha-2-macroglobulin 3.12
7 C4b-binding protein alpha chain 2.55 Fibrinogen alpha chain 2.70
8 Fibrinogen gamma chain 1.92 Putative uncharacterized protein DKFZp686C11235 2.33
9 Protein IGHV3-72 1.84 C4b-binding protein alpha chain 2.10
10 Haptoglobin 1.65 Fibrinogen gamma chain 1.91
11 Haptoglobin (Fragment) 1.41 Putative uncharacterized protein DKFZp686C15213 1.90
12 Actin, cytoplasmic 2 1.40 Apolipoprotein B (Including Ag(X) antigen) 1.74
13 Serum albumin 1.36 Ig gamma-3 chain C region 1.69
14 Apolipoprotein B (Including Ag(X) antigen) 1.31 IGH protein 1.67
15 Myosin-reactive immunoglobulin heavy chain variable region 1.18 Haptoglobin (Fragment) 1.66
16 IGH protein 1.16 Ig gamma-1 chain C region 1.61
17 Myosin-reactive immunoglobulin heavy chain variable region (Fragment) 1.15 Uncharacterized protein (Q6N089) 1.57
18 GCT-A10 heavy chain variable region (Fragment) 1.14 IgG H chain 1.56
19 Uncharacterized protein (A8K008) 1.13 Uncharacterized protein(A8K008) 1.54
20 Lectin galactoside-binding soluble 3 binding protein isoform 1 (Fragment) 1.11 Haptoglobin 1.49
Identified Proteins RPA % Identified Proteins RPA %
1 Full-length cDNA clone CS0DD006YL02 6.91 Full-length cDNA clone CS0DD006YL02 7.99
2 Ig mu chain C region(A0A087X2C0) 4.81 Ig mu chain C region(A0A087X2C0) 5.69
3 Serum albumin 4.72 Ig mu heavy chain disease protein 4.68
4 Ig mu chain C region(A0A087WYJ9) 4.66 Alpha-2-macroglobulin 4.55
5 Fibrinogen beta chain 3.60 Lipoprotein B (Fragment) 3.64
6 Fibrinogen alpha chain 3.28 APOB protein 3.42
7 Putative uncharacterized protein DKFZp686C11235 2.38 Apolipoprotein B (Including Ag(X) antigen) 3.37
8 Fibrinogen gamma chain 2.22 Fibrinogen beta chain 3.05
9 IGH protein 2.11 Fibrinogen alpha chain 2.77
10 Ig gamma-1 chain C region 2.03 Apolipoprotein B variant (Fragment) 2.68
11 IgG H chain 2.03 Protein IGHV3-72 2.11
12 Uncharacterized protein (A8K008) 2.02 Immunglobulin heavy chain variable region (Fragment) 1.86
13 Uncharacterized protein (Q6N089) 1.96 Fibrinogen gamma chain 1.45
14 Haptoglobin 1.92 Apolipoprotein E isoform 1 (Fragment) 1.34
15 Ig gamma-1 chain C region 1.91 Serum albumin 1.32
16 Protein IGHV3-72 1.90 Immunoblobulin light chain (Fragment) 1.23
17 Putative uncharacterized protein DKFZp686G11190 1.84 Myosin-reactive immunoglobulin heavy chain variable region (Fragment) 1.17
18 Haptoglobin (Fragment) 1.77 IGK protein 1.10
19 Alpha-2-macroglobulin 1.76 Lambda-chain (AA -20 to 215) 1.02
20 Ig gamma-3 chain C region 1.59 C4b-binding protein alpha chain 0.98
Identified Proteins RPA% Identified Proteins RPA%
1 Full-length cDNA clone CS0DD006YL02 12.44 Full-length cDNA clone CS0DD006YL02 8.00
2 Ig mu chain C region(A0A087X2C0) 8.99 Ig mu chain C region(A0A087X2C0) 5.76
3 Ig mu chain C region(A0A087WYJ9) 8.65 Ig mu chain C region(A0A087WYJ9) 5.46
4 Apolipoprotein B (Including Ag(X) antigen) 3.79 APOB protein 4.92
5 APOB protein 3.79 Apolipoprotein B (Including Ag(X) antigen) 4.52
6 Alpha-2-macroglobulin 3.48 Alpha-2-macroglobulin 4.45
7 Protein IGHV3-72 2.85 Fibrinogen alpha chain 3.93
8 Immunglobulin heavy chain variable region (Fragment) 2.28 Fibrinogen beta chain 3.43
9 Fibrinogen alpha chain 1.96 Actin, cytoplasmic 2 2.00
10 C4b-binding protein alpha chain 1.95 C4b-binding protein alpha chain 1.66
11 GCT-A10 heavy chain variable region (Fragment) 1.80 Protein IGHV3-72 1.60
12 MS-D3 heavy chain variable region (Fragment) 1.74 Actin, alpha skeletal muscle 1.32
13 Fibrinogen beta chain 1.52 Fibrinogen gamma chain 1.31
14 Haptoglobin (Fragment) 1.24 Apolipoprotein E isoform 1 (Fragment) 1.26
15 GCT-A1 heavy chain variable region (Fragment) 1.23 Serum albumin 1.25
16 Apolipoprotein E isoform 1 (Fragment) 1.20 Haptoglobin 1.22
17 Haptoglobin 1.06 Haptoglobin (Fragment) 1.22
18 Immunoblobulin light chain (Fragment) 1.03 Apolipoprotein C-III 1.07
19 Myosin-reactive immunoglobulin heavy chain variable region (Fragment) 0.99 Myosin-reactive immunoglobulin heavy chain variable region (Fragment) 0.97
20 Lambda-chain (AA -20 to 215) 0.97 Vinculin, isoform CRA_c 0.94
Patient 1 Patient 2
Patient 3 Patient 4




































































Supporting Table 3 
Table S3: Characterization of in vivo protein corona.  Full list of all the proteins identified in the liposomal 
protein corona recovered from 6 ovarian carcinoma patients (across all samples). 

















Full-length cDNA clone CS0DD006YL02 of Homo 
sapiens (human) OS=Homo sapiens PE=2 SV=1 Q86TT1_HUMAN 41 7.680 4.897 6.908 7.987 12.443 7.997 7.985 2.476 
2 
Ig mu chain C region OS=Homo sapiens 
GN=IGHM PE=1 SV=1 A0A087X2C0_HUMAN 64 5.419 3.529 4.812 5.693 8.994 5.756 5.701 1.813 
3 
Ig mu chain C region OS=Homo sapiens 
GN=IGHM PE=1 SV=1 A0A087WYJ9_HUMAN 66 5.174 3.402 4.659 0.000 8.654 5.457 4.558 2.831 
4 
Alpha-2-macroglobulin OS=Homo sapiens 
GN=A2M PE=1 SV=3 A2MG_HUMAN 163 3.494 3.119 1.758 4.549 3.482 4.448 3.475 1.018 
5 
Fibrinogen beta chain OS=Homo sapiens 
GN=FGB PE=1 SV=2 FIBB_HUMAN (+1) 56 5.166 3.952 3.604 3.050 1.524 3.431 3.454 1.191 
6 
Fibrinogen alpha chain OS=Homo sapiens 
GN=FGA PE=1 SV=2 FIBA_HUMAN 95 3.253 2.704 3.282 2.766 1.964 3.927 2.983 0.666 
7 
Apolipoprotein B (Including Ag(X) antigen) 
OS=Homo sapiens GN=APOB PE=4 SV=1 C0JYY2_HUMAN 516 1.309 1.744 1.096 3.368 3.794 4.518 2.638 1.439 
8 
Serum albumin OS=Homo sapiens GN=ALB 
PE=1 SV=2 ALBU_HUMAN 69 1.359 5.469 4.718 1.320 0.692 1.252 2.468 2.062 
9 
APOB protein OS=Homo sapiens GN=APOB 
PE=2 SV=1 Q7Z7Q0_HUMAN 92 0.000 0.000 1.205 3.421 3.786 4.924 2.223 2.102 
10 
Protein IGHV3-72 OS=Homo sapiens GN=IGHV3-
72 PE=1 SV=1 A0A087WW89_HUMAN 11 1.840 1.120 1.904 2.112 2.853 1.602 1.905 0.575 
11 
C4b-binding protein alpha chain OS=Homo 
sapiens GN=C4BPA PE=1 SV=2 C4BPA_HUMAN 67 2.553 2.098 1.179 0.979 1.953 1.657 1.736 0.589 
12 
Fibrinogen gamma chain OS=Homo sapiens 
GN=FGG PE=1 SV=3 FIBG_HUMAN 52 1.916 1.913 2.224 1.445 0.757 1.311 1.594 0.530 
13 
Haptoglobin (Fragment) OS=Homo sapiens 
GN=HP PE=1 SV=1 H3BS21_HUMAN 25 1.407 1.661 1.771 0.820 1.238 1.222 1.353 0.343 
14 
Haptoglobin OS=Homo sapiens GN=HP PE=1 
SV=4 H0Y300_HUMAN 49 1.653 1.490 1.923 0.734 1.056 1.223 1.347 0.429 
15 
IGH@ protein OS=Homo sapiens GN=IGH@ 
PE=1 SV=1 Q6GMX6_HUMAN 51 1.160 1.673 2.109 0.813 0.650 0.438 1.140 0.643 
16 
Ig gamma-1 chain C region OS=Homo sapiens 
GN=IGHG1 PE=1 SV=1 A0A087WV47_HUMAN (+1) 51 1.055 1.611 2.035 0.893 0.529 0.611 1.122 0.590 
17 
Uncharacterized protein OS=Homo sapiens PE=1 
SV=1 A8K008_HUMAN 52 1.127 1.545 2.023 0.928 0.502 0.565 1.115 0.587 
18 
Uncharacterized protein OS=Homo sapiens 
GN=DKFZp686P15220 PE=1 SV=1 Q6N089_HUMAN 52 1.035 1.571 1.959 0.797 0.468 0.497 1.054 0.601 
19 IgG H chain OS=Homo sapiens PE=1 SV=1 S6B291_HUMAN 51 1.013 1.557 2.025 0.795 0.451 0.415 1.043 0.638 
20 
Actin, cytoplasmic 2 OS=Homo sapiens 
GN=ACTG1 PE=1 SV=1 ACTG_HUMAN (+1) 42 1.395 1.141 0.453 0.835 0.421 2.001 1.041 0.605 
21 
Ig gamma-1 chain C region OS=Homo sapiens 
GN=IGHG1 PE=1 SV=1 A0A087WYC5_HUMAN 52 0.932 1.474 1.913 0.718 0.340 0.373 0.958 0.626 
22 
GCT-A10 heavy chain variable region (Fragment) 
OS=Homo sapiens PE=2 SV=1 A0A120HG46_HUMAN 14 1.142 0.717 1.088 0.651 1.800 0.336 0.956 0.510 
23 
cDNA FLJ14473 fis, clone MAMMA1001080, 
highly similar to Homo sapiens SNC73 protein 
(SNC73) mRNA OS=Homo sapiens PE=2 SV=1 Q96K68_HUMAN 53 1.045 1.412 1.015 0.851 0.551 0.776 0.942 0.292 
24 
Haptoglobin-related protein OS=Homo sapiens 
GN=HPR PE=2 SV=2 HPTR_HUMAN 39 1.093 1.135 1.135 0.654 0.816 0.738 0.929 0.217 
25 
Putative uncharacterized protein 
DKFZp686G11190 OS=Homo sapiens 
GN=DKFZp686G11190 PE=2 SV=1 Q6MZQ6_HUMAN 52 0.891 1.404 1.840 0.692 0.323 0.350 0.917 0.602 
26 
Myosin-reactive immunoglobulin heavy chain 
variable region (Fragment) OS=Homo sapiens 
PE=2 SV=1 Q9UL90_HUMAN 12 1.154 0.875 0.992 0.759 0.995 0.539 0.885 0.215 
27 
Putative uncharacterized protein 
DKFZp686C15213 OS=Homo sapiens 
GN=DKFZp686C15213 PE=2 SV=1 Q6MZU6_HUMAN 51 0.606 1.897 1.363 0.679 0.251 0.415 0.868 0.631 
28 
Ig gamma-3 chain C region OS=Homo sapiens 
GN=IGHG3 PE=1 SV=1 A0A087WXL8_HUMAN 57 0.794 1.689 1.587 0.599 0.202 0.289 0.860 0.640 
29 
Apolipoprotein E isoform 1 (Fragment) OS=Homo 
sapiens GN=APOE PE=2 SV=1 A0A0S2Z3D5_HUMAN (+1) 36 0.281 0.482 0.410 1.341 1.203 1.257 0.829 0.486 
30 
Putative uncharacterized protein 
DKFZp686C11235 OS=Homo sapiens 
GN=DKFZp686C11235 PE=2 SV=1 Q6MZV7_HUMAN 52 0.000 2.325 2.380 0.000 0.000 0.000 0.784 1.215 
31 
Ig mu heavy chain disease protein OS=Homo 
sapiens PE=1 SV=1 MUCB_HUMAN 43 0.000 0.000 0.000 4.682 0.000 0.000 0.780 1.911 
32 
IGK@ protein OS=Homo sapiens GN=IGK@ 
PE=1 SV=1 Q6PIL8_HUMAN 26 0.676 0.702 0.677 1.104 0.952 0.520 0.772 0.214 
33 
Complement C3 OS=Homo sapiens GN=C3 PE=1 
SV=2 CO3_HUMAN (+1) 187 0.635 1.376 1.184 0.636 0.260 0.512 0.767 0.425 
34 
Immunglobulin heavy chain variable region 
(Fragment) OS=Homo sapiens PE=4 SV=1 Q0ZCH9_HUMAN 13 0.000 0.000 0.000 1.857 2.278 0.000 0.689 1.076 
35 
Beta-globin OS=Homo sapiens GN=HBB PE=3 
SV=1 D9YZU5_HUMAN (+1) 16 0.499 0.314 1.517 0.541 0.470 0.477 0.636 0.438 
36 
MS-D4 heavy chain variable region 





































































IgG L chain OS=Homo sapiens PE=1 
SV=1 S6BGD6_HUMAN 25 0.490 0.621 0.628 0.893 0.760 0.353 0.624 0.191 
38 
Immunoglobulin heavy chain variant 
(Fragment) OS=Homo sapiens PE=2 SV=1 Q9NPP6_HUMAN 45 0.781 1.105 0.804 0.617 0.413 0.000 0.620 0.380 
39 
Anti-FactorVIII scFv (Fragment) OS=Homo 
sapiens PE=2 SV=1 A2KBC6_HUMAN 25 0.725 0.456 0.666 0.747 0.831 0.235 0.610 0.223 
40 
Lipoprotein B (Fragment) OS=Homo 
sapiens GN=APOB PE=4 SV=1 S5FLF7_HUMAN 10 0.000 0.000 0.000 3.644 0.000 0.000 0.607 1.488 
41 
Lambda-chain (AA -20 to 215) OS=Homo 
sapiens PE=1 SV=1 A2NUT2_HUMAN 25 0.000 0.803 0.819 1.020 0.973 0.000 0.602 0.474 
42 
Mutant hemoglobin alpha 2 globin chain 
OS=Homo sapiens GN=HBA2 PE=3 SV=1 A0A0K2BMD8_HUMAN (+2) 15 0.604 0.365 1.174 0.395 0.442 0.548 0.588 0.301 
43 
Protein IGHV3-74 (Fragment) OS=Homo 
sapiens GN=IGHV3-74 PE=1 SV=1 A0A0B4J1X5_HUMAN 13 0.656 0.421 0.586 0.596 0.918 0.316 0.582 0.207 
44 
Protein S isoform 1 (Fragment) OS=Homo 
sapiens GN=PROS1 PE=2 SV=1 A0A0S2Z4K3_HUMAN (+2) 75 0.838 0.560 0.374 0.425 0.542 0.705 0.574 0.173 
45 
Myosin-reactive immunoglobulin heavy 
chain variable region (Fragment) 
OS=Homo sapiens PE=2 SV=1 Q9UL88_HUMAN 14 1.180 0.000 0.000 1.171 0.000 0.965 0.553 0.610 
46 
Lectin galactoside-binding soluble 3 
binding protein isoform 1 (Fragment) 
OS=Homo sapiens GN=LGALS3BP PE=2 
SV=1 A0A0S2Z3Y1_HUMAN (+1) 65 1.115 0.414 0.242 0.343 0.354 0.560 0.505 0.317 
47 
Apolipoprotein C-III OS=Homo sapiens 
GN=APOC3 PE=2 SV=1 A3KPE2_HUMAN (+2) 11 0.145 0.166 0.173 0.828 0.643 1.068 0.504 0.399 
48 
cDNA FLJ53691, highly similar to 
Serotransferrin OS=Homo sapiens PE=2 
SV=1 B4E1B2_HUMAN 75 0.376 1.028 0.920 0.352 0.088 0.235 0.500 0.383 
49 
cDNA, FLJ94213, highly similar to Homo 
sapiens pregnancy-zone protein (PZP), 
mRNA OS=Homo sapiens PE=2 SV=1 B2R950_HUMAN (+1) 164 0.481 0.545 0.360 0.592 0.466 0.516 0.493 0.079 
50 
Thrombospondin-1 OS=Homo sapiens 
GN=THBS1 PE=1 SV=2 TSP1_HUMAN 129 0.785 0.350 0.244 0.300 0.363 0.852 0.482 0.264 
51 
Protein IGHV5-51 (Fragment) OS=Homo 
sapiens GN=IGHV5-51 PE=1 SV=1 A0A0C4DH38_HUMAN 13 0.451 0.421 0.439 0.420 0.680 0.407 0.470 0.104 
52 
Vinculin, isoform CRA_c OS=Homo 
sapiens GN=VCL PE=4 SV=1 A0A024QZN4_HUMAN (+2) 117 0.610 0.378 0.228 0.358 0.227 0.944 0.458 0.277 
53 
Fibronectin 1, isoform CRA_n OS=Homo 
sapiens GN=FN1 PE=4 SV=1 A0A024R462_HUMAN 259 0.485 0.384 0.351 0.378 0.469 0.665 0.455 0.116 
54 
Apolipoprotein B variant (Fragment) 
OS=Homo sapiens PE=2 SV=1 Q59HB3_HUMAN 184 0.000 0.000 0.000 2.681 0.000 0.000 0.447 1.094 
55 
Keratin 1 OS=Homo sapiens GN=KRT1 
PE=3 SV=1 H6VRF8_HUMAN (+3) 66 0.452 0.512 0.346 0.545 0.342 0.418 0.436 0.084 
56 
Filamin-A OS=Homo sapiens GN=FLNA 
PE=1 SV=4 FLNA_HUMAN 281 0.595 0.351 0.212 0.311 0.160 0.889 0.420 0.275 
57 
Putative uncharacterized protein 
DKFZp686L19235 OS=Homo sapiens 
GN=DKFZp686L19235 PE=2 SV=1 Q6MZV6_HUMAN 52 0.738 1.000 0.741 0.000 0.000 0.000 0.413 0.463 
58 
Ig heavy chain V-III region BUT OS=Homo 
sapiens PE=1 SV=1 HV306_HUMAN 12 0.355 0.266 0.238 0.493 0.774 0.343 0.412 0.198 
59 
IBM-B2 heavy chain variable region 
(Fragment) OS=Homo sapiens PE=2 SV=1 A0A125QYY9_HUMAN 14 0.381 0.554 0.000 0.423 0.726 0.378 0.410 0.241 
60 
Alpha-1-antitrypsin OS=Homo sapiens 
GN=SERPINA1 PE=1 SV=3 A1AT_HUMAN (+1) 47 0.442 0.738 0.638 0.291 0.150 0.200 0.410 0.239 
61 
Talin-1 OS=Homo sapiens GN=TLN1 
PE=1 SV=3 TLN1_HUMAN 270 0.610 0.370 0.213 0.317 0.170 0.775 0.409 0.236 
62 
Actinin, alpha 1, isoform CRA_a OS=Homo 
sapiens GN=ACTN1 PE=4 SV=1 A0A024R694_HUMAN (+1) 103 0.672 0.443 0.194 0.301 0.146 0.673 0.405 0.231 
63 
Apolipoprotein A-I, isoform CRA_a 
OS=Homo sapiens GN=APOA1 PE=4 
SV=1 A0A024R3E3_HUMAN (+1) 31 0.395 0.442 0.461 0.544 0.242 0.303 0.398 0.110 
64 
Transferrin variant (Fragment) OS=Homo 
sapiens PE=2 SV=1 Q53H26_HUMAN 77 0.374 1.037 0.940 0.000 0.000 0.000 0.392 0.485 
65 
von Willebrand factor OS=Homo sapiens 
GN=VWF PE=1 SV=4 VWF_HUMAN 309 0.760 0.347 0.421 0.124 0.132 0.546 0.388 0.246 
66 
Ig gamma-4 chain C region (Fragment) 
OS=Homo sapiens GN=IGHG4 PE=1 
SV=2 A0A0G2JPD4_HUMAN (+1) 36 0.340 0.837 0.820 0.316 0.000 0.000 0.386 0.373 
67 
von Willebrand factor OS=Homo sapiens 
GN=VWF PE=4 SV=1 L8E853_HUMAN 298 0.771 0.358 0.441 0.000 0.138 0.592 0.383 0.284 
68 
Immunoblobulin light chain (Fragment) 
OS=Homo sapiens PE=1 SV=1 Q0KKI6_HUMAN (+1) 24 0.000 0.000 0.000 1.234 1.032 0.000 0.378 0.588 
69 
Rheumatoid factor RF-ET9 (Fragment) 
OS=Homo sapiens PE=2 SV=1 A2J1N6_HUMAN 13 0.000 0.000 0.586 0.876 0.748 0.000 0.368 0.414 
70 
Coagulation factor XIII A chain OS=Homo 
sapiens GN=F13A1 PE=1 SV=4 F13A_HUMAN 83 0.558 0.341 0.247 0.181 0.117 0.722 0.361 0.234 
71 
Apolipoprotein C-I, isoform CRA_a 






































































Rheumatoid factor RF-ET6 (Fragment) 
OS=Homo sapiens PE=2 SV=1 A2J1N5_HUMAN 10 0.479 0.319 0.238 0.410 0.619 0.000 0.344 0.214 
73 
Complement factor H OS=Homo sapiens 
GN=CFH PE=1 SV=4 CFAH_HUMAN 139 0.383 0.473 0.394 0.295 0.162 0.241 0.325 0.114 
74 
Keratin, type I cytoskeletal 10 OS=Homo 
sapiens GN=KRT10 PE=1 SV=6 K1C10_HUMAN 59 0.370 0.325 0.202 0.440 0.187 0.299 0.304 0.097 
75 
Protein APOC4-APOC2 OS=Homo 
sapiens GN=APOC4-APOC2 PE=1 SV=1 K7ER74_HUMAN 20 0.160 0.205 0.119 0.387 0.398 0.529 0.300 0.162 
76 
MS-D3 heavy chain variable region 
(Fragment) OS=Homo sapiens PE=2 SV=1 A0A0X9T7T4_HUMAN 15 0.000 0.000 0.000 0.000 1.739 0.000 0.290 0.710 
77 
Ig heavy chain V-III region WEA OS=Homo 
sapiens PE=1 SV=1 HV302_HUMAN 12 0.444 0.000 0.238 0.455 0.589 0.000 0.288 0.250 
78 
Uncharacterized protein OS=Homo 
sapiens PE=2 SV=1 A0A5E4_HUMAN 25 0.000 0.000 0.000 0.893 0.831 0.000 0.287 0.446 
79 
Keratin, type I cytoskeletal 9 OS=Homo 
sapiens GN=KRT9 PE=1 SV=3 K1C9_HUMAN 62 0.361 0.302 0.200 0.389 0.171 0.227 0.275 0.089 
80 
cDNA FLJ75066, highly similar to Homo 
sapiens complement component 1, r 
subcomponent (C1R), mRNA OS=Homo 
sapiens PE=2 SV=1 A8K5J8_HUMAN (+1) 80 0.400 0.285 0.280 0.199 0.177 0.272 0.269 0.078 
81 
Epididymis tissue protein Li 173 OS=Homo 
sapiens GN=SERPING1 PE=2 SV=1 E9KL26_HUMAN (+1) 55 0.281 0.490 0.338 0.248 0.080 0.150 0.264 0.144 
82 
Myosin, heavy polypeptide 9, non-muscle, 
isoform CRA_a OS=Homo sapiens 
GN=MYH9 PE=4 SV=1 A0A024R1N1_HUMAN (+1) 227 0.439 0.123 0.103 0.209 0.082 0.626 0.264 0.221 
83 
Cryocrystalglobulin CC1 heavy chain 
variable region (Fragment) OS=Homo 
sapiens PE=2 SV=1 B1N7B6_HUMAN 13 0.410 0.316 0.000 0.315 0.510 0.000 0.259 0.213 
84 
Putative uncharacterized protein 
DKFZp686I04196 (Fragment) OS=Homo 
sapiens GN=DKFZp686I04196 PE=2 
SV=1 Q6N093_HUMAN 46 0.000 0.000 1.469 0.000 0.000 0.000 0.245 0.600 
85 
Heat shock cognate 71 kDa protein 
OS=Homo sapiens GN=HSPA8 PE=1 
SV=1 HSP7C_HUMAN (+1) 71 0.330 0.296 0.094 0.148 0.062 0.480 0.235 0.161 
86 
Apolipoprotein C-IV OS=Homo sapiens 
GN=APOC4 PE=2 SV=1 A5YAK2_HUMAN 15 0.000 0.091 0.000 0.334 0.472 0.509 0.234 0.233 
87 
Hemopexin OS=Homo sapiens GN=HPX 
PE=1 SV=2 HEMO_HUMAN 52 0.143 0.527 0.449 0.105 0.043 0.079 0.224 0.208 
88 
Epididymis secretory protein Li 52 
OS=Homo sapiens GN=HEL-S-52 PE=2 
SV=1 V9HWG7_HUMAN (+1) 66 0.347 0.228 0.115 0.110 0.067 0.454 0.220 0.153 
89 
Actin, alpha skeletal muscle OS=Homo 
sapiens GN=ACTA1 PE=1 SV=1 ACTS_HUMAN (+1) 42 0.000 0.000 0.000 0.000 0.000 1.315 0.219 0.537 
90 
Keratin, type II cytoskeletal 2 epidermal 
OS=Homo sapiens GN=KRT2 PE=1 SV=2 K22E_HUMAN 65 0.295 0.225 0.154 0.294 0.109 0.217 0.216 0.075 
91 
Putative uncharacterized protein 
DKFZp686M08189 OS=Homo sapiens 
GN=DKFZp686M08189 PE=2 SV=1 Q6MZX9_HUMAN 52 0.697 0.000 0.000 0.587 0.000 0.000 0.214 0.333 
92 
Fermitin family homolog 3 OS=Homo 
sapiens GN=FERMT3 PE=1 SV=1 URP2_HUMAN 76 0.273 0.150 0.132 0.192 0.064 0.456 0.211 0.139 
93 
Complement C4-B OS=Homo sapiens 
GN=C4B PE=1 SV=2 CO4B_HUMAN 193 0.177 0.331 0.289 0.177 0.103 0.174 0.208 0.085 
94 
Pyruvate kinase PKM OS=Homo sapiens 
GN=PKM PE=1 SV=4 KPYM_HUMAN (+1) 58 0.340 0.252 0.148 0.133 0.038 0.334 0.208 0.121 
95 
GCT-A1 heavy chain variable region 
(Fragment) OS=Homo sapiens PE=2 SV=1 A0A125U0V2_HUMAN 14 0.000 0.000 0.000 0.000 1.231 0.000 0.205 0.503 
96 
Gelsolin OS=Homo sapiens GN=GSN 
PE=1 SV=1 GELS_HUMAN 86 0.304 0.202 0.144 0.148 0.087 0.328 0.202 0.095 
97 
cDNA FLJ32131 fis, clone 
PEBLM2000267, highly similar to Tubulin 
alpha-ubiquitous chain OS=Homo sapiens 
PE=2 SV=1 B3KPS3_HUMAN (+2) 46 0.359 0.139 0.197 0.139 0.000 0.307 0.190 0.129 
98 
cDNA FLJ56821, highly similar to Inter-
alpha-trypsin inhibitor heavy chain H1 
OS=Homo sapiens PE=2 SV=1 B7Z549_HUMAN (+1) 76 0.154 0.312 0.194 0.204 0.081 0.178 0.187 0.075 
99 
CD5 antigen-like OS=Homo sapiens 
GN=CD5L PE=1 SV=1 CD5L_HUMAN 38 0.210 0.216 0.301 0.156 0.163 0.077 0.187 0.075 
100 
Ig heavy chain V-III region GAL OS=Homo 
sapiens PE=1 SV=1 HV320_HUMAN 13 0.000 0.491 0.000 0.000 0.612 0.000 0.184 0.287 
101 
Immunglobulin heavy chain variable region 
(Fragment) OS=Homo sapiens PE=4 SV=1 Q0ZCH6_HUMAN 14 0.228 0.163 0.170 0.163 0.253 0.126 0.184 0.047 
102 
Complement component 1, q 
subcomponent, C chain, isoform CRA_a 
OS=Homo sapiens GN=C1QC PE=4 SV=1 A0A024RAA7_HUMAN (+1) 26 0.164 0.193 0.146 0.193 0.153 0.226 0.179 0.030 
103 
Tubulin alpha-4A chain OS=Homo sapiens 





































































Actinin alpha 4 isoform 1 (Fragment) 
OS=Homo sapiens GN=ACTN4 PE=2 
SV=1 A0A0S2Z3G9_HUMAN (+1) 105 0.416 0.230 0.000 0.108 0.000 0.308 0.177 0.170 
105 
cDNA FLJ53487, highly similar to 
Coagulation factor XIII A chain (EC 
2.3.2.13) OS=Homo sapiens PE=2 SV=1 B4E2L8_HUMAN 70 0.000 0.274 0.000 0.169 0.000 0.579 0.170 0.230 
106 
Profilin-1 OS=Homo sapiens GN=PFN1 
PE=1 SV=2 PROF1_HUMAN 15 0.213 0.274 0.000 0.121 0.000 0.392 0.167 0.156 
107 
Immunglobulin heavy chain variable region 
(Fragment) OS=Homo sapiens PE=4 SV=1 Q0ZCF6_HUMAN 15 0.213 0.122 0.127 0.243 0.295 0.000 0.167 0.106 
108 
cDNA FLJ35730 fis, clone TESTI2003131, 
highly similar to ALPHA-1-
ANTICHYMOTRYPSIN OS=Homo sapiens 
PE=2 SV=1 B3KS79_HUMAN 51 0.146 0.340 0.289 0.089 0.061 0.069 0.166 0.120 
109 
cDNA FLJ53025, highly similar to 
Complement C4-B OS=Homo sapiens 
PE=2 SV=1 B7Z1F8_HUMAN 30 0.000 0.989 0.000 0.000 0.000 0.000 0.165 0.404 
110 
Immunoglobulin J chain OS=Homo 
sapiens GN=JCHAIN PE=1 SV=4 IGJ_HUMAN 18 0.178 0.127 0.079 0.202 0.270 0.131 0.164 0.067 
111 
78 kDa glucose-regulated protein 
OS=Homo sapiens GN=HSPA5 PE=1 
SV=2 GRP78_HUMAN (+1) 72 0.259 0.165 0.033 0.076 0.031 0.375 0.156 0.139 
112 
Inter-alpha (Globulin) inhibitor H2 
OS=Homo sapiens GN=ITIH2 PE=2 SV=1 A2RTY6_HUMAN (+3) 106 0.131 0.241 0.166 0.163 0.079 0.155 0.156 0.053 
113 
IGL@ protein OS=Homo sapiens 
GN=IGL@ PE=1 SV=1 Q6PIK1_HUMAN 25 0.000 0.000 0.000 0.437 0.495 0.000 0.155 0.241 
114 
Moesin OS=Homo sapiens GN=MSN 
PE=1 SV=3 MOES_HUMAN (+1) 68 0.212 0.121 0.077 0.121 0.065 0.337 0.155 0.103 
115 
cDNA FLJ57038, highly similar to Filamin-
A OS=Homo sapiens PE=2 SV=1 B4E2F9_HUMAN 83 0.424 0.000 0.000 0.000 0.000 0.488 0.152 0.236 
116 
Apolipoprotein M OS=Homo sapiens 
GN=APOM PE=1 SV=2 APOM_HUMAN 21 0.076 0.152 0.045 0.239 0.168 0.224 0.151 0.078 
117 
Complement component 1, q 
subcomponent, B chain, isoform CRA_a 
OS=Homo sapiens GN=C1QB PE=4 SV=1 A0A024RAB9_HUMAN (+3) 27 0.138 0.152 0.071 0.236 0.098 0.196 0.149 0.061 
118 
Beta 5-tubulin OS=Homo sapiens 
GN=TUBB PE=2 SV=1 Q5SU16_HUMAN (+1) 50 0.394 0.082 0.067 0.082 0.018 0.235 0.146 0.142 
119 
IgG H chain OS=Homo sapiens PE=2 
SV=1 S6B2A6_HUMAN 32 0.000 0.000 0.684 0.185 0.000 0.000 0.145 0.274 
120 
Rheumatoid factor RF-IP12 (Fragment) 
OS=Homo sapiens PE=2 SV=1 A2J1M8_HUMAN 11 0.242 0.166 0.000 0.166 0.281 0.000 0.143 0.119 
121 
Protein IGHV3-73 OS=Homo sapiens 
GN=IGHV3-73 PE=1 SV=1 A0A0G2JN55_HUMAN 9 0.000 0.000 0.000 0.000 0.835 0.000 0.139 0.341 
122 
Lipoprotein, Lp(A) OS=Homo sapiens 
GN=LPA PE=1 SV=1 Q1HP67_HUMAN 227 0.005 0.296 0.342 0.014 0.076 0.078 0.135 0.146 
123 
Keratin, type I cytoskeletal 16 OS=Homo 
sapiens GN=KRT16 PE=1 SV=4 K1C16_HUMAN 51 0.084 0.134 0.065 0.205 0.173 0.127 0.131 0.053 
124 
Heat shock protein HSP 90-alpha 
OS=Homo sapiens GN=HSP90AA1 PE=1 
SV=5 HS90A_HUMAN (+1) 85 0.176 0.134 0.084 0.070 0.052 0.270 0.131 0.082 
125 
Putative uncharacterized protein 
DKFZp686C02220 (Fragment) OS=Homo 
sapiens GN=DKFZp686C02220 PE=2 
SV=1 Q6N091_HUMAN 54 0.000 0.465 0.000 0.287 0.000 0.000 0.125 0.202 
126 
Platelet factor 4 OS=Homo sapiens 
GN=PF4 PE=1 SV=2 PLF4_HUMAN 11 0.194 0.124 0.000 0.166 0.000 0.267 0.125 0.108 
127 
Apolipoprotein D (Fragment) OS=Homo 
sapiens GN=APOD PE=1 SV=1 C9JF17_HUMAN 24 0.000 0.000 0.000 0.247 0.203 0.294 0.124 0.139 
128 
Keratin, type I cytoskeletal 14 OS=Homo 
sapiens GN=KRT14 PE=1 SV=4 K1C14_HUMAN 52 0.113 0.123 0.000 0.210 0.136 0.136 0.120 0.068 
129 
Inter-alpha (Globulin) inhibitor H4 (Plasma 
Kallikrein-sensitive glycoprotein) 
OS=Homo sapiens GN=ITIH4 PE=2 SV=1 B2RMS9_HUMAN (+1) 103 0.093 0.191 0.254 0.097 0.026 0.051 0.119 0.087 
130 
Tubulin beta-1 chain OS=Homo sapiens 
GN=TUBB1 PE=1 SV=1 TBB1_HUMAN 50 0.277 0.100 0.076 0.064 0.027 0.165 0.118 0.090 
131 
Protein SAA2-SAA4 OS=Homo sapiens 
GN=SAA2-SAA4 PE=4 SV=1 A0A096LPE2_HUMAN 23 0.000 0.139 0.124 0.079 0.135 0.230 0.118 0.076 
132 
Protein disulfide-isomerase OS=Homo 
sapiens PE=2 SV=1 B3KQT9_HUMAN (+2) 54 0.266 0.152 0.035 0.042 0.000 0.207 0.117 0.107 
133 
Band 3 anion transport protein OS=Homo 
sapiens GN=SLC4A1 PE=1 SV=3 B3AT_HUMAN (+3) 102 0.193 0.018 0.173 0.103 0.104 0.075 0.111 0.064 
134 
CP protein OS=Homo sapiens GN=CP 
PE=2 SV=1 A5PL27_HUMAN (+3) 122 0.057 0.269 0.168 0.090 0.022 0.058 0.110 0.092 
135 
Integrin beta-3 OS=Homo sapiens 
GN=ITGB3 PE=1 SV=2 ITB3_HUMAN (+1) 87 0.165 0.063 0.044 0.068 0.041 0.277 0.110 0.094 
136 
Alpha-1B-glycoprotein OS=Homo sapiens 
GN=A1BG PE=1 SV=4 A1BG_HUMAN (+1) 54 0.109 0.279 0.167 0.051 0.016 0.033 0.109 0.100 




































































GN=SERPIND1 PE=1 SV=3 
138 
Ig heavy chain V-III region CAM OS=Homo 
sapiens PE=1 SV=1 HV307_HUMAN 14 0.152 0.000 0.136 0.130 0.221 0.000 0.107 0.089 
139 
Apolipoprotein L, 1, isoform CRA_b 
OS=Homo sapiens GN=APOL1 PE=4 
SV=1 A0A024R1G8_HUMAN (+11) 46 0.035 0.040 0.052 0.168 0.173 0.166 0.106 0.070 
140 
Glycoprotein Ib (Platelet), alpha 
polypeptide OS=Homo sapiens 
GN=GP1BA PE=1 SV=1 A0A0C4DGZ8_HUMAN (+2) 69 0.131 0.079 0.021 0.053 0.032 0.298 0.102 0.104 
141 
Complement C5 OS=Homo sapiens 
GN=C5 PE=1 SV=4 CO5_HUMAN 188 0.094 0.182 0.180 0.075 0.035 0.044 0.102 0.065 
142 
Endoplasmin OS=Homo sapiens 
GN=HSP90B1 PE=1 SV=1 ENPL_HUMAN (+2) 92 0.139 0.099 0.047 0.050 0.029 0.243 0.101 0.080 
143 
Rheumatoid factor C6 light chain 
(Fragment) OS=Homo sapiens 
GN=V<kappa>1 PE=2 SV=1 A0N5G1_HUMAN 13 0.082 0.140 0.000 0.280 0.102 0.000 0.101 0.104 
144 
Clusterin OS=Homo sapiens GN=CLU 
PE=1 SV=1 CLUS_HUMAN 52 0.113 0.088 0.073 0.105 0.094 0.124 0.099 0.018 
145 
Adenylyl cyclase-associated protein 
OS=Homo sapiens GN=CAP1 PE=3 SV=1 D3DPU2_HUMAN 52 0.246 0.123 0.073 0.044 0.000 0.102 0.098 0.084 
146 
Complement C1s subcomponent 
OS=Homo sapiens GN=C1S PE=1 SV=1 C1S_HUMAN 77 0.090 0.207 0.074 0.059 0.052 0.092 0.096 0.057 
147 
Complement C4-A OS=Homo sapiens 





dehydrogenase OS=Homo sapiens 










































cDNA FLJ54184, highly similar to 
Tropomyosin alpha-4 chain OS=Homo 
sapiens PE=2 SV=1 B4DVY2_HUMAN (+2) 26 0.184 0.088 0.037 0.088 0.000 0.158 0.092 0.070 
150 
Heat shock protein 90kDa alpha 
(Cytosolic), class B member 1, isoform 
CRA_a OS=Homo sapiens 
GN=HSP90AB1 PE=3 SV=1 A0A024RD80_HUMAN (+2) 83 0.122 0.088 0.063 0.055 0.048 0.177 0.092 0.050 
151 
C4b-binding protein beta chain OS=Homo 
sapiens GN=C4BPB PE=1 SV=1 C4BPB_HUMAN 28 0.171 0.098 0.051 0.081 0.079 0.063 0.091 0.043 
152 
Anti-Influenza A hemagglutinin heavy 
chain variable region (Fragment) 
OS=Homo sapiens PE=2 SV=1 G1FM90_HUMAN 15 0.213 0.152 0.000 0.000 0.177 0.000 0.090 0.101 
153 
Integrin alpha-IIb OS=Homo sapiens 
GN=ITGA2B PE=1 SV=3 ITA2B_HUMAN 113 0.132 0.040 0.055 0.060 0.047 0.198 0.089 0.063 
154 
Vitronectin OS=Homo sapiens GN=VTN 
PE=4 SV=1 D9ZGG2_HUMAN (+1) 54 0.059 0.127 0.203 0.034 0.025 0.076 0.087 0.067 
155 
Keratin, type II cytoskeletal 5 OS=Homo 
sapiens GN=KRT5 PE=1 SV=3 K2C5_HUMAN 62 0.112 0.088 0.069 0.118 0.050 0.085 0.087 0.025 
156 
Ig heavy chain V-III region GA OS=Homo 
sapiens PE=1 SV=1 HV308_HUMAN 13 0.205 0.000 0.000 0.175 0.000 0.136 0.086 0.097 
157 
GCT-A2 heavy chain variable region 
(Fragment) OS=Homo sapiens PE=2 SV=1 A0A125U0V4_HUMAN 14 0.000 0.098 0.000 0.098 0.316 0.000 0.085 0.123 
158 
IgGFc-binding protein OS=Homo sapiens 
GN=FCGBP PE=1 SV=1 A0A087WXI2_HUMAN (+1) 445 0.152 0.084 0.062 0.052 0.062 0.098 0.085 0.037 
159 
Plasminogen OS=Homo sapiens GN=PLG 
PE=1 SV=2 PLMN_HUMAN 91 0.076 0.216 0.136 0.030 0.019 0.032 0.085 0.077 
160 
Ficolin (Collagen/fibrinogen domain 
containing) 3 (Hakata antigen), isoform 
CRA_b OS=Homo sapiens GN=FCN3 
PE=2 SV=1 Q6UXM4_HUMAN (+1) 32 0.117 0.057 0.074 0.114 0.055 0.092 0.085 0.027 
161 
Vitamin D-binding protein OS=Homo 
sapiens GN=GC PE=1 SV=1 D6RF35_HUMAN 53 0.030 0.189 0.225 0.026 0.000 0.000 0.078 0.101 
162 
Calreticulin OS=Homo sapiens GN=CALR 
PE=1 SV=1 CALR_HUMAN (+2) 48 0.144 0.105 0.040 0.028 0.000 0.147 0.077 0.063 
163 
cDNA FLJ53075, highly similar to 
Kininogen-1 OS=Homo sapiens PE=2 
SV=1 B4DPP8_HUMAN (+1) 46 0.046 0.149 0.207 0.050 0.000 0.000 0.075 0.084 
164 
14-3-3 protein zeta/delta OS=Homo 
sapiens GN=YWHAZ PE=1 SV=1 1433Z_HUMAN (+1) 28 0.057 0.098 0.034 0.081 0.032 0.147 0.075 0.044 
165 
Transitional endoplasmic reticulum 
ATPase OS=Homo sapiens GN=VCP 
PE=1 SV=4 TERA_HUMAN (+1) 89 0.138 0.067 0.016 0.041 0.000 0.185 0.074 0.073 
166 
Uncharacterized protein (Fragment) 
OS=Homo sapiens PE=1 SV=1 A0A0J9YX35_HUMAN 13 0.205 0.000 0.000 0.000 0.238 0.000 0.074 0.115 
167 
cDNA FLJ41552 fis, clone 
COLON2004478, highly similar to Protein 
Tro alpha1 H,myeloma OS=Homo sapiens 
PE=2 SV=1 Q6ZW64_HUMAN 53 0.000 0.000 0.000 0.000 0.434 0.000 0.072 0.177 
168 
Platelet glycoprotein V OS=Homo sapiens 





































































Platelet basic protein OS=Homo sapiens 
GN=PPBP PE=1 SV=3 CXCL7_HUMAN (+1) 14 0.190 0.000 0.000 0.000 0.063 0.168 0.070 0.088 
170 
Proteoglycan 4, isoform CRA_a OS=Homo 
sapiens GN=PRG4 PE=4 SV=1 A0A024R930_HUMAN (+2) 151 0.042 0.033 0.035 0.054 0.111 0.132 0.068 0.043 
171 
Protein IGHV3-13 (Fragment) OS=Homo 
sapiens GN=IGHV3-13 PE=1 SV=1 A0A0A0MS11_HUMAN 13 0.000 0.000 0.000 0.000 0.408 0.000 0.068 0.167 
172 
Complement component 9, isoform CRA_a 
OS=Homo sapiens GN=C9 PE=4 SV=1 A0A024R035_HUMAN (+1) 63 0.059 0.152 0.151 0.022 0.000 0.019 0.067 0.068 
173 
Protein disulfide-isomerase OS=Homo 
sapiens GN=P4HB PE=3 SV=1 A0A024R8S5_HUMAN (+1) 57 0.215 0.064 0.025 0.000 0.000 0.093 0.066 0.082 
174 
Epididymis luminal protein 180 (Fragment) 
OS=Homo sapiens GN=HEL180 PE=2 
SV=1 B6EDE2_HUMAN 13 0.000 0.000 0.000 0.385 0.000 0.000 0.064 0.157 
175 
Heat shock 70 kDa protein 1B OS=Homo 
sapiens GN=HSPA1B PE=1 SV=1 A0A0G2JIW1_HUMAN (+3) 70 0.099 0.085 0.000 0.039 0.000 0.159 0.064 0.063 
176 
Alpha-1-acid glycoprotein 1 OS=Homo 
sapiens GN=ORM1 PE=1 SV=1 A1AG1_HUMAN (+1) 24 0.089 0.095 0.159 0.038 0.000 0.000 0.063 0.062 
177 
Zyxin OS=Homo sapiens GN=ZYX PE=1 
SV=1 ZYX_HUMAN 61 0.105 0.015 0.062 0.075 0.036 0.087 0.063 0.033 
178 
Anti-streptococcal/anti-myosin 
immunoglobulin kappa light chain variable 
region (Fragment) OS=Homo sapiens 
PE=2 SV=1 Q96SA9_HUMAN 12 0.000 0.000 0.159 0.000 0.221 0.000 0.063 0.100 
179 
Catalase OS=Homo sapiens GN=CAT 
PE=1 SV=3 CATA_HUMAN 60 0.098 0.038 0.095 0.053 0.037 0.059 0.063 0.027 
180 
Integrin-linked protein kinase OS=Homo 
sapiens GN=ILK PE=1 SV=1 A0A0A0MTH3_HUMAN (+2) 55 0.126 0.108 0.000 0.025 0.000 0.118 0.063 0.061 
181 
GCT-A5 light chain variable region 
(Fragment) OS=Homo sapiens PE=2 SV=1 A0A0X9UWL5_HUMAN 12 0.000 0.000 0.000 0.228 0.147 0.000 0.063 0.100 
182 
Myosin-reactive immunoglobulin heavy 
chain variable region (Fragment) 
OS=Homo sapiens PE=2 SV=1 Q9UL89_HUMAN 13 0.082 0.000 0.293 0.000 0.000 0.000 0.062 0.118 
183 
cDNA FLJ54622, highly similar to 
Prothrombin (EC 3.4.21.5) OS=Homo 
sapiens PE=2 SV=1 B4DDT3_HUMAN (+1) 53 0.060 0.172 0.072 0.034 0.000 0.033 0.062 0.059 
184 
Prenylcysteine oxidase 1 OS=Homo 
sapiens GN=PCYOX1 PE=1 SV=3 PCYOX_HUMAN 57 0.019 0.056 0.000 0.096 0.078 0.124 0.062 0.047 
185 
Carboxypeptidase N subunit 2 OS=Homo 
sapiens GN=CPN2 PE=1 SV=3 CPN2_HUMAN 61 0.070 0.097 0.062 0.067 0.036 0.039 0.062 0.023 
186 
V2-17 protein (Fragment) OS=Homo 
sapiens GN=V2-17 PE=1 SV=1 Q5NV90_HUMAN 10 0.000 0.183 0.095 0.000 0.088 0.000 0.061 0.075 
187 
Multimerin-1 OS=Homo sapiens 
GN=MMRN1 PE=1 SV=3 MMRN1_HUMAN 138 0.073 0.026 0.045 0.036 0.010 0.166 0.059 0.056 
188 
Ig gamma-1 chain C region OS=Homo 
sapiens GN=IGHG1 PE=1 SV=1 A0A087X1C7_HUMAN 50 0.000 0.000 0.000 0.000 0.354 0.000 0.059 0.144 
189 
Tropomyosin 3 isoform 1 (Fragment) 
OS=Homo sapiens GN=TPM3 PE=2 SV=1 A0A0S2Z4G4_HUMAN (+1) 29 0.129 0.063 0.000 0.000 0.000 0.162 0.059 0.072 
190 
Alpha-2-antiplasmin OS=Homo sapiens 
GN=SERPINF2 PE=1 SV=3 A2AP_HUMAN 55 0.058 0.091 0.113 0.033 0.032 0.021 0.058 0.037 
191 
Calpain 1, (Mu/I) large subunit, isoform 
CRA_a OS=Homo sapiens GN=CAPN1 
PE=4 SV=1 A0A024R580_HUMAN (+2) 82 0.071 0.045 0.012 0.033 0.022 0.165 0.058 0.056 
192 
Ig heavy chain variable region (Fragment) 
OS=Homo sapiens PE=2 SV=1 A0A068LRW6_HUMAN (+2) 14 0.114 0.000 0.102 0.000 0.000 0.126 0.057 0.063 
193 
Enolase 1, (Alpha), isoform CRA_a 
OS=Homo sapiens GN=ENO1 PE=2 SV=1 A0A024R4F1_HUMAN (+1) 47 0.091 0.058 0.051 0.039 0.000 0.100 0.056 0.036 
194 
Apolipoprotein A-IV OS=Homo sapiens 
GN=APOA4 PE=1 SV=3 APOA4_HUMAN 45 0.000 0.041 0.042 0.101 0.088 0.065 0.056 0.037 
195 
MS-D1 light chain variable region 
(Fragment) OS=Homo sapiens PE=2 SV=1 A0A0X9TD47_HUMAN 12 0.000 0.000 0.000 0.190 0.147 0.000 0.056 0.088 
196 
Serpin peptidase inhibitor, clade C 
(Antithrombin), member 1, isoform CRA_a 
OS=Homo sapiens GN=SERPINC1 PE=3 
SV=1 A0A024R944_HUMAN (+1) 53 0.030 0.129 0.099 0.043 0.000 0.033 0.056 0.048 
197 
Uncharacterized protein OS=Homo 
sapiens PE=1 SV=1 B4E1Z4_HUMAN 141 0.038 0.123 0.142 0.023 0.000 0.008 0.056 0.061 
198 
GCT-A8 heavy chain variable region 
(Fragment) OS=Homo sapiens PE=2 SV=1 A0A0X9V9C4_HUMAN 13 0.000 0.000 0.330 0.000 0.000 0.000 0.055 0.135 
199 
Protein AMBP OS=Homo sapiens 
GN=AMBP PE=1 SV=1 AMBP_HUMAN 39 0.055 0.140 0.061 0.035 0.023 0.000 0.052 0.048 
200 
Fructose-bisphosphate aldolase A 
OS=Homo sapiens GN=ALDOA PE=1 
SV=2 ALDOA_HUMAN (+2) 39 0.082 0.047 0.000 0.058 0.000 0.105 0.049 0.043 
201 
Clathrin heavy chain OS=Homo sapiens 
GN=CLTC PE=1 SV=1 A0A087WVQ6_HUMAN (+1) 192 0.103 0.031 0.015 0.021 0.012 0.095 0.046 0.041 
202 
Inter-alpha-trypsin inhibitor heavy chain H3 





































































Pleckstrin OS=Homo sapiens GN=PLEK 
PE=1 SV=3 PLEK_HUMAN 40 0.080 0.091 0.000 0.000 0.000 0.103 0.046 0.051 
204 
A30 (Fragment) OS=Homo sapiens PE=4 
SV=1 A2MYE1_HUMAN (+1) 10 0.000 0.000 0.000 0.273 0.000 0.000 0.046 0.112 
205 
Glycogen phosphorylase, brain form 
OS=Homo sapiens GN=PYGB PE=1 SV=5 PYGB_HUMAN (+1) 97 0.071 0.061 0.015 0.038 0.000 0.085 0.045 0.033 
206 
Coagulation factor XIII B chain OS=Homo 
sapiens GN=F13B PE=1 SV=3 F13B_HUMAN 76 0.056 0.054 0.063 0.048 0.017 0.031 0.045 0.017 
207 
Rheumatoid factor RF-ET10 (Fragment) 
OS=Homo sapiens PE=2 SV=1 A2J1N7_HUMAN 10 0.000 0.000 0.000 0.000 0.265 0.000 0.044 0.108 
208 
cDNA FLJ61290, highly similar to Neutral 
alpha-glucosidase AB OS=Homo sapiens 
PE=2 SV=1 B4DJ30_HUMAN (+2) 113 0.052 0.044 0.013 0.016 0.008 0.120 0.042 0.042 
209 
Phosphoglucomutase-1 OS=Homo 
sapiens GN=PGM1 PE=1 SV=3 PGM1_HUMAN 61 0.061 0.052 0.000 0.022 0.000 0.116 0.042 0.044 
210 
Complement component 1, q 
subcomponent, A chain, isoform CRA_a 
OS=Homo sapiens GN=C1QA PE=4 SV=1 A0A024RAG6_HUMAN (+2) 26 0.061 0.035 0.000 0.035 0.051 0.068 0.042 0.024 
211 
HCG2039812, isoform CRA_b (Fragment) 
OS=Homo sapiens GN=KRT6A PE=2 
SV=1 A0A0S2Z428_HUMAN (+3) 60 0.000 0.084 0.000 0.099 0.066 0.000 0.041 0.047 
212 
Protein IGKV2D-24 (Fragment) OS=Homo 
sapiens GN=IGKV2D-24 PE=4 SV=1 A0A075B6R9_HUMAN (+1) 13 0.000 0.000 0.000 0.105 0.000 0.136 0.040 0.063 
213 
Protein IGHV1-46 (Fragment) OS=Homo 
sapiens GN=IGHV1-46 PE=4 SV=1 A0A0B4J1V4_HUMAN (+1) 13 0.000 0.070 0.000 0.000 0.170 0.000 0.040 0.070 
214 
Class IVb beta tubulin OS=Homo sapiens 
PE=2 SV=1 Q8IWP6_HUMAN (+3) 50 0.000 0.000 0.000 0.000 0.000 0.235 0.039 0.096 
215 
cDNA FLJ78516 OS=Homo sapiens PE=2 
SV=1 A8K2W3_HUMAN (+1) 47 0.102 0.000 0.041 0.029 0.000 0.063 0.039 0.039 
216 
Transketolase (Fragment) OS=Homo 
sapiens PE=2 SV=1 Q53EM5_HUMAN (+2) 68 0.063 0.040 0.000 0.020 0.000 0.104 0.038 0.040 
217 
Myosin light polypeptide 6 OS=Homo 
sapiens GN=MYL6 PE=1 SV=1 B7Z6Z4_HUMAN (+6) 27 0.138 0.000 0.000 0.000 0.000 0.087 0.038 0.060 
218 
Spectrin alpha chain, erythrocytic 1 
OS=Homo sapiens GN=SPTA1 PE=1 
SV=1 A0A087WZE4_HUMAN (+1) 281 0.072 0.000 0.068 0.039 0.033 0.013 0.037 0.029 
219 
L-lactate dehydrogenase B chain 
OS=Homo sapiens GN=LDHB PE=1 SV=2 LDHB_HUMAN (+1) 37 0.043 0.037 0.000 0.062 0.000 0.079 0.037 0.032 
220 
Mannan-binding lectin serine protease 1 
OS=Homo sapiens GN=MASP1 PE=1 
SV=3 MASP1_HUMAN 79 0.067 0.040 0.018 0.029 0.028 0.030 0.035 0.017 
221 
Complement component C6 OS=Homo 
sapiens GN=C6 PE=1 SV=3 CO6_HUMAN 105 0.015 0.091 0.073 0.013 0.008 0.011 0.035 0.037 
222 
GDP dissociation inhibitor 1 isoform 1 
(Fragment) OS=Homo sapiens GN=GDI1 
PE=2 SV=1 A0A0S2Z3X8_HUMAN (+2) 51 0.104 0.027 0.019 0.000 0.000 0.058 0.035 0.040 
223 
Ankyrin-1 OS=Homo sapiens GN=ANK1 
PE=1 SV=3 ANK1_HUMAN 206 0.067 0.000 0.067 0.031 0.021 0.020 0.034 0.027 
224 
Ig heavy chain variable region (Fragment) 
OS=Homo sapiens PE=2 SV=1 A0A068LKQ2_HUMAN 13 0.000 0.000 0.000 0.000 0.204 0.000 0.034 0.083 
225 
Cofilin-1 OS=Homo sapiens GN=CFL1 
PE=1 SV=3 COF1_HUMAN (+3) 19 0.056 0.048 0.000 0.000 0.000 0.093 0.033 0.039 
226 
Polymeric immunoglobulin receptor 
OS=Homo sapiens GN=PIGR PE=1 SV=4 PIGR_HUMAN 83 0.032 0.016 0.017 0.022 0.107 0.000 0.032 0.038 
227 
Coronin OS=Homo sapiens GN=CORO1A 
PE=3 SV=1 A0A024R611_HUMAN (+1) 51 0.084 0.027 0.019 0.018 0.000 0.046 0.032 0.029 
228 
Transferrin receptor protein 1 OS=Homo 
sapiens GN=TFRC PE=1 SV=2 TFR1_HUMAN 85 0.069 0.027 0.028 0.027 0.000 0.041 0.032 0.023 
229 
Hexokinase (Fragment) OS=Homo sapiens 
PE=2 SV=1 Q59FD4_HUMAN 106 0.040 0.034 0.000 0.009 0.000 0.105 0.031 0.040 
230 
Soluble scavenger receptor cysteine-rich 
domain-containing protein SSC5D 
OS=Homo sapiens GN=SSC5D PE=1 
SV=3 SRCRL_HUMAN 166 0.055 0.025 0.029 0.022 0.027 0.032 0.031 0.012 
231 
cDNA FLJ55606, highly similar to Alpha-2-
HS-glycoprotein OS=Homo sapiens PE=2 
SV=1 B7Z8Q2_HUMAN (+2) 47 0.000 0.078 0.091 0.019 0.000 0.000 0.031 0.042 
232 
Ig heavy chain V-III region JON OS=Homo 
sapiens PE=1 SV=1 HV319_HUMAN 13 0.082 0.000 0.000 0.000 0.102 0.000 0.031 0.048 
233 
Peptidyl-prolyl cis-trans isomerase 
OS=Homo sapiens PE=2 SV=1 A8K486_HUMAN (+3) 18 0.000 0.000 0.000 0.051 0.000 0.131 0.030 0.053 
234 
Spectrin, beta, erythrocytic (Includes 
spherocytosis, clinical type I) variant 
(Fragment) OS=Homo sapiens PE=2 SV=1 Q59FP5_HUMAN 268 0.060 0.007 0.052 0.025 0.016 0.018 0.030 0.021 
235 
RAP1B, member of RAS oncogene family, 
isoform CRA_a OS=Homo sapiens 
GN=RAP1B PE=4 SV=1 A0A024RB87_HUMAN (+3) 21 0.000 0.065 0.000 0.000 0.000 0.112 0.030 0.048 




































































GN=F5 PE=1 SV=1 
237 
Ubiquitin-activating enzyme E1 (A1S9T 
and BN75 temperature sensitivity 
complementing), isoform CRA_a 
OS=Homo sapiens GN=UBE1 PE=3 SV=1 A0A024R1A3_HUMAN (+1) 118 0.050 0.043 0.012 0.000 0.000 0.070 0.029 0.029 
238 
cDNA, FLJ93914, highly similar to Homo 
sapiens histidine-rich glycoprotein (HRG), 
mRNA OS=Homo sapiens PE=2 SV=1 B2R8I2_HUMAN (+1) 60 0.036 0.061 0.040 0.023 0.015 0.000 0.029 0.021 
239 
Protein unc-13 homolog D OS=Homo 
sapiens GN=UNC13D PE=1 SV=1 UN13D_HUMAN 123 0.052 0.026 0.000 0.000 0.000 0.096 0.029 0.039 
240 
Apolipoprotein A-II OS=Homo sapiens 
GN=APOA2 PE=1 SV=1 APOA2_HUMAN (+3) 11 0.000 0.000 0.000 0.166 0.000 0.000 0.028 0.068 
241 
Nucleosome assembly protein 1-like 1, 
isoform CRA_a OS=Homo sapiens 
GN=NAP1L1 PE=3 SV=1 A0A024RBB7_HUMAN (+12) 45 0.059 0.030 0.021 0.000 0.000 0.052 0.027 0.025 
242 
Serum paraoxonase/arylesterase 1 
OS=Homo sapiens GN=PON1 PE=1 SV=3 PON1_HUMAN 40 0.000 0.068 0.048 0.046 0.000 0.000 0.027 0.031 
243 
Protein IGKV2D-28 OS=Homo sapiens 
GN=IGKV2D-28 PE=1 SV=1 A0A0A0MTQ6_HUMAN (+2) 11 0.000 0.000 0.000 0.000 0.161 0.000 0.027 0.066 
244 
Beta-2-glycoprotein 1 OS=Homo sapiens 
GN=APOH PE=1 SV=3 APOH_HUMAN (+1) 38 0.000 0.060 0.100 0.000 0.000 0.000 0.027 0.043 
245 
cDNA FLJ50805, highly similar to 
Erythrocyte membrane protein band 4.2 
OS=Homo sapiens PE=2 SV=1 B7Z4C3_HUMAN (+1) 77 0.055 0.000 0.049 0.035 0.017 0.000 0.026 0.024 
246 
Transgelin-2 OS=Homo sapiens 
GN=TAGLN2 PE=1 SV=3 TAGL2_HUMAN (+1) 22 0.048 0.000 0.000 0.000 0.000 0.107 0.026 0.044 
247 
Cryocrystalglobulin CC1 kappa light chain 
variable region (Fragment) OS=Homo 
sapiens PE=2 SV=1 B1N7B8_HUMAN 12 0.000 0.000 0.000 0.152 0.000 0.000 0.025 0.062 
248 
Syntaxin-binding protein 2 OS=Homo 
sapiens GN=STXBP2 PE=1 SV=2 STXB2_HUMAN 66 0.032 0.035 0.000 0.000 0.000 0.080 0.024 0.032 
249 
Phosphoglycerate kinase OS=Homo 
sapiens PE=2 SV=1 B4E1H9_HUMAN (+2) 35 0.030 0.039 0.000 0.026 0.000 0.050 0.024 0.021 
250 
cDNA FLJ77947, highly similar to Human 
complement protein C8 beta subunit 
mRNA OS=Homo sapiens PE=2 SV=1 A8K9M5_HUMAN (+6) 67 0.024 0.048 0.071 0.000 0.000 0.000 0.024 0.030 
251 
Beta-parvin OS=Homo sapiens 
GN=PARVB PE=1 SV=1 PARVB_HUMAN 42 0.038 0.033 0.000 0.000 0.000 0.070 0.023 0.029 
252 
Programmed cell death 6-interacting 
protein OS=Homo sapiens GN=PDCD6IP 
PE=1 SV=1 PDC6I_HUMAN (+1) 96 0.028 0.019 0.000 0.000 0.000 0.092 0.023 0.036 
253 
T-complex protein 1 subunit gamma 
OS=Homo sapiens PE=2 SV=1 B3KX11_HUMAN (+4) 58 0.064 0.000 0.000 0.000 0.000 0.071 0.023 0.035 
254 
Nicotinate phosphoribosyltransferase 
(Fragment) OS=Homo sapiens 
GN=NAPRT PE=1 SV=1 H0YDA6_HUMAN 14 0.000 0.000 0.068 0.000 0.063 0.000 0.022 0.034 
255 
Glucose-6-phosphate isomerase 
(Fragment) OS=Homo sapiens GN=GPI 
PE=1 SV=1 A0A0A0MTS2_HUMAN 65 0.066 0.042 0.022 0.000 0.000 0.000 0.022 0.027 
256 
Arachidonate 12-lipoxygenase, 12S-type 
OS=Homo sapiens GN=ALOX12 PE=1 
SV=4 LOX12_HUMAN 76 0.056 0.000 0.025 0.000 0.000 0.046 0.021 0.025 
257 
ATP-dependent 6-phosphofructokinase, 
platelet type OS=Homo sapiens GN=PFKP 
PE=1 SV=2 PFKAP_HUMAN 86 0.037 0.053 0.000 0.000 0.000 0.034 0.021 0.024 
258 
IQ motif containing GTPase activating 
protein 2, isoform CRA_b OS=Homo 
sapiens GN=IQGAP2 PE=4 SV=1 A0A024RAJ8_HUMAN (+2) 181 0.032 0.023 0.000 0.013 0.000 0.055 0.020 0.021 
259 
Glucose-6-phosphate 1-dehydrogenase 
OS=Homo sapiens GN=G6PD PE=1 SV=4 G6PD_HUMAN 59 0.054 0.031 0.016 0.000 0.000 0.020 0.020 0.021 
260 
Nidogen-1 OS=Homo sapiens GN=NID1 
PE=1 SV=3 NID1_HUMAN 136 0.051 0.007 0.000 0.013 0.007 0.043 0.020 0.021 
261 
cDNA, FLJ95650, highly similar to Homo 
sapiens karyopherin (importin) beta 1 
(KPNB1), mRNA OS=Homo sapiens PE=2 
SV=1 B2RBR9_HUMAN (+1) 97 0.044 0.024 0.010 0.000 0.000 0.042 0.020 0.020 
262 
cDNA FLJ78207, highly similar to Human 
complement protein component C7 mRNA 
OS=Homo sapiens PE=2 SV=1 A8K2T4_HUMAN (+2) 93 0.000 0.074 0.046 0.000 0.000 0.000 0.020 0.032 
263 
Chloride intracellular channel protein 1 
OS=Homo sapiens GN=CLIC1 PE=1 SV=4 CLIC1_HUMAN (+2) 27 0.039 0.034 0.000 0.000 0.000 0.044 0.019 0.022 
264 
Plasma kallikrein (Fragment) OS=Homo 
sapiens GN=KLKB1 PE=1 SV=1 H0YAC1_HUMAN (+1) 77 0.014 0.041 0.049 0.012 0.000 0.000 0.019 0.021 
265 
Rho-associated protein kinase 2 
OS=Homo sapiens GN=ROCK2 PE=1 
SV=4 ROCK2_HUMAN 161 0.033 0.014 0.000 0.000 0.000 0.066 0.019 0.026 
266 
Tyrosine-protein phosphatase non-




































































GN=PTPN6 PE=1 SV=1 
267 
Triosephosphate isomerase OS=Homo 
sapiens PE=2 SV=1 B4DUI5_HUMAN (+4) 23 0.069 0.040 0.000 0.000 0.000 0.000 0.018 0.030 
268 
cDNA FLJ50442, highly similar to T-
complex protein 1 subunit epsilon 
OS=Homo sapiens PE=2 SV=1 B4DDU6_HUMAN (+5) 55 0.048 0.017 0.000 0.000 0.000 0.043 0.018 0.022 
269 
Ig heavy chain variable region (Fragment) 
OS=Homo sapiens PE=2 SV=1 A0A068LN03_HUMAN 13 0.000 0.000 0.000 0.105 0.000 0.000 0.018 0.043 
270 
Protein IGKV1-16 (Fragment) OS=Homo 
sapiens GN=IGKV1-16 PE=1 SV=1 A0A0A0MT74_HUMAN 13 0.000 0.000 0.000 0.105 0.000 0.000 0.018 0.043 
271 
Chaperonin containing TCP1, subunit 7 
(Eta) variant (Fragment) OS=Homo 
sapiens PE=2 SV=1 Q53HV2_HUMAN (+1) 59 0.036 0.039 0.000 0.000 0.000 0.030 0.017 0.019 
272 
Complement component C8 alpha chain 
OS=Homo sapiens GN=C8A PE=1 SV=2 CO8A_HUMAN 65 0.025 0.042 0.037 0.000 0.000 0.000 0.017 0.020 
273 
Coronin OS=Homo sapiens GN=CORO1C 
PE=3 SV=1 A0A024RBI5_HUMAN (+3) 53 0.080 0.000 0.000 0.000 0.000 0.022 0.017 0.032 
274 
EH domain-containing protein 3 OS=Homo 
sapiens GN=EHD3 PE=1 SV=1 A0A0C4DH83_HUMAN (+1) 62 0.026 0.022 0.000 0.015 0.000 0.038 0.017 0.015 
275 
Puromycin-sensitive aminopeptidase 
OS=Homo sapiens GN=NPEPPS PE=1 
SV=2 PSA_HUMAN 103 0.010 0.027 0.000 0.000 0.000 0.063 0.017 0.025 
276 
Chaperonin containing TCP1, subunit 8 
(Theta) variant (Fragment) OS=Homo 
sapiens PE=2 SV=1 Q53HU0_HUMAN (+2) 60 0.044 0.015 0.000 0.000 0.000 0.039 0.016 0.021 
277 
Protein disulfide-isomerase A6 OS=Homo 
sapiens GN=PDIA6 PE=1 SV=1 PDIA6_HUMAN 48 0.022 0.038 0.000 0.000 0.000 0.037 0.016 0.019 
278 
Protein S100-A8 OS=Homo sapiens 
GN=S100A8 PE=1 SV=1 S10A8_HUMAN 11 0.097 0.000 0.000 0.000 0.000 0.000 0.016 0.040 
279 
Capping protein (Actin filament) muscle Z-
line, beta, isoform CRA_a OS=Homo 
sapiens GN=CAPZB PE=1 SV=1 B1AK87_HUMAN (+3) 29 0.055 0.000 0.000 0.000 0.000 0.041 0.016 0.025 
280 
Rheumatoid factor RF-IP4 (Fragment) 
OS=Homo sapiens PE=2 SV=1 A2J1M5_HUMAN 10 0.000 0.000 0.095 0.000 0.000 0.000 0.016 0.039 
281 
LTBP1 protein OS=Homo sapiens 
GN=LTBP1 PE=2 SV=1 B7ZLY3_HUMAN (+3) 148 0.029 0.009 0.000 0.012 0.009 0.036 0.016 0.014 
282 
cDNA FLJ51409, highly similar to 
Thrombospondin-4 OS=Homo sapiens 
PE=2 SV=1 B7Z832_HUMAN (+2) 96 0.028 0.010 0.015 0.009 0.014 0.018 0.016 0.007 
283 
Alpha-1,4 glucan phosphorylase 
OS=Homo sapiens PE=2 SV=1 B2R825_HUMAN (+1) 97 0.038 0.000 0.000 0.000 0.000 0.055 0.015 0.025 
284 
Serum amyloid P-component OS=Homo 
sapiens GN=APCS PE=1 SV=2 SAMP_HUMAN (+1) 25 0.000 0.055 0.038 0.000 0.000 0.000 0.015 0.025 
285 
Cytoplasmic FMR1 interacting protein 1 
isoform A (Fragment) OS=Homo sapiens 
GN=CYFIP1 PE=2 SV=1 X5D2F4_HUMAN 145 0.029 0.019 0.000 0.006 0.000 0.036 0.015 0.016 
286 
Protein disulfide-isomerase A4 OS=Homo 
sapiens GN=ERP70 PE=3 SV=1 A0A090N8Y2_HUMAN (+1) 73 0.029 0.013 0.000 0.000 0.000 0.048 0.015 0.020 
287 
cDNA FLJ50491, highly similar to Amyloid 
beta A4 protein (APP) (ABPP)(Alzheimer 
disease amyloid protein) (Cerebral 
vascularamyloid peptide) (CVAP) 
(Protease nexin-II) (PN-II)(APPI) (PreA4) 
OS=Homo sapiens PE=2 SV=1 B4DGD0_HUMAN 81 0.046 0.000 0.000 0.000 0.000 0.044 0.015 0.023 
288 
CD36 antigen (Collagen type I receptor, 
thrombospondin receptor) OS=Homo 
sapiens GN=CD36 PE=2 SV=1 A4D1B1_HUMAN (+6) 53 0.020 0.000 0.000 0.000 0.000 0.067 0.014 0.027 
289 
L-lactate dehydrogenase A chain 
OS=Homo sapiens GN=LDHA PE=1 SV=2 LDHA_HUMAN (+1) 37 0.000 0.037 0.000 0.000 0.000 0.048 0.014 0.022 
290 
Proto-oncogene tyrosine-protein kinase 
Src OS=Homo sapiens GN=SRC PE=1 
SV=3 SRC_HUMAN 60 0.027 0.038 0.000 0.000 0.000 0.020 0.014 0.016 
291 
V-type proton ATPase catalytic subunit A 
OS=Homo sapiens GN=ATP6V1A PE=1 
SV=2 VATA_HUMAN 68 0.024 0.000 0.000 0.000 0.000 0.060 0.014 0.025 
292 
Heat shock 60kDa protein 1 (Chaperonin), 
isoform CRA_a OS=Homo sapiens 
GN=HSPD1 PE=2 SV=1 A0A024R3X4_HUMAN (+2) 61 0.035 0.000 0.000 0.000 0.000 0.048 0.014 0.022 
293 
cDNA, FLJ93545, highly similar to Homo 
sapiens 5-aminoimidazole-4-carboxamide 
ribonucleotide formyltransferase/IMP 
cyclohydrolase (ATIC), mRNA OS=Homo 
sapiens PE=2 SV=1 B2R7P8_HUMAN (+2) 65 0.041 0.014 0.000 0.000 0.000 0.027 0.014 0.017 
294 
cDNA, FLJ92620, highly similar to Homo 
sapiens staphylococcal nuclease domain 
containing 1 (SND1),mRNA OS=Homo 
sapiens PE=2 SV=1 B2R5U1_HUMAN (+3) 100 0.027 0.014 0.000 0.000 0.000 0.041 0.014 0.017 




































































OS=Homo sapiens GN=UBA7 PE=1 SV=2 
296 
Afamin OS=Homo sapiens GN=AFM PE=1 
SV=1 AFAM_HUMAN 69 0.000 0.040 0.028 0.013 0.000 0.000 0.013 0.017 
297 
Angiotensinogen variant (Fragment) 
OS=Homo sapiens PE=2 SV=1 Q53GY3_HUMAN (+3) 53 0.000 0.017 0.063 0.000 0.000 0.000 0.013 0.025 
298 
Dihydropyrimidinase-like 2 variant 
(Fragment) OS=Homo sapiens PE=2 SV=1 Q59GB4_HUMAN 68 0.063 0.000 0.000 0.000 0.000 0.017 0.013 0.025 
299 
Alpha-1-acid glycoprotein 2 OS=Homo 
sapiens GN=ORM2 PE=1 SV=2 A1AG2_HUMAN 24 0.000 0.000 0.079 0.000 0.000 0.000 0.013 0.032 
300 
Isocitrate dehydrogenase [NADP], 
mitochondrial OS=Homo sapiens 
GN=IDH2 PE=1 SV=2 IDHP_HUMAN (+1) 51 0.021 0.000 0.000 0.000 0.000 0.058 0.013 0.023 
301 
Integrin beta-1 OS=Homo sapiens 
GN=ITGB1 PE=1 SV=2 ITB1_HUMAN 88 0.018 0.000 0.000 0.000 0.000 0.060 0.013 0.024 
302 
Bridging integrator 2 OS=Homo sapiens 
GN=BIN2 PE=1 SV=1 A0A087X188_HUMAN (+4) 65 0.025 0.000 0.000 0.035 0.000 0.018 0.013 0.015 
303 
Protein diaphanous homolog 1 OS=Homo 
sapiens GN=DIAPH1 PE=1 SV=1 A0A0G2JH68_HUMAN (+3) 141 0.019 0.016 0.000 0.000 0.000 0.042 0.013 0.017 
304 
Chaperonin containing TCP1, subunit 6A 
(Zeta 1), isoform CRA_a OS=Homo 
sapiens GN=CCT6A PE=3 SV=1 A0A024RDL1_HUMAN (+2) 58 0.055 0.000 0.000 0.000 0.000 0.020 0.013 0.022 
305 
Lipopolysaccharide-binding protein 
OS=Homo sapiens GN=LBP PE=1 SV=3 LBP_HUMAN (+1) 53 0.000 0.017 0.036 0.000 0.000 0.022 0.013 0.015 
306 
Oncoprotein-induced transcript 3 protein 
OS=Homo sapiens GN=OIT3 PE=1 SV=2 OIT3_HUMAN 60 0.036 0.000 0.000 0.000 0.000 0.039 0.012 0.019 
307 
Calcium-transporting ATPase OS=Homo 
sapiens PE=2 SV=1 A8K9K1_HUMAN (+1) 109 0.015 0.000 0.000 0.000 0.000 0.059 0.012 0.024 
308 
Lumican OS=Homo sapiens GN=LUM 
PE=1 SV=2 LUM_HUMAN (+1) 38 0.000 0.036 0.038 0.000 0.000 0.000 0.012 0.019 
309 
cDNA, FLJ94361, highly similar to Homo 
sapiens serine (or cysteine) proteinase 
inhibitor, clade A(alpha-1 antiproteinase, 
antitrypsin), member 6 (SERPINA6), 
mRNA OS=Homo sapiens PE=2 SV=1 B2R9F2_HUMAN (+1) 45 0.000 0.051 0.021 0.000 0.000 0.000 0.012 0.021 
310 
Hydroxysteroid (17-beta) dehydrogenase 
4, isoform CRA_b (Fragment) OS=Homo 
sapiens GN=HSD17B4 PE=2 SV=1 A0A0S2Z4J1_HUMAN (+2) 80 0.020 0.000 0.000 0.000 0.000 0.051 0.012 0.021 
311 
Anti-HER3 scFv (Fragment) OS=Homo 
sapiens PE=2 SV=1 A2J422_HUMAN 26 0.000 0.070 0.000 0.000 0.000 0.000 0.012 0.029 
312 
Ig heavy chain V-III region TRO OS=Homo 
sapiens PE=1 SV=1 HV301_HUMAN 13 0.000 0.000 0.000 0.070 0.000 0.000 0.012 0.029 
313 
Beta-arrestin-1 (Fragment) OS=Homo 
sapiens GN=ARRB1 PE=1 SV=7 E9PM35_HUMAN 29 0.037 0.031 0.000 0.000 0.000 0.000 0.011 0.018 
314 
N-acetylmuramoyl-L-alanine amidase 
OS=Homo sapiens GN=PGLYRP2 PE=1 
SV=1 PGRP2_HUMAN 62 0.000 0.037 0.031 0.000 0.000 0.000 0.011 0.018 
315 
Fibulin-1 OS=Homo sapiens GN=FBLN1 
PE=1 SV=4 FBLN1_HUMAN 77 0.000 0.041 0.012 0.012 0.000 0.000 0.011 0.016 
316 
Selectin P (Granule membrane protein 
140kDa, antigen CD62), isoform CRA_b 
OS=Homo sapiens GN=SELP PE=4 SV=1 A0A024R8Y9_HUMAN (+7) 91 0.018 0.015 0.000 0.000 0.000 0.032 0.011 0.013 
317 
LIM and senescent cell antigen-like-
containing domain protein 3 OS=Homo 
sapiens GN=LIMS4 PE=1 SV=1 A0A0J9YXC7_HUMAN (+1) 46 0.035 0.030 0.000 0.000 0.000 0.000 0.011 0.017 
318 
T-complex protein 1 subunit delta 
OS=Homo sapiens PE=2 SV=1 A8K3C3_HUMAN (+1) 58 0.064 0.000 0.000 0.000 0.000 0.000 0.011 0.026 
319 
T-complex protein 1 subunit alpha 
OS=Homo sapiens GN=TCP1 PE=1 SV=1 TCPA_HUMAN 60 0.044 0.000 0.000 0.000 0.000 0.020 0.011 0.018 
320 
Glutathione reductase, mitochondrial 
OS=Homo sapiens GN=GSR PE=1 SV=2 GSHR_HUMAN (+1) 56 0.048 0.016 0.000 0.000 0.000 0.000 0.011 0.019 
321 
Phospholipase A2, group VII (Platelet-
activating factor acetylhydrolase, plasma), 
isoform CRA_a OS=Homo sapiens 
GN=PLA2G7 PE=4 SV=1 A0A024RD39_HUMAN (+2) 50 0.000 0.000 0.000 0.036 0.027 0.000 0.010 0.017 
322 
14-3-3 protein eta OS=Homo sapiens 
GN=YWHAH PE=1 SV=4 1433F_HUMAN (+1) 28 0.000 0.000 0.000 0.000 0.000 0.063 0.010 0.026 
323 
Tripeptidyl-peptidase 2 OS=Homo sapiens 
GN=TPP2 PE=1 SV=1 Q5VZU9_HUMAN (+1) 140 0.038 0.007 0.000 0.000 0.000 0.017 0.010 0.015 
324 
cGMP-dependent protein kinase 1 
OS=Homo sapiens GN=PRKG1 PE=1 
SV=1 A0A0A0MSB3_HUMAN (+1) 52 0.000 0.026 0.000 0.000 0.000 0.034 0.010 0.016 
325 
Alanine--tRNA ligase, cytoplasmic 
OS=Homo sapiens GN=AARS PE=1 SV=2 SYAC_HUMAN 107 0.010 0.009 0.000 0.009 0.000 0.033 0.010 0.012 
326 
Complement factor I OS=Homo sapiens 
GN=CFI PE=1 SV=2 CFAI_HUMAN (+2) 66 0.016 0.014 0.029 0.000 0.000 0.000 0.010 0.012 
327 
Reelin OS=Homo sapiens GN=RELN 
PE=1 SV=1 J3KQ66_HUMAN (+1) 388 0.025 0.011 0.005 0.000 0.000 0.018 0.010 0.010 




































































GN=DPP3 PE=1 SV=2 
329 
TNC variant protein (Fragment) OS=Homo 
sapiens GN=TNC variant protein PE=2 
SV=1 Q4LE33_HUMAN 244 0.017 0.006 0.000 0.011 0.020 0.000 0.009 0.009 
330 
Phosphodiesterase 5A OS=Homo sapiens 
PE=2 SV=1 I6NLS4_HUMAN (+1) 100 0.000 0.018 0.000 0.000 0.000 0.035 0.009 0.015 
331 
Carboxypeptidase N catalytic chain 
OS=Homo sapiens GN=CPN1 PE=1 SV=1 CBPN_HUMAN 52 0.000 0.035 0.018 0.000 0.000 0.000 0.009 0.015 
332 
IgG H chain OS=Homo sapiens PE=2 
SV=1 S6AWF0_HUMAN 25 0.000 0.000 0.000 0.000 0.053 0.000 0.009 0.022 
333 
NAD-dependent malic enzyme, 
mitochondrial OS=Homo sapiens GN=ME2 
PE=1 SV=1 MAOM_HUMAN 65 0.025 0.000 0.000 0.000 0.000 0.027 0.009 0.013 
334 
cDNA FLJ56381, highly similar to 
Dynamin-1-like protein (EC 3.6.5.5) 
OS=Homo sapiens PE=2 SV=1 B4DYR6_HUMAN (+5) 85 0.013 0.011 0.000 0.000 0.000 0.028 0.008 0.011 
335 
Thyroxine-binding globulin OS=Homo 
sapiens GN=SERPINA7 PE=1 SV=2 THBG_HUMAN 46 0.000 0.020 0.031 0.000 0.000 0.000 0.008 0.014 
336 
Ras-related C3 botulinum toxin substrate 2 
(Rho family, small GTP binding protein 
Rac2), isoform CRA_a OS=Homo sapiens 
GN=RAC2 PE=3 SV=1 A0A024R1P2_HUMAN (+5) 21 0.051 0.000 0.000 0.000 0.000 0.000 0.008 0.021 
337 
Collagen alpha-1(VI) chain OS=Homo 
sapiens GN=COL6A1 PE=1 SV=1 A0A087X0S5_HUMAN (+1) 108 0.020 0.008 0.000 0.000 0.000 0.022 0.008 0.010 
338 
Rho GTPase activating protein OS=Homo 
sapiens PE=2 SV=1 A9UK01_HUMAN (+1) 75 0.014 0.000 0.000 0.012 0.000 0.024 0.008 0.010 
339 
ATP-citrate synthase OS=Homo sapiens 
GN=ACLY PE=3 SV=1 A0A024R1T9_HUMAN (+3) 121 0.018 0.008 0.000 0.000 0.000 0.024 0.008 0.010 
340 
Proteoglycan 1, secretory granule, isoform 
CRA_a OS=Homo sapiens GN=PRG1 
PE=4 SV=1 A0A024QZL1_HUMAN (+1) 18 0.000 0.000 0.000 0.000 0.049 0.000 0.008 0.020 
341 
Coatomer subunit alpha OS=Homo 
sapiens GN=COPA PE=1 SV=2 COPA_HUMAN 138 0.027 0.000 0.000 0.000 0.000 0.021 0.008 0.013 
342 
cDNA FLJ78437, highly similar to Homo 
sapiens cartilage oligomeric matrix protein 
(COMP), mRNA OS=Homo sapiens PE=2 
SV=1 A8K3I0_HUMAN (+4) 83 0.026 0.000 0.000 0.000 0.000 0.021 0.008 0.012 
343 
Glutathione S-transferase P OS=Homo 
sapiens GN=GSTP1 PE=1 SV=2 GSTP1_HUMAN (+1) 23 0.046 0.000 0.000 0.000 0.000 0.000 0.008 0.019 
344 
IgG H chain OS=Homo sapiens PE=2 
SV=1 S6B2B6_HUMAN 29 0.000 0.000 0.000 0.000 0.046 0.000 0.008 0.019 
345 Fibulin-1 OS=Homo sapiens PE=2 SV=1 B4DUV1_HUMAN 70 0.000 0.046 0.000 0.000 0.000 0.000 0.008 0.019 
346 
Ras suppressor protein 1 variant 5 
OS=Homo sapiens GN=RSU1 PE=4 SV=1 B0YJ73_HUMAN (+1) 26 0.000 0.000 0.000 0.000 0.000 0.045 0.008 0.018 
347 
Integrin alpha-6 OS=Homo sapiens 
GN=ITGA6 PE=1 SV=5 ITA6_HUMAN 127 0.017 0.000 0.000 0.000 0.000 0.028 0.007 0.012 
348 
PDZ and LIM domain protein 1 OS=Homo 
sapiens GN=PDLIM1 PE=1 SV=4 PDLI1_HUMAN (+1) 36 0.044 0.000 0.000 0.000 0.000 0.000 0.007 0.018 
349 
Vacuolar protein sorting 35 variant 
(Fragment) OS=Homo sapiens PE=2 SV=1 Q53FR4_HUMAN (+2) 92 0.012 0.010 0.000 0.010 0.000 0.013 0.007 0.006 
350 
Vasodilator-stimulated phosphoprotein 
isoform 1 OS=Homo sapiens GN=VASP 
PE=2 SV=1 A0A024R0V4_HUMAN (+2) 40 0.000 0.000 0.000 0.000 0.000 0.044 0.007 0.018 
351 
Signal transducer and activator of 
transcription (Fragment) OS=Homo 
sapiens PE=2 SV=1 Q59H39_HUMAN (+1) 90 0.018 0.000 0.000 0.000 0.000 0.026 0.007 0.012 
352 
Septin 6, isoform CRA_b OS=Homo 
sapiens GN=SEPT6 PE=1 SV=1 B1AMS2_HUMAN (+9) 49 0.043 0.000 0.000 0.000 0.000 0.000 0.007 0.018 
353 
Insulin-like growth factor-binding protein 
complex acid labile subunit OS=Homo 
sapiens GN=IGFALS PE=1 SV=1 ALS_HUMAN (+2) 66 0.000 0.000 0.043 0.000 0.000 0.000 0.007 0.018 
354 
Sushi, von Willebrand factor type A, EGF 
and pentraxin domain-containing protein 1 
OS=Homo sapiens GN=SVEP1 PE=1 
SV=1 A0A0A0MSD0_HUMAN (+1) 390 0.038 0.000 0.002 0.000 0.002 0.000 0.007 0.015 
355 
EMILIN-1 OS=Homo sapiens 
GN=EMILIN1 PE=1 SV=1 A0A0C4DFX3_HUMAN (+1) 107 0.010 0.000 0.000 0.000 0.000 0.033 0.007 0.013 
356 
Ras GTPase-activating protein 3 
OS=Homo sapiens GN=RASA3 PE=1 
SV=3 RASA3_HUMAN 96 0.000 0.000 0.000 0.000 0.000 0.043 0.007 0.017 
357 
Glycyl-tRNA synthetase OS=Homo 
sapiens GN=GARS PE=4 SV=1 A0A090N8G0_HUMAN (+1) 78 0.027 0.000 0.000 0.000 0.000 0.015 0.007 0.012 
358 
cDNA FLJ53218, highly similar to Homo 
sapiens SAC1 suppressor of actin 
mutations 1-like (SACM1L), mRNA 
OS=Homo sapiens PE=2 SV=1 B4DVV3_HUMAN (+2) 56 0.000 0.000 0.000 0.000 0.000 0.042 0.007 0.017 
359 
Collagen alpha-3(VI) chain OS=Homo 





































































Platelet endothelial cell adhesion molecule 
OS=Homo sapiens GN=PECAM1 PE=1 
SV=1 A0A075B738_HUMAN (+2) 83 0.013 0.000 0.000 0.000 0.000 0.028 0.007 0.012 
361 
Solute carrier family 2, facilitated glucose 
transporter member 14 OS=Homo sapiens 
GN=SLC2A14 PE=2 SV=1 GTR14_HUMAN (+1) 56 0.019 0.000 0.000 0.000 0.000 0.021 0.007 0.010 
362 
cDNA, FLJ96812, highly similar to Homo 
sapiens threonyl-tRNA synthetase (TARS), 
mRNA OS=Homo sapiens PE=1 SV=1 B2RDX5_HUMAN (+2) 82 0.000 0.011 0.000 0.000 0.000 0.029 0.007 0.012 
363 
Serine/threonine-protein phosphatase 2A 
65 kDa regulatory subunit A alpha isoform 
OS=Homo sapiens GN=PPP2R1A PE=1 
SV=4 2AAA_HUMAN (+5) 65 0.025 0.014 0.000 0.000 0.000 0.000 0.006 0.011 
364 
UDP-glucose:glycoprotein 
glucosyltransferase 1 OS=Homo sapiens 
GN=UGGT1 PE=1 SV=3 UGGG1_HUMAN 177 0.012 0.000 0.000 0.000 0.000 0.027 0.006 0.011 
365 
Serpin peptidase inhibitor, clade A (Alpha-
1 antiproteinase, antitrypsin), member 4, 
isoform CRA_a OS=Homo sapiens 
GN=SERPINA4 PE=3 SV=1 A0A024R6I9_HUMAN (+2) 49 0.000 0.019 0.019 0.000 0.000 0.000 0.006 0.010 
366 
6-phosphogluconate dehydrogenase, 
decarboxylating OS=Homo sapiens 
GN=PGD PE=1 SV=3 6PGD_HUMAN (+1) 53 0.020 0.017 0.000 0.000 0.000 0.000 0.006 0.010 
367 
Dynamin-2 OS=Homo sapiens GN=DNM2 
PE=1 SV=2 DYN2_HUMAN 98 0.011 0.000 0.000 0.000 0.000 0.024 0.006 0.010 
368 
Myosin light chain kinase, smooth muscle 
OS=Homo sapiens GN=MYLK PE=1 SV=4 MYLK_HUMAN 211 0.010 0.011 0.000 0.000 0.000 0.014 0.006 0.006 
369 
Calnexin OS=Homo sapiens GN=CANX 
PE=1 SV=2 CALX_HUMAN 68 0.000 0.000 0.000 0.000 0.000 0.035 0.006 0.014 
370 
Lipopolysaccharide-responsive and beige-
like anchor protein OS=Homo sapiens 
GN=LRBA PE=1 SV=1 E9PEM5_HUMAN 287 0.011 0.000 0.000 0.000 0.000 0.023 0.006 0.009 
371 
Xaa-Pro aminopeptidase 1 OS=Homo 
sapiens GN=XPNPEP1 PE=1 SV=3 XPP1_HUMAN 70 0.000 0.000 0.000 0.000 0.000 0.034 0.006 0.014 
372 
CD47 OS=Homo sapiens GN=CD47 PE=2 
SV=1 A0A0A1TSG4_HUMAN (+1) 32 0.033 0.000 0.000 0.000 0.000 0.000 0.006 0.014 
373 
cDNA FLJ59760, highly similar to 1,4-
alpha-glucan branching enzyme (EC 
2.4.1.18) OS=Homo sapiens PE=2 SV=1 B4DUF1_HUMAN (+3) 76 0.021 0.012 0.000 0.000 0.000 0.000 0.006 0.009 
374 
Hepatocyte growth factor activator 
OS=Homo sapiens GN=HGFAC PE=1 
SV=1 D6RAR4_HUMAN (+1) 71 0.000 0.019 0.013 0.000 0.000 0.000 0.005 0.009 
375 
cDNA, FLJ94267, highly similar to Homo 
sapiens glutathione S-transferase omega 1 
(GSTO1), mRNA OS=Homo sapiens PE=2 
SV=1 B2R983_HUMAN (+4) 28 0.000 0.033 0.000 0.000 0.000 0.000 0.005 0.013 
376 
Apolipoprotein A-V, isoform CRA_a 
OS=Homo sapiens GN=APOA5 PE=4 
SV=1 A0A0B4RUS7_HUMAN (+3) 41 0.000 0.000 0.000 0.000 0.032 0.000 0.005 0.013 
377 
Platelet glycoprotein VI OS=Homo sapiens 
GN=GP6 PE=1 SV=4 GPVI_HUMAN 37 0.000 0.000 0.000 0.000 0.000 0.032 0.005 0.013 
378 
Aldehyde dehydrogenase family 16 
member A1 OS=Homo sapiens 
GN=ALDH16A1 PE=1 SV=2 A16A1_HUMAN (+3) 85 0.000 0.011 0.000 0.000 0.000 0.021 0.005 0.009 
379 
MHC class I antigen (Fragment) OS=Homo 
sapiens GN=HLA-A PE=3 SV=1 F6IQV5_HUMAN 38 0.000 0.000 0.000 0.000 0.000 0.031 0.005 0.013 
380 
X-DING-CD4 (Fragment) OS=Homo 
sapiens PE=2 SV=1 R4H484_HUMAN 30 0.000 0.030 0.000 0.000 0.000 0.000 0.005 0.012 
381 
cDNA FLJ53963, highly similar to 
Leukocyte elastase inhibitor OS=Homo 
sapiens PE=2 SV=1 B4E3A8_HUMAN (+2) 39 0.000 0.000 0.000 0.000 0.000 0.030 0.005 0.012 
382 
SLAM family member 5 OS=Homo sapiens 
GN=CD84 PE=1 SV=1 SLAF5_HUMAN 39 0.000 0.000 0.000 0.000 0.000 0.030 0.005 0.012 
383 
Tyrosine-protein kinase BTK OS=Homo 
sapiens GN=BTK PE=1 SV=3 BTK_HUMAN 76 0.014 0.000 0.000 0.000 0.000 0.015 0.005 0.008 
384 
ATP synthase subunit alpha, mitochondrial 
OS=Homo sapiens GN=ATP5A1 PE=1 
SV=1 ATPA_HUMAN (+1) 60 0.000 0.000 0.000 0.000 0.000 0.029 0.005 0.012 
385 
Attractin OS=Homo sapiens GN=ATRN 
PE=1 SV=2 ATRN_HUMAN (+1) 159 0.000 0.017 0.006 0.006 0.000 0.000 0.005 0.007 
386 
Actin related protein 2/3 complex, subunit 
1B, 41kDa OS=Homo sapiens 
GN=ARPC1B PE=2 SV=1 A4D275_HUMAN (+1) 41 0.000 0.000 0.000 0.000 0.000 0.029 0.005 0.012 
387 
Coagulation factor VIII OS=Homo sapiens 
GN=F8 PE=1 SV=1 FA8_HUMAN 267 0.010 0.000 0.007 0.000 0.000 0.011 0.005 0.005 
388 
ATP synthase subunit beta, mitochondrial 
OS=Homo sapiens GN=ATP5B PE=1 





































































cDNA FLJ45348 fis, clone BRHIP3011269, 
weakly similar to Prenylcysteine oxidase 
(EC 1.8.3.5) OS=Homo sapiens PE=2 
SV=1 B3KXF9_HUMAN (+2) 42 0.000 0.000 0.000 0.000 0.000 0.028 0.005 0.011 
390 
HMHA1 protein (Fragment) OS=Homo 
sapiens GN=HMHA1 PE=2 SV=1 Q8IYN3_HUMAN 124 0.009 0.000 0.000 0.000 0.000 0.019 0.005 0.008 
391 
Phosphoglucomutase-2 OS=Homo 
sapiens GN=PGM2 PE=1 SV=4 PGM2_HUMAN 68 0.000 0.000 0.000 0.000 0.000 0.026 0.004 0.011 
392 
Protein 4.1 OS=Homo sapiens GN=EPB41 
PE=1 SV=4 41_HUMAN (+2) 97 0.011 0.000 0.015 0.000 0.000 0.000 0.004 0.007 
393 
cDNA FLJ56358, highly similar to Cytosolic 
nonspecific dipeptidase OS=Homo sapiens 
PE=2 SV=1 B4DPF1_HUMAN (+2) 42 0.025 0.000 0.000 0.000 0.000 0.000 0.004 0.010 
394 
Fatty acid synthase OS=Homo sapiens 
GN=FASN PE=1 SV=1 A0A0U1RQF0_HUMAN (+1) 273 0.012 0.000 0.000 0.000 0.000 0.013 0.004 0.006 
395 
Bromodomain adjacent to zinc finger 
domain protein 2B OS=Homo sapiens 
GN=BAZ2B PE=1 SV=3 BAZ2B_HUMAN 240 0.009 0.000 0.000 0.000 0.000 0.015 0.004 0.006 
396 
Acyl-coenzyme A oxidase OS=Homo 
sapiens GN=ACOX1 PE=3 SV=1 A0A024R8L7_HUMAN (+2) 75 0.000 0.000 0.000 0.000 0.000 0.024 0.004 0.010 
397 
ARP3 actin-related protein 3 homolog 
(Yeast), isoform CRA_a OS=Homo 
sapiens GN=ACTR3 PE=3 SV=1 A0A024RAI1_HUMAN (+3) 47 0.023 0.000 0.000 0.000 0.000 0.000 0.004 0.009 
398 
Hypoxia up-regulated protein 1 OS=Homo 
sapiens GN=HYOU1 PE=1 SV=1 A0A087X054_HUMAN (+2) 105 0.000 0.000 0.000 0.000 0.000 0.022 0.004 0.009 
399 
Coatomer subunit beta' OS=Homo sapiens 
GN=COPB2 PE=1 SV=2 COPB2_HUMAN 102 0.010 0.000 0.000 0.000 0.000 0.012 0.004 0.006 
400 
Nck-associated protein 1 OS=Homo 
sapiens GN=NCKAP1 PE=1 SV=1 NCKP1_HUMAN 129 0.008 0.000 0.000 0.000 0.000 0.014 0.004 0.006 
401 
Carboxypeptidase B2 OS=Homo sapiens 
GN=CPB2 PE=1 SV=1 A0A087WSY5_HUMAN (+1) 44 0.000 0.000 0.022 0.000 0.000 0.000 0.004 0.009 
402 
ADAM metallopeptidase domain 10, 
isoform CRA_b OS=Homo sapiens 
GN=ADAM10 PE=4 SV=1 A0A024R5U5_HUMAN (+1) 84 0.000 0.000 0.000 0.000 0.000 0.021 0.003 0.009 
403 
Complement factor properdin isoform 1 
(Fragment) OS=Homo sapiens GN=CFP 
PE=2 SV=1 A0A0S2Z4I5_HUMAN (+1) 51 0.021 0.000 0.000 0.000 0.000 0.000 0.003 0.009 
404 
Neurobeachin-like protein 2 OS=Homo 
sapiens GN=NBEAL2 PE=1 SV=2 NBEL2_HUMAN 303 0.005 0.000 0.000 0.000 0.000 0.016 0.003 0.006 
405 
Collagen alpha-2(VI) chain OS=Homo 
sapiens GN=COL6A2 PE=1 SV=4 CO6A2_HUMAN 109 0.010 0.000 0.000 0.000 0.000 0.011 0.003 0.005 
406 
cDNA FLJ61564, highly similar to Plexin 
domain-containing protein 2 OS=Homo 
sapiens PE=2 SV=1 B4E367_HUMAN (+1) 58 0.000 0.000 0.000 0.000 0.000 0.020 0.003 0.008 
407 
Kinesin-like protein KIF2A OS=Homo 
sapiens GN=KIF2A PE=1 SV=3 KIF2A_HUMAN 80 0.020 0.000 0.000 0.000 0.000 0.000 0.003 0.008 
408 
Protein kinase C substrate 80K-H, isoform 
CRA_a OS=Homo sapiens GN=PRKCSH 
PE=4 SV=1 A0A024R7F1_HUMAN (+5) 59 0.000 0.000 0.000 0.000 0.000 0.020 0.003 0.008 
409 
Coronin OS=Homo sapiens GN=CORO1B 
PE=3 SV=1 A0A024R5K1_HUMAN (+5) 54 0.020 0.000 0.000 0.000 0.000 0.000 0.003 0.008 
410 
T-complex protein 1 subunit beta 
OS=Homo sapiens GN=CCT2 PE=1 SV=2 F5GWF6_HUMAN (+3) 57 0.019 0.000 0.000 0.000 0.000 0.000 0.003 0.008 
411 
cDNA FLJ76863, highly similar to Homo 
sapiens stress-induced-phosphoprotein 1 
(Hsp70/Hsp90-organizing protein) (STIP1), 
mRNA OS=Homo sapiens PE=2 SV=1 A8K690_HUMAN (+2) 63 0.000 0.000 0.000 0.000 0.000 0.019 0.003 0.008 
412 
Laminin, gamma 1 (Formerly LAMB2), 
isoform CRA_a OS=Homo sapiens 
GN=LAMC1 PE=4 SV=1 A0A024R972_HUMAN (+1) 174 0.006 0.000 0.000 0.000 0.005 0.007 0.003 0.003 
413 
Coagulation factor IX OS=Homo sapiens 
GN=F9 p22 PE=2 SV=1 F2RM37_HUMAN (+1) 52 0.000 0.018 0.000 0.000 0.000 0.000 0.003 0.007 
414 
Heparanase, isoform CRA_a OS=Homo 
sapiens GN=HPSE PE=4 SV=1 A0A024RDB8_HUMAN (+2) 61 0.017 0.000 0.000 0.000 0.000 0.000 0.003 0.007 
415 
cDNA, FLJ95309, highly similar to Homo 
sapiens adenosine monophosphate 
deaminase 2 (isoform L)(AMPD2), mRNA 
OS=Homo sapiens PE=2 SV=1 B2RB47_HUMAN 101 0.000 0.000 0.000 0.000 0.000 0.017 0.003 0.007 
416 
cDNA FLJ50778, highly similar to Protein 
flightless-1 homolog OS=Homo sapiens 
PE=2 SV=1 B4DIX0_HUMAN (+1) 141 0.000 0.000 0.000 0.000 0.000 0.017 0.003 0.007 
417 
Type 1 tumor necrosis factor receptor 
shedding aminopeptidase regulator, 
isoform CRA_a OS=Homo sapiens 
GN=ARTS-1 PE=4 SV=1 A0A024RAR8_HUMAN (+13) 107 0.000 0.000 0.000 0.000 0.000 0.016 0.003 0.007 
418 
Phospholipid transfer protein, isoform 
CRA_c OS=Homo sapiens GN=PLTP 





































































HLA-B associated transcript 5, isoform 
CRA_b OS=Homo sapiens GN=ABHD16A 
PE=1 SV=1 A0A0G2JJD3_HUMAN (+2) 68 0.016 0.000 0.000 0.000 0.000 0.000 0.003 0.006 
420 
Signal transducer and activator of 
transcription OS=Homo sapiens PE=2 
SV=1 B4DNP0_HUMAN (+4) 76 0.000 0.000 0.000 0.000 0.000 0.015 0.003 0.006 
421 
ATPase Ca++ transporting cardiac muscle 
slow twitch 2 isoform 1 (Fragment) 
OS=Homo sapiens GN=ATP2A2 PE=2 
SV=1 A0A0S2Z3L2_HUMAN (+2) 115 0.000 0.000 0.000 0.000 0.000 0.015 0.003 0.006 
422 
Glycerol-3-phosphate dehydrogenase 
(Fragment) OS=Homo sapiens GN=GPD2 
PE=3 SV=1 Q53T76_HUMAN 77 0.000 0.000 0.000 0.000 0.000 0.015 0.003 0.006 
423 
N-acylaminoacyl-peptide hydrolase, 
isoform CRA_b OS=Homo sapiens 
GN=APEH PE=4 SV=1 A0A024R2U9_HUMAN (+2) 81 0.000 0.000 0.000 0.000 0.000 0.015 0.002 0.006 
424 
Malic enzyme OS=Homo sapiens PE=2 
SV=1 A8K168_HUMAN (+1) 64 0.000 0.014 0.000 0.000 0.000 0.000 0.002 0.006 
425 
Integrin alpha-2 OS=Homo sapiens 
GN=ITGA2 PE=1 SV=1 ITA2_HUMAN 129 0.000 0.000 0.000 0.000 0.000 0.014 0.002 0.006 
426 
cDNA FLJ78440, highly similar to Human 
lactoferrin OS=Homo sapiens PE=2 SV=1 A8K494_HUMAN (+8) 78 0.014 0.000 0.000 0.000 0.000 0.000 0.002 0.006 
427 
cDNA FLJ55918, highly similar to 
Echinoderm microtubule-associated 
protein-like 2 OS=Homo sapiens PE=2 
SV=1 B7Z2F5_HUMAN (+2) 87 0.000 0.000 0.000 0.000 0.000 0.014 0.002 0.006 
428 
NHL repeat-containing protein 2 OS=Homo 
sapiens GN=NHLRC2 PE=1 SV=1 NHLC2_HUMAN 79 0.013 0.000 0.000 0.000 0.000 0.000 0.002 0.006 
429 
Coagulation factor XII OS=Homo sapiens 
GN=F12 PE=4 SV=1 A0A0R7FJH5_HUMAN (+2) 68 0.000 0.013 0.000 0.000 0.000 0.000 0.002 0.005 
430 
Aconitate hydratase, mitochondrial 
OS=Homo sapiens GN=ACO2 PE=1 SV=1 A2A274_HUMAN (+7) 88 0.000 0.000 0.000 0.000 0.000 0.013 0.002 0.005 
431 
Carnitine palmitoyltransferase 1A (Liver), 
isoform CRA_a OS=Homo sapiens 
GN=CPT1A PE=3 SV=1 A0A024R5F4_HUMAN (+2) 88 0.000 0.000 0.000 0.000 0.000 0.013 0.002 0.005 
432 
cDNA FLJ50510, highly similar to Heat 
shock 70 kDa protein 4 OS=Homo sapiens 
PE=2 SV=1 B4DH02_HUMAN (+3) 94 0.000 0.000 0.000 0.000 0.000 0.013 0.002 0.005 
433 
Prolow-density lipoprotein receptor-related 
protein 1 OS=Homo sapiens GN=LRP1 
PE=1 SV=2 LRP1_HUMAN 505 0.004 0.002 0.000 0.000 0.003 0.003 0.002 0.002 
434 
Cytoplasmic aconitate hydratase 
OS=Homo sapiens GN=ACO1 PE=1 SV=3 ACOC_HUMAN (+1) 98 0.000 0.000 0.000 0.000 0.000 0.012 0.002 0.005 
435 
cDNA FLJ77762, highly similar to Homo 
sapiens cullin-associated and neddylation-
dissociated 1 (CAND1), mRNA OS=Homo 
sapiens PE=2 SV=1 A8K8U1_HUMAN (+1) 136 0.012 0.000 0.000 0.000 0.000 0.000 0.002 0.005 
436 
Phosphatidylinositol-glycan-specific 
phospholipase D OS=Homo sapiens 
GN=GPLD1 PE=1 SV=3 PHLD_HUMAN 92 0.000 0.000 0.010 0.000 0.000 0.000 0.002 0.004 
437 
cDNA FLJ51067, highly similar to DNA 
damage-binding protein 1 OS=Homo 
sapiens PE=2 SV=1 B4DSA8_HUMAN (+3) 112 0.010 0.000 0.000 0.000 0.000 0.000 0.002 0.004 
438 
Spectrin beta chain, non-erythrocytic 2 
OS=Homo sapiens GN=SPTBN2 PE=1 
SV=3 SPTN2_HUMAN 271 0.000 0.000 0.009 0.000 0.000 0.000 0.001 0.004 
439 
Epididymis luminal protein 102 OS=Homo 
sapiens GN=SPTBN1 PE=2 SV=1 B2ZZ89_HUMAN (+2) 275 0.000 0.000 0.000 0.000 0.000 0.009 0.001 0.003 
440 
Dynactin subunit 1 OS=Homo sapiens 
GN=DCTN1 PE=1 SV=3 DCTN1_HUMAN (+2) 142 0.000 0.000 0.000 0.000 0.000 0.008 0.001 0.003 
441 
Laminin subunit beta-1 OS=Homo sapiens 
GN=LAMB1 PE=1 SV=1 G3XAI2_HUMAN (+1) 200 0.000 0.000 0.000 0.000 0.007 0.000 0.001 0.003 
442 
Cytoplasmic dynein 1 heavy chain 1 
OS=Homo sapiens GN=DYNC1H1 PE=1 
SV=5 DYHC1_HUMAN 532 0.006 0.000 0.000 0.000 0.000 0.000 0.001 0.002 
443 
Tenascin-X OS=Homo sapiens GN=TNXB 
PE=1 SV=1 A0A087X0I0_HUMAN (+2) 213 0.000 0.000 0.000 0.000 0.000 0.006 0.001 0.002 
444 
Hornerin OS=Homo sapiens GN=HRNR 
PE=1 SV=2 HORN_HUMAN 282 0.000 0.000 0.000 0.003 0.000 0.000 0.001 0.001 
445 
Hemicentin-1 OS=Homo sapiens 







































































Supporting Table 4 
Table S4: Blood-circulation proteome analysis. Full list of proteins identified in plasma samples recovered 
from 6 ovarian carcinoma patients (across all samples). 


















Serum albumin OS=Homo sapiens GN=ALB 
PE=1 SV=2 ALBU_HUMAN 69 5.712 8.072 7.063 9.004 7.367 14.689 8.651 3.154 
2 
Putative uncharacterized protein 
DKFZp686C11235 OS=Homo sapiens 
GN=DKFZp686C11235 PE=1 SV=1 Q6MZV7_HUMAN 52 2.575 3.134 2.616 3.189 2.506 2.863 2.814 0.295 
3 
IGH@ protein OS=Homo sapiens GN=IGH@ 
PE=1 SV=1 Q6GMX6_HUMAN 51 2.195 2.551 2.253 2.503 2.837 2.488 2.471 0.230 
4 
Putative uncharacterized protein 
DKFZp686I04196 (Fragment) OS=Homo 
sapiens GN=DKFZp686I04196 PE=1 SV=1 Q6N093_HUMAN 46 2.030 3.134 2.077 2.659 2.218 2.532 2.442 0.421 
5 
Ig gamma-1 chain C region OS=Homo sapiens 
GN=IGHG1 PE=1 SV=1 A0A087WV47_HUMAN (+1) 51 2.220 2.459 2.184 2.455 2.746 2.424 2.415 0.202 
6 cDNA FLJ78387 OS=Homo sapiens PE=1 SV=1 A8K008_HUMAN 52 2.283 2.420 2.142 2.473 2.702 2.451 2.412 0.189 
7 
Transferrin variant (Fragment) OS=Homo 
sapiens PE=2 SV=1 Q53H26_HUMAN 77 1.810 2.250 1.807 2.637 2.602 2.911 2.336 0.459 
8 
Putative uncharacterized protein 
DKFZp686C15213 OS=Homo sapiens 
GN=DKFZp686C15213 PE=1 SV=1 Q6MZU6_HUMAN 51 1.855 2.855 1.890 2.408 1.928 2.187 2.187 0.390 
9 
Haptoglobin OS=Homo sapiens GN=HP PE=1 
SV=4 H0Y300_HUMAN 49 2.319 1.639 2.471 1.875 2.006 2.433 2.124 0.336 
10 
Putative uncharacterized protein 
DKFZp686G11190 OS=Homo sapiens 
GN=DKFZp686G11190 PE=1 SV=1 Q6MZQ6_HUMAN 52 1.860 2.023 1.820 2.110 2.399 1.976 2.031 0.209 
11 
Ig gamma-3 chain C region OS=Homo sapiens 
GN=IGHG3 PE=4 SV=1 A0A087WXL8_HUMAN 57 1.808 2.290 1.776 2.273 1.676 2.274 2.016 0.291 
12 
Haptoglobin (Fragment) OS=Homo sapiens 
GN=HP PE=1 SV=1 H3BS21_HUMAN 25 2.332 1.540 2.289 1.508 1.744 2.461 1.979 0.429 
13 
Fibrinogen alpha chain OS=Homo sapiens 
GN=FGA PE=1 SV=2 FIBA_HUMAN 95 1.819 1.720 2.368 2.092 1.694 2.035 1.955 0.260 
14 
Ig gamma-1 chain C region OS=Homo sapiens 
GN=IGHG1 PE=1 SV=1 A0A087WYC5_HUMAN 52 2.120 2.330 2.083 2.362 2.613 0.000 1.918 0.959 
15 
Complement C3 OS=Homo sapiens GN=C3 
PE=1 SV=2 CO3_HUMAN (+1) 187 1.927 2.207 1.820 1.536 1.835 1.889 1.869 0.216 
16 
Alpha-2-macroglobulin OS=Homo sapiens 
GN=A2M PE=1 SV=3 A2MG_HUMAN 163 1.514 1.740 1.007 1.667 2.265 1.715 1.651 0.406 
17 
Fibrinogen beta chain OS=Homo sapiens 
GN=FGB PE=1 SV=2 FIBB_HUMAN (+1) 56 1.441 1.291 1.667 1.537 1.259 1.707 1.484 0.187 
18 
Lambda-chain (AA -20 to 215) OS=Homo 
sapiens PE=1 SV=1 A2NUT2_HUMAN 25 1.284 1.446 1.479 1.489 1.169 1.362 1.372 0.126 
19 
IGL@ protein OS=Homo sapiens GN=IGL@ 
PE=2 SV=1 Q6PIQ7_HUMAN 25 1.234 1.465 1.550 1.392 1.113 1.340 1.349 0.158 
20 
IGL@ protein OS=Homo sapiens GN=IGL@ 
PE=1 SV=1 Q8N355_HUMAN 25 1.267 1.446 1.444 1.431 1.132 1.340 1.343 0.126 
21 
Protein IGHV3-72 OS=Homo sapiens 
GN=IGHV3-72 PE=4 SV=1 A0A087WW89_HUMAN 11 1.421 1.195 1.161 1.538 1.265 1.199 1.296 0.150 
22 
cDNA FLJ14473 fis, clone MAMMA1001080, 
highly similar to Homo sapiens SNC73 protein 
(SNC73) mRNA OS=Homo sapiens PE=2 SV=1 Q96K68_HUMAN 53 1.172 1.630 1.096 1.286 0.980 1.337 1.250 0.226 
23 
Alpha-1-antitrypsin OS=Homo sapiens 
GN=SERPINA1 PE=1 SV=3 A1AT_HUMAN (+1) 47 1.402 1.339 0.965 1.173 1.283 1.169 1.222 0.156 
24 
Putative uncharacterized protein 
DKFZp686P15220 OS=Homo sapiens 
GN=DKFZp686P15220 PE=1 SV=1 Q6N089_HUMAN 52 2.120 2.348 0.000 0.000 2.622 0.000 1.182 1.304 
25 
Ig gamma-4 chain C region OS=Homo sapiens 
GN=IGHG4 PE=1 SV=1 IGHG4_HUMAN (+1) 36 1.127 1.370 0.905 1.061 1.494 1.099 1.176 0.216 
26 
Haptoglobin-related protein OS=Homo sapiens 
GN=HPR PE=1 SV=2 HPTR_HUMAN 39 1.376 1.048 1.287 0.992 1.035 1.183 1.153 0.155 
27 IgG H chain OS=Homo sapiens PE=1 SV=1 S6B291_HUMAN 51 2.137 0.000 2.115 0.000 2.664 0.000 1.153 1.278 
28 
Fibrinogen gamma chain OS=Homo sapiens 
GN=FGG PE=1 SV=3 FIBG_HUMAN 52 1.056 0.984 1.287 1.162 0.972 1.109 1.095 0.119 
29 IgG L chain OS=Homo sapiens PE=1 SV=1 S6BGD6_HUMAN 25 1.048 1.165 1.215 1.180 0.890 1.033 1.088 0.122 
30 
Ig mu chain C region OS=Homo sapiens 





































































Immunoglobulin heavy chain variant (Fragment) 
OS=Homo sapiens PE=2 SV=1 Q9NPP6_HUMAN 45 0.967 1.325 0.910 0.999 0.866 1.086 1.026 0.165 
32 
Hemopexin OS=Homo sapiens GN=HPX PE=1 
SV=2 HEMO_HUMAN 52 0.894 1.102 1.075 0.948 0.865 1.225 1.018 0.139 
33 IgG H chain OS=Homo sapiens PE=2 SV=1 S6BGE0_HUMAN 32 1.162 1.247 1.059 1.103 1.043 0.000 0.936 0.464 
34 
Apolipoprotein B (Including Ag(X) antigen) 
OS=Homo sapiens GN=APOB PE=4 SV=1 C0JYY2_HUMAN 516 0.736 1.033 0.672 0.840 1.211 0.942 0.906 0.199 
35 
Ig mu chain C region OS=Homo sapiens 
GN=IGHM PE=1 SV=1 A0A087WYJ9_HUMAN 66 0.877 0.904 1.101 1.048 1.497 0.000 0.904 0.496 
36 
Epididymis tissue protein Li 173 OS=Homo 
sapiens PE=2 SV=1 E9KL26_HUMAN (+1) 55 1.014 0.990 0.776 0.765 0.902 0.879 0.888 0.104 
37 
IGL@ protein OS=Homo sapiens GN=IGL@ 
PE=1 SV=1 Q6PIK1_HUMAN 25 0.828 0.883 1.004 1.025 0.668 0.879 0.881 0.130 
38 
Myosin-reactive immunoglobulin heavy chain 
variable region (Fragment) OS=Homo sapiens 
PE=2 SV=1 Q9UL88_HUMAN 14 1.328 0.772 0.692 1.036 0.596 0.824 0.875 0.267 
39 
IGK@ protein OS=Homo sapiens GN=IGK@ 
PE=1 SV=1 Q6PIL8_HUMAN 26 0.780 0.993 0.897 0.837 0.910 0.676 0.849 0.111 
40 
Ig gamma-1 chain C region OS=Homo sapiens 
GN=IGHG1 PE=1 SV=1 A0A087X1C7_HUMAN 50 0.000 0.000 2.148 0.000 2.699 0.000 0.808 1.264 
41 
cDNA FLJ53691, highly similar to 
Serotransferrin OS=Homo sapiens PE=2 SV=1 B4E1B2_HUMAN 75 1.870 0.000 0.000 2.746 0.000 0.000 0.769 1.224 
42 
Ig gamma-1 chain C region OS=Homo sapiens 
GN=IGHG1 PE=1 SV=1 A0A087X079_HUMAN 52 2.161 0.000 0.000 2.399 0.000 0.000 0.760 1.180 
43 
Epididymis secretory protein Li 51 OS=Homo 
sapiens GN=HEL-S-51 PE=2 SV=1 V9HWI6_HUMAN (+1) 53 0.630 0.682 0.581 0.648 0.543 0.974 0.676 0.154 
44 
Kininogen 1, isoform CRA_a OS=Homo sapiens 
GN=KNG1 PE=4 SV=1 D3DNU8_HUMAN 48 0.493 0.587 0.688 0.584 0.580 0.858 0.632 0.127 
45 
Plasminogen OS=Homo sapiens GN=PLG 
PE=1 SV=2 PLMN_HUMAN 91 0.613 0.578 0.542 0.473 0.571 1.008 0.631 0.191 
46 
Alpha-2 globin chain OS=Homo sapiens 
GN=HBA2 PE=3 SV=1 D1MGQ2_HUMAN (+2) 15 0.253 0.657 1.379 0.548 0.495 0.330 0.610 0.404 
47 
Vitronectin OS=Homo sapiens GN=VTN PE=4 
SV=1 D9ZGG2_HUMAN (+1) 54 0.634 0.557 0.660 0.537 0.558 0.692 0.606 0.064 
48 
Inter-alpha (Globulin) inhibitor H4 (Plasma 
Kallikrein-sensitive glycoprotein) OS=Homo 
sapiens GN=ITIH4 PE=2 SV=1 B2RMS9_HUMAN (+1) 103 0.578 0.675 0.603 0.530 0.698 0.533 0.603 0.071 
49 
Complement C4-B OS=Homo sapiens GN=C4B 
PE=1 SV=2 CO4B_HUMAN 193 0.560 0.749 0.586 0.441 0.613 0.666 0.603 0.104 
50 
Alpha-1-acid glycoprotein 1 OS=Homo sapiens 
GN=ORM1 PE=1 SV=1 A1AG1_HUMAN (+1) 24 0.792 0.528 0.715 0.544 0.406 0.504 0.582 0.144 
51 
Inter-alpha-trypsin inhibitor heavy chain H2 
OS=Homo sapiens GN=ITIH2 PE=1 SV=1 Q5T985_HUMAN 105 0.539 0.599 0.495 0.529 0.663 0.659 0.581 0.071 
52 
Complement factor H OS=Homo sapiens 
GN=CFH PE=1 SV=4 CFAH_HUMAN 139 0.538 0.530 0.557 0.390 0.574 0.830 0.570 0.143 
53 
Ig kappa chain V-III region WOL OS=Homo 
sapiens PE=1 SV=1 KV305_HUMAN 12 0.493 0.626 0.404 0.604 0.541 0.595 0.544 0.084 
54 
Complement C4-A OS=Homo sapiens GN=C4A 
PE=1 SV=2 CO4A_HUMAN 193 0.552 0.749 0.591 0.000 0.598 0.646 0.523 0.265 
55 
Inter-alpha-trypsin inhibitor heavy chain H1 
OS=Homo sapiens GN=ITIH1 PE=1 SV=3 ITIH1_HUMAN 101 0.489 0.590 0.466 0.469 0.652 0.451 0.520 0.082 
56 
CP protein OS=Homo sapiens GN=CP PE=2 
SV=1 A5PL27_HUMAN (+1) 122 0.381 0.620 0.476 0.472 0.566 0.572 0.514 0.087 
57 
cDNA FLJ35730 fis, clone TESTI2003131, 
highly similar to ALPHA-1-
ANTICHYMOTRYPSIN OS=Homo sapiens 
PE=2 SV=1 B3KS79_HUMAN 51 0.646 0.562 0.518 0.379 0.546 0.399 0.508 0.102 
58 
IBM-B2 heavy chain variable region (Fragment) 
OS=Homo sapiens PE=2 SV=1 A0A125QYY9_HUMAN 14 0.422 0.570 0.472 0.587 0.563 0.392 0.501 0.084 
59 
Prothrombin OS=Homo sapiens GN=F2 PE=1 
SV=2 THRB_HUMAN 70 0.416 0.429 0.296 0.435 0.384 0.738 0.450 0.150 
60 
Myosin-reactive immunoglobulin heavy chain 
variable region (Fragment) OS=Homo sapiens 
PE=2 SV=1 Q9UL90_HUMAN 12 0.669 0.509 0.367 0.483 0.309 0.275 0.435 0.147 
61 
Putative uncharacterized protein 
DKFZp686L19235 OS=Homo sapiens 
GN=DKFZp686L19235 PE=2 SV=1 Q6MZV6_HUMAN 52 0.886 0.000 0.838 0.000 0.803 0.000 0.421 0.462 
62 
Alpha-1B-glycoprotein OS=Homo sapiens 
GN=A1BG PE=1 SV=4 A1BG_HUMAN (+1) 54 0.391 0.487 0.399 0.233 0.421 0.498 0.405 0.095 
63 
APOB protein OS=Homo sapiens GN=APOB 
PE=2 SV=1 Q7Z7Q0_HUMAN 92 0.000 0.000 0.000 1.030 0.000 1.290 0.387 0.605 
64 
Heparin cofactor 2 OS=Homo sapiens 
GN=SERPIND1 PE=1 SV=3 HEP2_HUMAN 57 0.378 0.379 0.332 0.441 0.415 0.357 0.384 0.039 
65 
cDNA, FLJ93914, highly similar to Homo 
sapiens histidine-rich glycoprotein (HRG), 





































































Apolipoprotein A-I, isoform CRA_a OS=Homo 
sapiens GN=APOA1 PE=4 SV=1 A0A024R3E3_HUMAN (+1) 31 0.313 0.364 0.284 0.421 0.509 0.319 0.368 0.084 
67 
Myosin-reactive immunoglobulin light chain 
variable region (Fragment) OS=Homo sapiens 
PE=1 SV=1 Q9UL83_HUMAN 12 0.317 0.352 0.330 0.524 0.271 0.366 0.360 0.087 
68 
Hemoglobin, beta OS=Homo sapiens GN=HBB 
PE=3 SV=1 D9YZU5_HUMAN (+1) 16 0.079 0.411 0.880 0.393 0.377 0.000 0.357 0.311 
69 
Uncharacterized protein OS=Homo sapiens 
PE=2 SV=1 B4E1Z4_HUMAN 141 0.333 0.350 0.375 0.309 0.293 0.471 0.355 0.064 
70 
Uncharacterized protein OS=Homo sapiens 
PE=2 SV=1 Q8NEJ1_HUMAN 25 1.031 0.000 0.000 0.000 0.000 1.077 0.351 0.544 
71 
Beta-2-glycoprotein I (Fragment) OS=Homo 
sapiens PE=2 SV=1 D9IWP9_HUMAN 36 0.293 0.313 0.281 0.215 0.271 0.641 0.336 0.153 
72 
Anti-FactorVIII scFv (Fragment) OS=Homo 
sapiens PE=2 SV=1 A2KBC6_HUMAN 25 0.355 0.376 0.370 0.387 0.352 0.132 0.329 0.097 
73 Transthyretin OS=Homo sapiens PE=2 SV=1 A6XGL1_HUMAN (+2) 20 0.169 0.188 0.374 0.556 0.348 0.330 0.327 0.141 
74 
Fibronectin 1, isoform CRA_n OS=Homo 
sapiens GN=FN1 PE=4 SV=1 A0A024R462_HUMAN 259 0.334 0.181 0.369 0.226 0.398 0.378 0.314 0.089 
75 
cDNA FLJ56954, highly similar to Inter-alpha-
trypsin inhibitor heavy chain H1 OS=Homo 
sapiens PE=2 SV=1 B7Z539_HUMAN 72 0.510 0.000 0.520 0.000 0.715 0.000 0.291 0.327 
76 
C4b-binding protein alpha chain OS=Homo 
sapiens GN=C4BPA PE=1 SV=2 C4BPA_HUMAN 67 0.202 0.294 0.151 0.180 0.201 0.689 0.286 0.203 
77 
MS-D4 heavy chain variable region (Fragment) 
OS=Homo sapiens PE=2 SV=1 A0A0X9UWK7_HUMAN 14 0.332 0.268 0.346 0.242 0.331 0.196 0.286 0.060 
78 
GCT-A10 heavy chain variable region 
(Fragment) OS=Homo sapiens PE=2 SV=1 A0A120HG46_HUMAN 14 0.392 0.000 0.566 0.000 0.629 0.000 0.265 0.300 
79 
Serpin peptidase inhibitor, clade C 
(Antithrombin), member 1, isoform CRA_a 
OS=Homo sapiens GN=SERPINC1 PE=3 SV=1 A0A024R944_HUMAN (+1) 53 0.255 0.239 0.241 0.283 0.280 0.259 0.260 0.019 
80 
cDNA FLJ53025, highly similar to Complement 
C4-B OS=Homo sapiens PE=2 SV=1 B7Z1F8_HUMAN 30 0.000 1.534 0.000 0.000 0.000 0.000 0.256 0.626 
81 
Protein IGHV3-74 (Fragment) OS=Homo 
sapiens GN=IGHV3-74 PE=1 SV=1 A0A0B4J1X5_HUMAN 13 0.357 0.253 0.339 0.223 0.357 0.000 0.255 0.137 
82 
Protein SAA2-SAA4 OS=Homo sapiens 
GN=SAA2-SAA4 PE=4 SV=1 A0A096LPE2_HUMAN 23 0.275 0.286 0.306 0.294 0.101 0.263 0.254 0.077 
83 
IGL@ protein OS=Homo sapiens GN=IGL@ 
PE=1 SV=1 Q8N5F4_HUMAN 25 0.000 0.000 1.514 0.000 0.000 0.000 0.252 0.618 
84 A30 (Fragment) OS=Homo sapiens PE=4 SV=1 A2MYE1_HUMAN (+1) 10 0.211 0.470 0.220 0.290 0.186 0.110 0.248 0.123 
85 
Protein AMBP OS=Homo sapiens GN=AMBP 
PE=1 SV=1 AMBP_HUMAN 39 0.217 0.229 0.271 0.161 0.214 0.394 0.248 0.080 
86 
Ig lambda-7 chain C region OS=Homo sapiens 
GN=IGLC7 PE=1 SV=2 LAC7_HUMAN 11 0.000 1.452 0.000 0.000 0.000 0.000 0.242 0.593 
87 
Complement C5 OS=Homo sapiens GN=C5 
PE=1 SV=4 CO5_HUMAN 188 0.234 0.270 0.255 0.201 0.234 0.240 0.239 0.023 
88 
Apolipoprotein A-II OS=Homo sapiens 
GN=APOA2 PE=1 SV=1 APOA2_HUMAN (+1) 11 0.269 0.213 0.240 0.308 0.379 0.000 0.235 0.129 
89 
Gelsolin OS=Homo sapiens GN=GSN PE=1 
SV=1 GELS_HUMAN 86 0.182 0.137 0.184 0.292 0.243 0.275 0.219 0.061 
90 
cDNA FLJ55606, highly similar to Alpha-2-HS-
glycoprotein OS=Homo sapiens PE=2 SV=1 B7Z8Q2_HUMAN (+2) 47 0.144 0.220 0.178 0.267 0.178 0.304 0.215 0.061 
91 
Insulin-like growth factor-binding protein 
complex acid labile subunit OS=Homo sapiens 
GN=IGFALS PE=1 SV=1 ALS_HUMAN (+1) 66 0.198 0.178 0.253 0.212 0.232 0.208 0.214 0.026 
92 
Histidine-rich glycoprotein OS=Homo sapiens 
GN=HRG PE=1 SV=1 HRG_HUMAN 60 0.000 0.415 0.382 0.000 0.000 0.467 0.211 0.232 
93 
Actin, cytoplasmic 1 OS=Homo sapiens 
GN=ACTB PE=1 SV=1 ACTB_HUMAN (+2) 42 0.272 0.179 0.241 0.368 0.077 0.105 0.207 0.109 
94 
Ig heavy chain V-III region GAL OS=Homo 
sapiens PE=1 SV=1 HV320_HUMAN 13 0.000 0.433 0.000 0.409 0.392 0.000 0.206 0.226 
95 
Complement factor H-related protein 1 
OS=Homo sapiens GN=CFHR1 PE=1 SV=2 FHR1_HUMAN 38 0.289 0.210 0.324 0.000 0.000 0.405 0.205 0.170 
96 
Complement component 9, isoform CRA_a 
OS=Homo sapiens GN=C9 PE=4 SV=1 A0A024R035_HUMAN (+1) 63 0.221 0.268 0.189 0.161 0.118 0.218 0.196 0.052 
97 
N-acetylmuramoyl-L-alanine amidase OS=Homo 
sapiens GN=PGLYRP2 PE=1 SV=1 PGRP2_HUMAN 62 0.191 0.212 0.149 0.203 0.180 0.230 0.194 0.028 
98 
cDNA, FLJ94213, highly similar to Homo 
sapiens pregnancy-zone protein (PZP), mRNA 
OS=Homo sapiens PE=2 SV=1 B2R950_HUMAN (+1) 164 0.188 0.235 0.156 0.139 0.257 0.184 0.193 0.045 
99 
GCT-A4 light chain variable region (Fragment) 
OS=Homo sapiens PE=2 SV=1 A0A0X9T7V9_HUMAN 12 0.176 0.157 0.147 0.201 0.193 0.229 0.184 0.030 
100 
Apolipoprotein A-IV OS=Homo sapiens 
GN=APOA4 PE=1 SV=3 APOA4_HUMAN 45 0.094 0.115 0.205 0.247 0.155 0.244 0.177 0.066 
101 
Inter-alpha-trypsin inhibitor heavy chain H3 





































































MS-D1 light chain variable region (Fragment) 
OS=Homo sapiens PE=2 SV=1 A0A0X9TD47_HUMAN 12 0.000 0.235 0.220 0.322 0.271 0.000 0.175 0.140 
103 
Apolipoprotein E OS=Homo sapiens GN=APOE 
PE=1 SV=1 APOE_HUMAN (+1) 36 0.141 0.183 0.159 0.188 0.167 0.198 0.173 0.021 
104 
Uncharacterized protein OS=Homo sapiens 
PE=2 SV=1 A0A5E4_HUMAN 25 1.031 0.000 0.000 0.000 0.000 0.000 0.172 0.421 
105 
Apolipoprotein D OS=Homo sapiens GN=APOD 
PE=1 SV=1 APOD_HUMAN 21 0.161 0.112 0.147 0.184 0.177 0.235 0.169 0.041 
106 
Zinc-alpha-2-glycoprotein OS=Homo sapiens 
GN=AZGP1 PE=1 SV=2 ZA2G_HUMAN 34 0.174 0.152 0.207 0.185 0.082 0.210 0.168 0.048 
107 
IGL@ protein OS=Homo sapiens GN=IGL@ 
PE=2 SV=1 Q567P1_HUMAN 25 0.997 0.000 0.000 0.000 0.000 0.000 0.166 0.407 
108 
Immunglobulin heavy chain variable region 
(Fragment) OS=Homo sapiens PE=4 SV=1 Q0ZCH6_HUMAN 14 0.211 0.134 0.126 0.242 0.166 0.118 0.166 0.050 
109 
Coagulation factor XII OS=Homo sapiens 
GN=F12 PE=1 SV=3 FA12_HUMAN (+1) 68 0.155 0.138 0.129 0.142 0.157 0.259 0.163 0.048 
110 
Alpha-2-antiplasmin OS=Homo sapiens 
GN=SERPINF2 PE=1 SV=3 A2AP_HUMAN 55 0.154 0.154 0.160 0.149 0.143 0.210 0.162 0.024 
111 
GCT-A5 light chain variable region (Fragment) 
OS=Homo sapiens PE=2 SV=1 A0A0X9UWL5_HUMAN 12 0.317 0.352 0.293 0.000 0.000 0.000 0.160 0.177 
112 
Complement component C6 OS=Homo sapiens 
GN=C6 PE=1 SV=3 CO6_HUMAN 105 0.177 0.165 0.134 0.115 0.168 0.194 0.159 0.029 
113 
Serum amyloid P-component OS=Homo 
sapiens GN=APCS PE=1 SV=2 SAMP_HUMAN (+1) 25 0.203 0.188 0.141 0.116 0.130 0.176 0.159 0.035 
114 
Complement component C8 gamma chain 
OS=Homo sapiens GN=C8G PE=1 SV=3 CO8G_HUMAN 22 0.211 0.171 0.160 0.176 0.042 0.175 0.156 0.058 
115 
Alpha-1-acid glycoprotein 2 OS=Homo sapiens 
GN=ORM2 PE=1 SV=2 A1AG2_HUMAN 24 0.141 0.196 0.220 0.101 0.116 0.137 0.152 0.047 
116 
Serum paraoxonase/arylesterase 1 OS=Homo 
sapiens GN=PON1 PE=1 SV=3 PON1_HUMAN 40 0.106 0.141 0.121 0.169 0.139 0.233 0.152 0.045 
117 
Complement component 1, q subcomponent, B 
chain, isoform CRA_a OS=Homo sapiens 
GN=C1QB PE=4 SV=1 A0A024RAB9_HUMAN (+3) 27 0.125 0.157 0.114 0.161 0.120 0.224 0.150 0.041 
118 
Uncharacterized protein OS=Homo sapiens 
PE=1 SV=1 Q8TCD0_HUMAN 26 0.000 0.000 0.000 0.874 0.000 0.000 0.146 0.357 
119 
Retinol binding protein 4, plasma, isoform 
CRA_b OS=Homo sapiens GN=RBP4 PE=1 
SV=2 Q5VY30_HUMAN (+2) 23 0.129 0.061 0.153 0.168 0.121 0.239 0.145 0.059 
120 
IGL@ protein OS=Homo sapiens GN=IGL@ 
PE=1 SV=1 Q5FWF9_HUMAN 25 0.000 0.000 0.863 0.000 0.000 0.000 0.144 0.352 
121 
Complement component 1, q subcomponent, C 
chain, isoform CRA_a OS=Homo sapiens 
GN=C1QC PE=4 SV=1 A0A024RAA7_HUMAN (+1) 26 0.114 0.163 0.169 0.112 0.089 0.190 0.139 0.040 
122 
HCG40889, isoform CRA_b OS=Homo sapiens 
GN=hCG_40889 PE=4 SV=1 A0A024R962_HUMAN 139 0.000 0.000 0.000 0.000 0.000 0.834 0.139 0.340 
123 
GCT-A5 heavy chain variable region (Fragment) 
OS=Homo sapiens PE=2 SV=1 A0A0X9T0H6_HUMAN 12 0.458 0.000 0.367 0.000 0.000 0.000 0.137 0.215 
124 
Complement component C8 alpha chain 
OS=Homo sapiens GN=C8A PE=1 SV=2 CO8A_HUMAN 65 0.175 0.152 0.135 0.112 0.121 0.127 0.137 0.023 
125 
Vitamin K-dependent protein S OS=Homo 
sapiens GN=PROS1 PE=1 SV=1 PROS_HUMAN (+2) 75 0.141 0.175 0.088 0.084 0.179 0.139 0.134 0.041 
126 
Afamin OS=Homo sapiens GN=AFM PE=1 
SV=1 AFAM_HUMAN 69 0.073 0.102 0.057 0.112 0.188 0.271 0.134 0.081 
127 
Plasma kallikrein heavy chain (Fragment) 
OS=Homo sapiens GN=KLKB1 PE=3 SV=1 H0YAC1_HUMAN 77 0.082 0.098 0.120 0.113 0.157 0.221 0.132 0.050 
128 
Complement C1r subcomponent OS=Homo 
sapiens GN=C1R PE=2 SV=1 B4DPQ0_HUMAN 82 0.113 0.155 0.113 0.112 0.102 0.181 0.129 0.031 
129 
CD5 antigen-like OS=Homo sapiens GN=CD5L 
PE=1 SV=1 CD5L_HUMAN 38 0.122 0.111 0.127 0.089 0.122 0.202 0.129 0.038 
130 
GCT-A8 heavy chain variable region (Fragment) 
OS=Homo sapiens PE=2 SV=1 A0A0X9V9C4_HUMAN 13 0.227 0.000 0.237 0.000 0.000 0.296 0.127 0.141 
131 
Complement C1s subcomponent OS=Homo 
sapiens GN=C1S PE=1 SV=1 C1S_HUMAN 77 0.104 0.140 0.103 0.107 0.133 0.164 0.125 0.025 
132 
Complement component 8, beta polypeptide, 
isoform CRA_b OS=Homo sapiens GN=C8B 
PE=2 SV=1 B7Z550_HUMAN (+4) 60 0.120 0.110 0.125 0.105 0.100 0.165 0.121 0.023 
133 
cDNA FLJ78207, highly similar to Human 
complement protein component C7 mRNA 
OS=Homo sapiens PE=2 SV=1 A8K2T4_HUMAN (+1) 93 0.141 0.146 0.099 0.068 0.080 0.189 0.121 0.046 
134 
Ig heavy chain V-III region WEA OS=Homo 
sapiens PE=1 SV=1 HV302_HUMAN 12 0.211 0.000 0.293 0.201 0.000 0.000 0.118 0.133 
135 
Carboxypeptidase B2 OS=Homo sapiens 
GN=CPB2 PE=4 SV=1 A0A087WSY5_HUMAN (+1) 44 0.086 0.128 0.100 0.143 0.116 0.125 0.116 0.020 
136 
Lumican OS=Homo sapiens GN=LUM PE=1 
SV=2 LUM_HUMAN (+1) 38 0.100 0.124 0.116 0.127 0.098 0.116 0.113 0.012 
137 
Vitamin D-binding protein OS=Homo sapiens 





































































Rheumatoid factor G9 light chain (Fragment) 
OS=Homo sapiens GN=V<lambda>3 PE=2 
SV=1 A0N5G3_HUMAN 13 0.000 0.000 0.643 0.000 0.000 0.000 0.107 0.263 
139 
Protein IGLV8-61 (Fragment) OS=Homo 
sapiens GN=IGLV8-61 PE=4 SV=2 A0A075B6I0_HUMAN (+1) 13 0.325 0.000 0.169 0.149 0.000 0.000 0.107 0.132 
140 
Apolipoprotein C-III OS=Homo sapiens 
GN=APOC3 PE=2 SV=1 A3KPE2_HUMAN (+2) 11 0.077 0.085 0.120 0.176 0.084 0.100 0.107 0.037 
141 
Protein IGLV2-11 (Fragment) OS=Homo 
sapiens GN=IGLV2-11 PE=4 SV=1 A0A075B6K3_HUMAN (+1) 13 0.260 0.000 0.373 0.000 0.000 0.000 0.105 0.167 
142 
Protein IGHV3-13 (Fragment) OS=Homo 
sapiens GN=IGHV3-13 PE=4 SV=1 A0A0A0MS11_HUMAN 13 0.227 0.217 0.000 0.186 0.000 0.000 0.105 0.116 
143 
Keratin 1 OS=Homo sapiens GN=KRT1 PE=3 
SV=1 H6VRF8_HUMAN (+3) 66 0.141 0.107 0.093 0.059 0.176 0.042 0.103 0.050 
144 
Cryocrystalglobulin CC1 kappa light chain 
variable region (Fragment) OS=Homo sapiens 
PE=2 SV=1 B1N7B8_HUMAN 12 0.141 0.000 0.000 0.282 0.193 0.000 0.103 0.121 
145 
Clusterin OS=Homo sapiens GN=CLU PE=1 
SV=1 CLUS_HUMAN 52 0.097 0.099 0.110 0.074 0.089 0.116 0.098 0.015 
146 
Protein IGKV2D-24 (Fragment) OS=Homo 
sapiens GN=IGKV2D-24 PE=4 SV=1 A0A075B6R9_HUMAN (+1) 13 0.065 0.072 0.000 0.149 0.214 0.085 0.097 0.074 
147 
Leucine-rich alpha-2-glycoprotein OS=Homo 
sapiens GN=HMFT1766 PE=2 SV=1 Q68CK4_HUMAN 38 0.111 0.111 0.104 0.115 0.085 0.058 0.097 0.022 
 
148 
Ig heavy chain variable region (Fragment) 
OS=Homo sapiens PE=2 SV=1 A0A068LKQ2_HUMAN 13 0.000 0.144 0.135 0.074 0.107 0.085 0.091 0.052 
149 
Pigment epithelium-derived factor OS=Homo 
sapiens GN=SERPINF1 PE=1 SV=4 PEDF_HUMAN 46 0.092 0.061 0.096 0.116 0.060 0.119 0.091 0.025 
150 
Immunoglobulin J chain OS=Homo sapiens 
GN=IGJ PE=1 SV=4 IGJ_HUMAN 18 0.047 0.000 0.098 0.161 0.103 0.122 0.089 0.057 
151 
Keratin, type I cytoskeletal 10 OS=Homo 
sapiens GN=KRT10 PE=1 SV=6 K1C10_HUMAN 59 0.129 0.111 0.082 0.025 0.134 0.047 0.088 0.045 
152 
Complement C2 OS=Homo sapiens GN=C2 
PE=1 SV=2 CO2_HUMAN (+3) 83 0.000 0.000 0.127 0.122 0.123 0.152 0.087 0.069 
153 
GCT-A1 heavy chain variable region (Fragment) 
OS=Homo sapiens PE=2 SV=1 A0A125U0V2_HUMAN 14 0.000 0.000 0.000 0.518 0.000 0.000 0.086 0.211 
154 IgG H chain OS=Homo sapiens PE=2 SV=1 S6B2B6_HUMAN 29 0.000 0.000 0.516 0.000 0.000 0.000 0.086 0.211 
155 
Keratin, type II cytoskeletal 2 epidermal 
OS=Homo sapiens GN=KRT2 PE=1 SV=2 K22E_HUMAN 65 0.097 0.116 0.075 0.037 0.143 0.000 0.078 0.052 
156 
APOL1 protein (Fragment) OS=Homo sapiens 
GN=APOL1 PE=2 SV=1 A5PL32_HUMAN (+2) 49 0.078 0.077 0.045 0.109 0.114 0.045 0.078 0.030 
157 
Angiotensinogen variant (Fragment) OS=Homo 
sapiens PE=2 SV=1 Q53GY3_HUMAN (+3) 53 0.064 0.044 0.042 0.073 0.096 0.104 0.070 0.026 
158 
Protein IGHV3-73 (Fragment) OS=Homo 
sapiens GN=IGHV3-73 PE=1 SV=1 A0A0B4J1V6_HUMAN 9 0.000 0.000 0.000 0.000 0.412 0.000 0.069 0.168 
159 
Rheumatoid factor C6 light chain (Fragment) 
OS=Homo sapiens GN=V<kappa>1 PE=2 SV=1 A0N5G1_HUMAN 13 0.195 0.108 0.000 0.000 0.107 0.000 0.068 0.081 
160 
Thyroxine-binding globulin OS=Homo sapiens 
GN=SERPINA7 PE=1 SV=2 THBG_HUMAN 46 0.073 0.092 0.048 0.084 0.071 0.036 0.067 0.021 
161 
Carboxypeptidase N subunit 2 OS=Homo 
sapiens GN=CPN2 PE=1 SV=3 CPN2_HUMAN 61 0.062 0.069 0.043 0.048 0.084 0.081 0.065 0.017 
162 
Ficolin-3 OS=Homo sapiens GN=FCN3 PE=1 
SV=2 FCN3_HUMAN 33 0.077 0.057 0.053 0.073 0.056 0.067 0.064 0.010 
163 
Complement factor I OS=Homo sapiens 
GN=CFI PE=1 SV=2 CFAI_HUMAN (+2) 66 0.032 0.064 0.047 0.029 0.056 0.142 0.062 0.041 
164 IgG L chain OS=Homo sapiens PE=2 SV=1 S6AWF4_HUMAN 20 0.000 0.000 0.000 0.363 0.000 0.000 0.060 0.148 
165 
Carboxypeptidase N catalytic chain OS=Homo 
sapiens GN=CPN1 PE=1 SV=1 CBPN_HUMAN 52 0.049 0.081 0.051 0.074 0.054 0.053 0.060 0.014 
166 
VH6DJ protein (Fragment) OS=Homo sapiens 
GN=VH6DJ PE=2 SV=1 A2N0T1_HUMAN 13 0.000 0.217 0.000 0.000 0.143 0.000 0.060 0.096 
167 
Keratin, type I cytoskeletal 9 OS=Homo sapiens 
GN=KRT9 PE=1 SV=3 K1C9_HUMAN 62 0.055 0.083 0.057 0.031 0.112 0.018 0.059 0.034 
168 
Coagulation factor V OS=Homo sapiens GN=F5 
PE=4 SV=1 A0A0A0MRJ7_HUMAN (+1) 252 0.064 0.071 0.054 0.046 0.070 0.048 0.059 0.011 
169 
Ig heavy chain V-III region BUT OS=Homo 
sapiens PE=1 SV=1 HV306_HUMAN 12 0.000 0.000 0.110 0.242 0.000 0.000 0.059 0.100 
170 
Galectin-3-binding protein OS=Homo sapiens 
GN=LGALS3BP PE=1 SV=1 LG3BP_HUMAN (+1) 65 0.117 0.072 0.041 0.022 0.036 0.051 0.056 0.034 
171 
V1-2 protein (Fragment) OS=Homo sapiens 
GN=V1-2 PE=4 SV=1 A2MYD6_HUMAN 10 0.338 0.000 0.000 0.000 0.000 0.000 0.056 0.138 
172 
Serpin peptidase inhibitor, clade A (Alpha-1 
antiproteinase, antitrypsin), member 4, isoform 
CRA_a OS=Homo sapiens GN=SERPINA4 
PE=3 SV=1 A0A024R6I9_HUMAN (+2) 49 0.043 0.067 0.036 0.079 0.076 0.034 0.056 0.021 
173 
V1-22 protein (Fragment) OS=Homo sapiens 
GN=V1-22 PE=1 SV=1 Q5NV88_HUMAN 11 0.000 0.000 0.000 0.176 0.000 0.150 0.054 0.084 
174 
Thrombospondin-1 OS=Homo sapiens 





































































MS-F1 light chain variable region (Fragment) 
OS=Homo sapiens PE=2 SV=1 A0A0X9V9B3_HUMAN 12 0.000 0.078 0.073 0.081 0.077 0.000 0.052 0.040 
176 
Coagulation factor XIII B chain OS=Homo 
sapiens GN=F13B PE=1 SV=3 F13B_HUMAN 76 0.039 0.025 0.064 0.032 0.055 0.094 0.051 0.025 
177 
V1-13 protein (Fragment) OS=Homo sapiens 
GN=V1-13 PE=4 SV=1 Q5NV69_HUMAN 10 0.211 0.000 0.000 0.000 0.093 0.000 0.051 0.087 
178 
Talin-1 OS=Homo sapiens GN=TLN1 PE=1 
SV=3 TLN1_HUMAN 270 0.095 0.031 0.070 0.088 0.005 0.010 0.050 0.040 
179 
Lipoprotein, Lp(A) OS=Homo sapiens GN=LPA 
PE=1 SV=1 Q1HP67_HUMAN 227 0.000 0.112 0.138 0.000 0.016 0.012 0.046 0.062 
180 
Lipopolysaccharide-binding protein OS=Homo 
sapiens GN=LBP PE=1 SV=3 LBP_HUMAN (+1) 53 0.040 0.062 0.058 0.055 0.026 0.031 0.045 0.015 
181 
Myosin-reactive immunoglobulin heavy chain 
variable region (Fragment) OS=Homo sapiens 
PE=2 SV=1 Q9UL89_HUMAN 13 0.000 0.000 0.271 0.000 0.000 0.000 0.045 0.111 
182 
Complement factor H-related protein 3 
OS=Homo sapiens GN=CFHR3 PE=1 SV=2 FHR3_HUMAN 37 0.148 0.000 0.000 0.000 0.000 0.119 0.045 0.070 
183 
cDNA, FLJ94361, highly similar to Homo 
sapiens serine (or cysteine) proteinase inhibitor, 
clade A(alpha-1 antiproteinase, antitrypsin), 
member 6 (SERPINA6), mRNA OS=Homo 
sapiens PE=2 SV=1 B2R9F2_HUMAN (+1) 45 0.019 0.083 0.020 0.043 0.052 0.037 0.042 0.024 
184 
Carbonic anhydrase 1 OS=Homo sapiens 
GN=CA1 PE=1 SV=2 CAH1_HUMAN (+1) 29 0.000 0.065 0.152 0.033 0.000 0.000 0.042 0.060 
185 
Hyaluronan-binding protein 2 OS=Homo sapiens 
GN=HABP2 PE=1 SV=1 HABP2_HUMAN 63 0.034 0.030 0.014 0.023 0.029 0.096 0.038 0.029 
186 
Protein IGHV5-51 (Fragment) OS=Homo 
sapiens GN=IGHV5-51 PE=1 SV=1 A0A0C4DH38_HUMAN 13 0.000 0.072 0.000 0.000 0.143 0.000 0.036 0.060 
187 
Serpin peptidase inhibitor, clade A (Alpha-1 
antiproteinase, antitrypsin), member 10, isoform 
CRA_b OS=Homo sapiens GN=SERPINA10 
PE=3 SV=1 A0A024R6I6_HUMAN (+3) 51 0.050 0.064 0.017 0.038 0.045 0.000 0.036 0.023 
188 
Glyceraldehyde-3-phosphate dehydrogenase 
OS=Homo sapiens GN=GAPDH PE=1 SV=3 G3P_HUMAN (+1) 36 0.035 0.039 0.061 0.067 0.000 0.000 0.034 0.029 
189 
Anti-HER3 scFv (Fragment) OS=Homo sapiens 
PE=2 SV=1 A2J422_HUMAN 26 0.000 0.000 0.085 0.112 0.000 0.000 0.033 0.051 
190 
Phosphatidylinositol-glycan-specific 
phospholipase D OS=Homo sapiens 
GN=GPLD1 PE=1 SV=3 PHLD_HUMAN 92 0.018 0.031 0.024 0.021 0.055 0.036 0.031 0.014 
191 
Coagulation factor XIII A chain OS=Homo 
sapiens GN=F13A1 PE=1 SV=4 F13A_HUMAN 83 0.046 0.000 0.037 0.041 0.022 0.033 0.030 0.017 
192 
Attractin OS=Homo sapiens GN=ATRN PE=1 
SV=2 ATRN_HUMAN 159 0.016 0.050 0.011 0.018 0.044 0.031 0.028 0.016 
193 
Single-chain Fv (Fragment) OS=Homo sapiens 
GN=scFv PE=1 SV=1 Q65ZC9_HUMAN 26 0.146 0.000 0.000 0.000 0.000 0.000 0.024 0.060 
194 
Myosin-reactive immunoglobulin light chain 
variable region (Fragment) OS=Homo sapiens 
PE=1 SV=1 Q9UL70_HUMAN 12 0.000 0.000 0.000 0.000 0.000 0.137 0.023 0.056 
195 
cDNA FLJ60461, highly similar to Peroxiredoxin-
2 (EC 1.11.1.15) OS=Homo sapiens PE=2 SV=1 B4DF70_HUMAN (+2) 20 0.000 0.000 0.132 0.000 0.000 0.000 0.022 0.054 
196 
Serpin peptidase inhibitor, clade A (Alpha-1 
antiproteinase, antitrypsin), member 5, isoform 
CRA_a OS=Homo sapiens GN=SERPINA5 
PE=3 SV=1 A0A024R6N9_HUMAN (+1) 46 0.000 0.000 0.019 0.032 0.020 0.048 0.020 0.018 
197 
Extracellular matrix protein 1 OS=Homo sapiens 
GN=ECM1 PE=1 SV=2 ECM1_HUMAN 61 0.014 0.000 0.022 0.040 0.000 0.036 0.019 0.017 
198 
Complement C1r subcomponent-like protein 
OS=Homo sapiens GN=C1RL PE=1 SV=2 C1RL_HUMAN 53 0.024 0.000 0.033 0.027 0.026 0.000 0.018 0.015 
199 
V2-19 protein (Fragment) OS=Homo sapiens 
GN=V2-19 PE=4 SV=1 Q5NV91_HUMAN 10 0.000 0.000 0.000 0.000 0.000 0.110 0.018 0.045 
200 
Myosin, heavy polypeptide 9, non-muscle, 
isoform CRA_a OS=Homo sapiens GN=MYH9 
PE=4 SV=1 A0A024R1N1_HUMAN (+1) 227 0.035 0.008 0.004 0.062 0.000 0.000 0.018 0.025 
201 Fibulin-1 OS=Homo sapiens PE=2 SV=1 B4DUV1_HUMAN 70 0.030 0.040 0.019 0.000 0.020 0.000 0.018 0.016 
202 
Ig heavy chain V-III region GA OS=Homo 
sapiens PE=1 SV=1 HV308_HUMAN 13 0.000 0.108 0.000 0.000 0.000 0.000 0.018 0.044 
203 
Filamin-A OS=Homo sapiens GN=FLNA PE=1 
SV=4 FLNA_HUMAN 281 0.032 0.013 0.022 0.040 0.000 0.000 0.018 0.016 
204 
Coagulation factor IX OS=Homo sapiens 
GN=F9 p22 PE=2 SV=1 F2RM37_HUMAN (+1) 52 0.024 0.000 0.000 0.000 0.027 0.053 0.017 0.021 
205 
Complement component 1, q subcomponent, A 
chain, isoform CRA_a OS=Homo sapiens 
GN=C1QA PE=4 SV=1 A0A024RAG6_HUMAN (+2) 26 0.049 0.054 0.000 0.000 0.000 0.000 0.017 0.027 
206 
Coagulation factor XI OS=Homo sapiens 
GN=F11 PE=1 SV=1 FA11_HUMAN 70 0.012 0.013 0.025 0.021 0.000 0.031 0.017 0.011 
207 
Apolipoprotein M OS=Homo sapiens GN=APOM 





































































Ig heavy chain variable region (Fragment) 
OS=Homo sapiens PE=2 SV=1 A0A068LRW6_HUMAN (+2) 14 0.000 0.000 0.000 0.000 0.099 0.000 0.017 0.041 
209 
Hepatocyte growth factor activator OS=Homo 
sapiens GN=HGFAC PE=1 SV=1 HGFA_HUMAN 71 0.024 0.020 0.019 0.014 0.000 0.023 0.017 0.009 
210 
HCG1782423 (Fragment) OS=Homo sapiens 
GN=IGLV2-18 PE=4 SV=1 A0A075B6J9_HUMAN (+1) 13 0.097 0.000 0.000 0.000 0.000 0.000 0.016 0.040 
211 
Fibulin-1 OS=Homo sapiens GN=FBLN1 PE=1 
SV=4 FBLN1_HUMAN 77 0.016 0.024 0.017 0.019 0.012 0.000 0.015 0.008 
212 
Complement factor H-related protein 2 
OS=Homo sapiens GN=CFHR2 PE=1 SV=1 FHR2_HUMAN (+1) 31 0.000 0.000 0.000 0.000 0.000 0.089 0.015 0.036 
213 
Fetuin-B OS=Homo sapiens GN=FETUB PE=1 
SV=2 FETUB_HUMAN 42 0.000 0.022 0.000 0.000 0.022 0.039 0.014 0.016 
214 A0A0F7TC28_HUMAN A0A0F7TC28_HUMAN 11 0.000 0.000 0.080 0.000 0.000 0.000 0.013 0.033 
215 
Properdin OS=Homo sapiens GN=CFP PE=1 
SV=2 PROP_HUMAN (+1) 51 0.000 0.018 0.017 0.000 0.000 0.043 0.013 0.017 
216 
Ig heavy chain V-III region CAM OS=Homo 
sapiens PE=1 SV=1 HV307_HUMAN 14 0.000 0.000 0.000 0.000 0.000 0.078 0.013 0.032 
217 
Ig kappa chain V-I region DEE OS=Homo 
sapiens PE=1 SV=1 KV105_HUMAN 12 0.000 0.000 0.000 0.000 0.077 0.000 0.013 0.032 
218 
Sex hormone-binding globulin OS=Homo 
sapiens GN=SHBG PE=4 SV=1 I3L145_HUMAN (+1) 37 0.023 0.025 0.000 0.026 0.000 0.000 0.012 0.014 
219 
Alpha-synuclein OS=Homo sapiens GN=SNCA 
PE=1 SV=1 E7EPV7_HUMAN (+3) 12 0.000 0.000 0.073 0.000 0.000 0.000 0.012 0.030 
220 
Sulfhydryl oxidase 1 OS=Homo sapiens 
GN=QSOX1 PE=1 SV=3 QSOX1_HUMAN 83 0.010 0.017 0.011 0.017 0.017 0.000 0.012 0.007 
221 
C-reactive protein OS=Homo sapiens GN=CRP 
PE=1 SV=1 CRP_HUMAN 25 0.034 0.038 0.000 0.000 0.000 0.000 0.012 0.018 
222 
Peptidase inhibitor 16 OS=Homo sapiens 
GN=PI16 PE=1 SV=1 PI16_HUMAN 49 0.017 0.000 0.000 0.020 0.000 0.034 0.012 0.014 
223 
Fermitin family homolog 3 OS=Homo sapiens 
GN=FERMT3 PE=1 SV=1 URP2_HUMAN 76 0.044 0.012 0.012 0.000 0.000 0.000 0.011 0.017 
224 
IBM-A3 heavy chain variable region (Fragment) 
OS=Homo sapiens PE=2 SV=1 A0A0X9UWM4_HUMAN 14 0.000 0.000 0.000 0.000 0.066 0.000 0.011 0.027 
225 
Catalase OS=Homo sapiens GN=CAT PE=1 
SV=3 CATA_HUMAN 60 0.000 0.000 0.066 0.000 0.000 0.000 0.011 0.027 
226 
Ficolin-2 OS=Homo sapiens GN=FCN2 PE=1 
SV=2 FCN2_HUMAN 34 0.000 0.000 0.000 0.028 0.000 0.032 0.010 0.016 
227 
Carbonic anhydrase 2 OS=Homo sapiens 
GN=CA2 PE=1 SV=2 CAH2_HUMAN (+2) 29 0.000 0.000 0.061 0.000 0.000 0.000 0.010 0.025 
228 
Cartilage acidic protein 1 OS=Homo sapiens 
GN=CRTAC1 PE=1 SV=2 CRAC1_HUMAN (+1) 71 0.012 0.013 0.012 0.020 0.000 0.000 0.010 0.008 
229 
Vinculin, isoform CRA_c OS=Homo sapiens 
GN=VCL PE=4 SV=1 A0A024QZN4_HUMAN (+2) 117 0.022 0.000 0.011 0.025 0.000 0.000 0.010 0.011 
230 
cDNA FLJ51023, highly similar to Vitamin K-
dependent protein C (EC 3.4.21.69) OS=Homo 
sapiens PE=2 SV=1 B4DPC8_HUMAN (+4) 31 0.027 0.000 0.000 0.000 0.030 0.000 0.010 0.015 
231 
von Willebrand factor OS=Homo sapiens 
GN=VWF PE=1 SV=4 VWF_HUMAN 309 0.019 0.005 0.031 0.000 0.000 0.000 0.009 0.013 
232 
cDNA FLJ78437, highly similar to Homo sapiens 
cartilage oligomeric matrix protein (COMP), 
mRNA OS=Homo sapiens PE=2 SV=1 A8K3I0_HUMAN (+4) 83 0.015 0.000 0.000 0.000 0.011 0.026 0.009 0.011 
233 
Conserved oligomeric Golgi complex subunit 3 
OS=Homo sapiens GN=COG3 PE=1 SV=3 COG3_HUMAN 94 0.000 0.000 0.037 0.015 0.000 0.000 0.009 0.015 
234 
Macrophage stimulating 1 (Hepatocyte growth 
factor-like) variant (Fragment) OS=Homo 
sapiens PE=2 SV=1 Q53GN8_HUMAN 80 0.021 0.018 0.000 0.000 0.000 0.014 0.009 0.010 
235 Zyxin OS=Homo sapiens GN=ZYX PE=1 SV=1 ZYX_HUMAN 61 0.028 0.000 0.000 0.016 0.000 0.000 0.007 0.012 
236 
Proteoglycan 4, isoform CRA_a OS=Homo 
sapiens GN=PRG4 PE=4 SV=1 A0A024R930_HUMAN (+2) 151 0.000 0.012 0.006 0.000 0.012 0.011 0.007 0.006 
237 
Butyrylcholinesterase, isoform CRA_b 
OS=Homo sapiens GN=BCHE PE=3 SV=1 D3DNN4_HUMAN 73 0.000 0.000 0.012 0.013 0.013 0.000 0.006 0.007 
238 
cDNA FLJ78503, highly similar to Homo sapiens 
keratin 13 (KRT13), transcript variant 1, mRNA 
OS=Homo sapiens PE=2 SV=1 A8K2H9_HUMAN 50 0.000 0.038 0.000 0.000 0.000 0.000 0.006 0.015 
239 
Keratin, type II cytoskeletal 5 OS=Homo sapiens 
GN=KRT5 PE=1 SV=3 K2C5_HUMAN 62 0.000 0.000 0.000 0.000 0.037 0.000 0.006 0.015 
240 
Extracellular link domain containing 1 OS=Homo 
sapiens GN=XLKD1 PE=2 SV=1 B2R672_HUMAN (+1) 35 0.000 0.000 0.000 0.000 0.000 0.031 0.005 0.013 
241 
Stomatin, isoform CRA_a OS=Homo sapiens 
GN=STOM PE=4 SV=1 A0A024R882_HUMAN (+2) 32 0.000 0.000 0.000 0.030 0.000 0.000 0.005 0.012 
242 
Pyruvate kinase PKM OS=Homo sapiens 
GN=PKM PE=1 SV=4 KPYM_HUMAN (+1) 58 0.029 0.000 0.000 0.000 0.000 0.000 0.005 0.012 
243 
Mannosyl-oligosaccharide 1,2-alpha-
mannosidase IA OS=Homo sapiens 





































































Transforming growth factor-beta-induced protein 
ig-h3 OS=Homo sapiens GN=TGFBI PE=1 
SV=1 BGH3_HUMAN (+1) 75 0.000 0.000 0.000 0.013 0.012 0.000 0.004 0.007 
245 
Vitamin K-dependent protein Z OS=Homo 
sapiens GN=PROZ PE=1 SV=2 PROZ_HUMAN 45 0.000 0.000 0.000 0.000 0.000 0.024 0.004 0.010 
246 
Integrin alpha-IIb OS=Homo sapiens 
GN=ITGA2B PE=1 SV=3 ITA2B_HUMAN 113 0.007 0.000 0.000 0.013 0.000 0.000 0.003 0.006 
247 
Actinin, alpha 1, isoform CRA_a OS=Homo 
sapiens GN=ACTN1 PE=4 SV=1 A0A024R694_HUMAN (+1) 103 0.008 0.000 0.000 0.009 0.000 0.000 0.003 0.005 
248 
Moesin OS=Homo sapiens GN=MSN PE=1 
SV=3 MOES_HUMAN (+1) 68 0.000 0.000 0.000 0.014 0.000 0.000 0.002 0.006 
249 
Biotinidase OS=Homo sapiens GN=BTD PE=1 
SV=2 BTD_HUMAN 61 0.014 0.000 0.000 0.000 0.000 0.000 0.002 0.006 
250 
Band 3 anion transport protein OS=Homo 
sapiens GN=SLC4A1 PE=1 SV=3 B3AT_HUMAN (+3) 102 0.000 0.000 0.013 0.000 0.000 0.000 0.002 0.005 
251 
Epididymis secretory protein Li 52 OS=Homo 
sapiens GN=HEL-S-52 PE=2 SV=1 V9HWG7_HUMAN (+1) 66 0.013 0.000 0.000 0.000 0.000 0.000 0.002 0.005 
252 
Dopamine beta-hydroxylase OS=Homo sapiens 
GN=DBH PE=1 SV=3 DOPO_HUMAN 69 0.000 0.000 0.013 0.000 0.000 0.000 0.002 0.005 
253 
Integrin beta-3 OS=Homo sapiens GN=ITGB3 
PE=1 SV=2 ITB3_HUMAN (+1) 87 0.000 0.000 0.000 0.011 0.000 0.000 0.002 0.005 
254 
IgGFc-binding protein OS=Homo sapiens 
GN=FCGBP PE=1 SV=3 FCGBP_HUMAN 572 0.001 0.003 0.002 0.002 0.000 0.003 0.002 0.001 
255 
Mannan-binding lectin serine protease 1 
OS=Homo sapiens GN=MASP1 PE=1 SV=3 MASP1_HUMAN 79 0.011 0.000 0.000 0.000 0.000 0.000 0.002 0.004 
256 
Spectrin alpha chain, erythrocytic 1 OS=Homo 
sapiens GN=SPTA1 PE=1 SV=1 A0A087WZE4_HUMAN (+1) 281 0.000 0.000 0.005 0.000 0.000 0.000 0.001 0.002 
257 
Ankyrin-1 OS=Homo sapiens GN=ANK1 PE=1 
SV=3 ANK1_HUMAN 206 0.000 0.000 0.004 0.000 0.000 0.000 0.001 0.002 
258 
Spectrin, beta, erythrocytic (Includes 
spherocytosis, clinical type I) variant (Fragment) 






























































































Supporting Table 5 
Table S5: Characterization of the in vivo protein corona.  Full list of common proteins identified in the 
liposomal protein corona in all 6 ovarian carcinoma patients. 
# Identified protein Accession Number Average 
RPA% 
STV 
1 Full-length cDNA clone CS0DD006YL02 of Neuroblastoma of Homo sapiens (human) OS=Homo sapiens PE=2 SV=1 Q86TT1_HUMAN 7.98 2.44 
2 Ig mu chain C region OS=Homo sapiens GN=IGHM PE=1 SV=1 A0A087X2C0_HUMAN 5.70 1.78 
3 Alpha-2-macroglobulin OS=Homo sapiens GN=A2M PE=1 SV=3 A2MG_HUMAN 3.47 1.01 
4 Fibrinogen beta chain OS=Homo sapiens GN=FGB PE=1 SV=2 FIBB_HUMAN (+1) 3.46 1.20 
5 Fibrinogen alpha chain OS=Homo sapiens GN=FGA PE=1 SV=2 FIBA_HUMAN 2.99 0.67 
6 Apolipoprotein B (Including Ag(X) antigen) OS=Homo sapiens GN=APOB PE=4 SV=1 C0JYY2_HUMAN 2.64 1.43 
7 Serum albumin OS=Homo sapiens GN=ALB PE=1 SV=2 ALBU_HUMAN 2.48 2.08 
8 Protein IGHV3-72 OS=Homo sapiens GN=IGHV3-72 PE=4 SV=1 A0A087WW89_HUMAN 1.91 0.57 
9 C4b-binding protein alpha chain OS=Homo sapiens GN=C4BPA PE=1 SV=2 C4BPA_HUMAN 1.74 0.59 
10 Fibrinogen gamma chain OS=Homo sapiens GN=FGG PE=1 SV=3 FIBG_HUMAN 1.60 0.54 
11 Haptoglobin (Fragment) OS=Homo sapiens GN=HP PE=1 SV=1 H3BS21_HUMAN 1.36 0.35 
12 Haptoglobin OS=Homo sapiens GN=HP PE=1 SV=4 H0Y300_HUMAN 1.35 0.44 
13 IGH@ protein OS=Homo sapiens GN=IGH@ PE=1 SV=1 Q6GMX6_HUMAN 1.14 0.65 
14 Ig gamma-1 chain C region OS=Homo sapiens GN=IGHG1 PE=1 SV=1 A0A087WV47_HUMAN (+1) 1.13 0.60 
15 cDNA FLJ78387 OS=Homo sapiens PE=1 SV=1 A8K008_HUMAN 1.12 0.60 
16 Putative uncharacterized protein DKFZp686P15220 OS=Homo sapiens GN=DKFZp686P15220 PE=1 SV=1 Q6N089_HUMAN 1.06 0.61 
17 IgG H chain OS=Homo sapiens PE=1 SV=1 S6B291_HUMAN 1.05 0.65 
18 Actin, cytoplasmic 1 OS=Homo sapiens GN=ACTB PE=1 SV=1 ACTB_HUMAN (+2) 1.04 0.60 
19 Ig gamma-1 chain C region OS=Homo sapiens GN=IGHG1 PE=1 SV=1 A0A087WYC5_HUMAN 0.96 0.63 
20 GCT-A10 heavy chain variable region (Fragment) OS=Homo sapiens PE=2 SV=1 A0A120HG46_HUMAN 0.96 0.51 
21 cDNA FLJ14473 fis, clone MAMMA1001080, highly similar to Homo sapiens SNC73 protein (SNC73) mRNA OS=Homo sapiens 
PE=2 SV=1 
Q96K68_HUMAN 0.94 0.30 
22 Haptoglobin-related protein OS=Homo sapiens GN=HPR PE=1 SV=2 HPTR_HUMAN 0.93 0.22 
23 Putative uncharacterized protein DKFZp686G11190 OS=Homo sapiens GN=DKFZp686G11190 PE=1 SV=1 Q6MZQ6_HUMAN 0.92 0.61 
24 Myosin-reactive immunoglobulin heavy chain variable region (Fragment) OS=Homo sapiens PE=2 SV=1 Q9UL90_HUMAN 0.89 0.22 
25 Putative uncharacterized protein DKFZp686C15213 OS=Homo sapiens GN=DKFZp686C15213 PE=1 SV=1 Q6MZU6_HUMAN 0.87 0.64 
26 Ig gamma-3 chain C region OS=Homo sapiens GN=IGHG3 PE=4 SV=1 A0A087WXL8_HUMAN 0.86 0.65 
27 Apolipoprotein E OS=Homo sapiens GN=APOE PE=1 SV=1 APOE_HUMAN (+1) 0.83 0.48 
28 IGL@ protein OS=Homo sapiens GN=IGL@ PE=1 SV=1 Q8N355_HUMAN 0.80 0.18 
29 IGK@ protein OS=Homo sapiens GN=IGK@ PE=1 SV=1 Q6PIL8_HUMAN 0.77 0.21 
30 Complement C3 OS=Homo sapiens GN=C3 PE=1 SV=2 CO3_HUMAN (+1) 0.77 0.43 
31 Hemoglobin, beta OS=Homo sapiens GN=HBB PE=3 SV=1 D9YZU5_HUMAN (+1) 0.64 0.44 
32 MS-D4 heavy chain variable region (Fragment) OS=Homo sapiens PE=2 SV=1 A0A0X9UWK7_HUMAN 0.63 0.13 
33 Anti-FactorVIII scFv (Fragment) OS=Homo sapiens PE=2 SV=1 A2KBC6_HUMAN 0.61 0.22 
34 Alpha-2 globin chain OS=Homo sapiens GN=HBA2 PE=3 SV=1 D1MGQ2_HUMAN (+2) 0.59 0.31 
35 Protein IGHV3-74 (Fragment) OS=Homo sapiens GN=IGHV3-74 PE=1 SV=1 A0A0B4J1X5_HUMAN 0.58 0.21 
36 Vitamin K-dependent protein S OS=Homo sapiens GN=PROS1 PE=1 SV=1 PROS_HUMAN (+2) 0.57 0.17 




































































38 Galectin-3-binding protein OS=Homo sapiens GN=LGALS3BP PE=1 SV=1 LG3BP_HUMAN (+1) 0.50 0.32 
39 Apolipoprotein C-III OS=Homo sapiens GN=APOC3 PE=2 SV=1 A3KPE2_HUMAN (+2) 0.50 0.40 
40 cDNA, FLJ94213, highly similar to Homo sapiens pregnancy-zone protein (PZP), mRNA OS=Homo sapiens PE=2 SV=1 B2R950_HUMAN (+1) 0.49 0.08 
41 Thrombospondin-1 OS=Homo sapiens GN=THBS1 PE=1 SV=2 TSP1_HUMAN 0.48 0.26 
42 Protein IGHV5-51 (Fragment) OS=Homo sapiens GN=IGHV5-51 PE=1 SV=1 A0A0C4DH38_HUMAN 0.47 0.10 
43 Vinculin, isoform CRA_c OS=Homo sapiens GN=VCL PE=4 SV=1 A0A024QZN4_HUMAN (+2) 0.46 0.28 
44 Fibronectin 1, isoform CRA_n OS=Homo sapiens GN=FN1 PE=4 SV=1 A0A024R462_HUMAN 0.46 0.11 
45 Keratin 1 OS=Homo sapiens GN=KRT1 PE=3 SV=1 H6VRF8_HUMAN (+3) 0.44 0.08 
46 Filamin-A OS=Homo sapiens GN=FLNA PE=1 SV=4 FLNA_HUMAN 0.42 0.27 
47 Alpha-1-antitrypsin OS=Homo sapiens GN=SERPINA1 PE=1 SV=3 A1AT_HUMAN (+1) 0.41 0.24 
48 Ig heavy chain V-III region BUT OS=Homo sapiens PE=1 SV=1 HV306_HUMAN 0.41 0.20 
49 Talin-1 OS=Homo sapiens GN=TLN1 PE=1 SV=3 TLN1_HUMAN 0.41 0.24 
50 Actinin, alpha 1, isoform CRA_a OS=Homo sapiens GN=ACTN1 PE=4 SV=1 A0A024R694_HUMAN (+1) 0.41 0.23 
51 Apolipoprotein A-I, isoform CRA_a OS=Homo sapiens GN=APOA1 PE=4 SV=1 A0A024R3E3_HUMAN (+1) 0.40 0.11 
52 von Willebrand factor OS=Homo sapiens GN=VWF PE=1 SV=4 VWF_HUMAN 0.39 0.25 
53 Coagulation factor XIII A chain OS=Homo sapiens GN=F13A1 PE=1 SV=4 F13A_HUMAN 0.36 0.23 
54 Complement factor H OS=Homo sapiens GN=CFH PE=1 SV=4 CFAH_HUMAN 0.33 0.12 
55 Keratin, type I cytoskeletal 10 OS=Homo sapiens GN=KRT10 PE=1 SV=6 K1C10_HUMAN 0.30 0.10 
56 Protein APOC4-APOC2 OS=Homo sapiens GN=APOC4-APOC2 PE=4 SV=1 K7ER74_HUMAN 0.30 0.16 
57 Keratin, type I cytoskeletal 9 OS=Homo sapiens GN=KRT9 PE=1 SV=3 K1C9_HUMAN 0.28 0.09 
58 Epididymis tissue protein Li 173 OS=Homo sapiens PE=2 SV=1 E9KL26_HUMAN (+1) 0.27 0.15 
59 Myosin, heavy polypeptide 9, non-muscle, isoform CRA_a OS=Homo sapiens GN=MYH9 PE=4 SV=1 A0A024R1N1_HUMAN (+1) 0.26 0.22 
60 Complement C1r subcomponent OS=Homo sapiens GN=C1R PE=2 SV=1 B4DPQ0_HUMAN 0.26 0.08 
61 Heat shock cognate 71 kDa protein OS=Homo sapiens GN=HSPA8 PE=1 SV=1 HSP7C_HUMAN (+1) 0.24 0.16 
62 Hemopexin OS=Homo sapiens GN=HPX PE=1 SV=2 HEMO_HUMAN 0.23 0.21 
63 Epididymis secretory protein Li 52 OS=Homo sapiens GN=HEL-S-52 PE=2 SV=1 V9HWG7_HUMAN (+1) 0.22 0.15 
64 Keratin, type II cytoskeletal 2 epidermal OS=Homo sapiens GN=KRT2 PE=1 SV=2 K22E_HUMAN 0.22 0.07 
65 Fermitin family homolog 3 OS=Homo sapiens GN=FERMT3 PE=1 SV=1 URP2_HUMAN 0.21 0.14 
66 Complement C4-B OS=Homo sapiens GN=C4B PE=1 SV=2 CO4B_HUMAN 0.21 0.09 
67 Pyruvate kinase PKM OS=Homo sapiens GN=PKM PE=1 SV=4 KPYM_HUMAN (+1) 0.21 0.12 
68 Gelsolin OS=Homo sapiens GN=GSN PE=1 SV=1 GELS_HUMAN 0.20 0.10 
69 CD5 antigen-like OS=Homo sapiens GN=CD5L PE=1 SV=1 CD5L_HUMAN 0.19 0.08 
70 Immunglobulin heavy chain variable region (Fragment) OS=Homo sapiens PE=4 SV=1 Q0ZCH6_HUMAN 0.18 0.05 
71 Complement component 1, q subcomponent, C chain, isoform CRA_a OS=Homo sapiens GN=C1QC PE=4 SV=1 A0A024RAA7_HUMAN (+1) 0.18 0.03 
72 Tubulin alpha-4A chain OS=Homo sapiens GN=TUBA4A PE=1 SV=1 TBA4A_HUMAN 0.18 0.11 
73 cDNA FLJ35730 fis, clone TESTI2003131, highly similar to ALPHA-1-ANTICHYMOTRYPSIN OS=Homo sapiens PE=2 SV=1 B3KS79_HUMAN 0.17 0.12 
74 Immunoglobulin J chain OS=Homo sapiens GN=IGJ PE=1 SV=4 IGJ_HUMAN 0.16 0.07 
75 Inter-alpha-trypsin inhibitor heavy chain H2 OS=Homo sapiens GN=ITIH2 PE=1 SV=1 Q5T985_HUMAN 0.16 0.05 
76 78 kDa glucose-regulated protein OS=Homo sapiens GN=HSPA5 PE=1 SV=2 GRP78_HUMAN (+1) 0.16 0.14 
77 Moesin OS=Homo sapiens GN=MSN PE=1 SV=3 MOES_HUMAN (+1) 0.16 0.10 
78 Apolipoprotein M OS=Homo sapiens GN=APOM PE=1 SV=2 APOM_HUMAN 0.15 0.08 
79 Complement component 1, q subcomponent, B chain, isoform CRA_a OS=Homo sapiens GN=C1QB PE=4 SV=1 A0A024RAB9_HUMAN (+3) 0.15 0.06 




































































81 Inter-alpha-trypsin inhibitor heavy chain H1 OS=Homo sapiens GN=ITIH1 PE=1 SV=3 ITIH1_HUMAN 0.14 0.06 
82 Lipoprotein, Lp(A) OS=Homo sapiens GN=LPA PE=1 SV=1 Q1HP67_HUMAN 0.14 0.15 
83 Keratin, type I cytoskeletal 16 OS=Homo sapiens GN=KRT16 PE=1 SV=4 K1C16_HUMAN 0.13 0.05 
84 Heat shock protein HSP 90-alpha OS=Homo sapiens GN=HSP90AA1 PE=1 SV=5 HS90A_HUMAN (+1) 0.13 0.08 
85 Inter-alpha (Globulin) inhibitor H4 (Plasma Kallikrein-sensitive glycoprotein) OS=Homo sapiens GN=ITIH4 PE=2 SV=1 B2RMS9_HUMAN (+1) 0.12 0.09 
86 Tubulin beta-1 chain OS=Homo sapiens GN=TUBB1 PE=1 SV=1 TBB1_HUMAN 0.12 0.09 
87 Band 3 anion transport protein OS=Homo sapiens GN=SLC4A1 PE=1 SV=3 B3AT_HUMAN (+3) 0.11 0.06 
88 CP protein OS=Homo sapiens GN=CP PE=2 SV=1 A5PL27_HUMAN (+1) 0.11 0.09 
89 Alpha-1B-glycoprotein OS=Homo sapiens GN=A1BG PE=1 SV=4 A1BG_HUMAN (+1) 0.11 0.10 
90 Integrin beta-3 OS=Homo sapiens GN=ITGB3 PE=1 SV=2 ITB3_HUMAN (+1) 0.11 0.09 
91 Heparin cofactor 2 OS=Homo sapiens GN=SERPIND1 PE=1 SV=3 HEP2_HUMAN 0.11 0.08 
92 APOL1 protein (Fragment) OS=Homo sapiens GN=APOL1 PE=2 SV=1 A5PL32_HUMAN (+2) 0.10 0.06 
93 Complement C5 OS=Homo sapiens GN=C5 PE=1 SV=4 CO5_HUMAN 0.10 0.07 
94 Endoplasmin OS=Homo sapiens GN=HSP90B1 PE=1 SV=1 ENPL_HUMAN (+2) 0.10 0.08 
95 Platelet glycoprotein Ib alpha (Fragment) OS=Homo sapiens GN=GP1BA PE=4 SV=1 A5CKE2_HUMAN (+2) 0.10 0.10 
96 Clusterin OS=Homo sapiens GN=CLU PE=1 SV=1 CLUS_HUMAN 0.10 0.02 
97 Complement C1s subcomponent OS=Homo sapiens GN=C1S PE=1 SV=1 C1S_HUMAN 0.10 0.06 
98 Glyceraldehyde-3-phosphate dehydrogenase OS=Homo sapiens GN=GAPDH PE=1 SV=3 G3P_HUMAN (+1) 0.09 0.05 
99 Heat shock protein 90kDa alpha (Cytosolic), class B member 1, isoform CRA_a OS=Homo sapiens GN=HSP90AB1 PE=3 SV=1 A0A024RD80_HUMAN (+2) 0.09 0.05 
100 C4b-binding protein beta chain OS=Homo sapiens GN=C4BPB PE=1 SV=1 C4BPB_HUMAN 0.09 0.04 
101 Integrin alpha-IIb OS=Homo sapiens GN=ITGA2B PE=1 SV=3 ITA2B_HUMAN 0.09 0.06 
102 Vitronectin OS=Homo sapiens GN=VTN PE=4 SV=1 D9ZGG2_HUMAN (+1) 0.09 0.07 
103 Keratin, type II cytoskeletal 5 OS=Homo sapiens GN=KRT5 PE=1 SV=3 K2C5_HUMAN 0.09 0.03 
104 Plasminogen OS=Homo sapiens GN=PLG PE=1 SV=2 PLMN_HUMAN 0.09 0.08 
105 Ficolin-3 OS=Homo sapiens GN=FCN3 PE=1 SV=2 FCN3_HUMAN 0.08 0.03 
106 14-3-3 protein zeta/delta OS=Homo sapiens GN=YWHAZ PE=1 SV=1 1433Z_HUMAN (+1) 0.07 0.04 
107 Proteoglycan 4, isoform CRA_a OS=Homo sapiens GN=PRG4 PE=4 SV=1 A0A024R930_HUMAN (+2) 0.07 0.04 
108 IgGFc-binding protein OS=Homo sapiens GN=FCGBP PE=1 SV=3 FCGBP_HUMAN 0.07 0.03 
109 Catalase OS=Homo sapiens GN=CAT PE=1 SV=3 CATA_HUMAN 0.06 0.03 
110 Zyxin OS=Homo sapiens GN=ZYX PE=1 SV=1 ZYX_HUMAN 0.06 0.03 
111 Carboxypeptidase N subunit 2 OS=Homo sapiens GN=CPN2 PE=1 SV=3 CPN2_HUMAN 0.06 0.02 
112 Multimerin-1 OS=Homo sapiens GN=MMRN1 PE=1 SV=3 MMRN1_HUMAN 0.06 0.06 
113 Alpha-2-antiplasmin OS=Homo sapiens GN=SERPINF2 PE=1 SV=3 A2AP_HUMAN 0.06 0.04 
114 Calpain 1, (Mu/I) large subunit, isoform CRA_a OS=Homo sapiens GN=CAPN1 PE=4 SV=1 A0A024R580_HUMAN (+2) 0.06 0.06 
115 Clathrin heavy chain OS=Homo sapiens GN=CLTC PE=1 SV=1 A0A087WVQ6_HUMAN (+1) 0.05 0.04 
116 Coagulation factor XIII B chain OS=Homo sapiens GN=F13B PE=1 SV=3 F13B_HUMAN 0.04 0.02 
117 cDNA FLJ61290, highly similar to Neutral alpha-glucosidase AB OS=Homo sapiens PE=2 SV=1 B4DJ30_HUMAN (+2) 0.04 0.04 
118 Complement component C6 OS=Homo sapiens GN=C6 PE=1 SV=3 CO6_HUMAN 0.04 0.04 
119 Mannan-binding lectin serine protease 1 OS=Homo sapiens GN=MASP1 PE=1 SV=3 MASP1_HUMAN 0.04 0.02 
120 Soluble scavenger receptor cysteine-rich domain-containing protein SSC5D OS=Homo sapiens GN=SSC5D PE=2 SV=3 SRCRL_HUMAN 0.03 0.01 
121 Spectrin, beta, erythrocytic (Includes spherocytosis, clinical type I) variant (Fragment) OS=Homo sapiens PE=2 SV=1 Q59FP5_HUMAN 0.03 0.02 




































































Supporting Table 6 
Table S6: Most-abundant proteins (top-20) identified by LC-MS/MS in ex vivo protein coronas (formed 
after incubation of PEGylated liposomal doxorubicin with plasma samples) obtained from ovarian carcinoma 
patients (n=6) and from healthy controls (n=6). RPA% values represent the average and standard deviation 
from the 6 biological replicates. 
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